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Osteoporosis and depression are prevalent among older postmenopausal women 65 years
or older. Bisphosphonates (BPs) and selective serotonin reuptake inhibitors (SSRIs) or serotonin
norepinephrine reuptake inhibitors (SNRIs) are commonly used medications to treat these
conditions. Inhibitory effects of BPs on osteoclasts are responsible for the reduction in fracture
risk. SSRIs, however, are associated with increased fracture risk through decreasing osteoblasts
and increasing osteoclastic activity. These effects of SSRIs could attenuate the beneficial effects
of BPs. This dissertation describes the concomitant use of BPs and SSRIs among postmeopausa

women and reports findings from examining the association between concomitant use of BPs
and SSRIs and fracture risk.
Separate cross-sectional analyses were performed using data from the 2004-2008 Medical
Expenditure Panel Survey (MEPS) and Medicare Part D prescriptions claims data (2008-2010) to
examine usage patterns of BPs and SSRIs/SNRIs for women aged ≥45 years and ≥65 years,
respectively. For our second objective, a nested-case control was conducted using Medicare
claims data (2008-2010). Data from Medicare inpatient claims were linked to Medicare Part D
data for all female BP users 65 years or older. We used Cox proportional hazards model to
assess the increased risk of osteoporotic-related fractures among propensity score matched (1:1
ratio) cohorts of concomitant users of BPs and SSRIs and BP alone users.
Concomitant use of BPs and SSRIs was prevalent and increased with age for each
timeframe examined. Findings showed that approximately 12% (using MEPS) and 28% (using
Medicare data) of women on BPs were also on SSRIs. For the second objective, 4,214 propensity
score matched pairs (average age=80.4 years) of subjects were analyzed. Findings showed that
concomitant use of BPs and SSRIs was associated with statistically significant increased risk for
any fracture (HR=1.29, 95% CI, 1.07-1.57), but statistically non-significant increased risk for hip
(HR=1.16, 95% CI, 0.92-1.47) and vertebral fractures (HR=1.55, 95% CI, 0.97-2.48).
Current findings indicate that concomitant use of BPs and SSRIs is not uncommon
among postmenopausal women and suggest potential attenuation of antifracture efficacy of BPs
by SSRIs. Further studies are needed to understand the clinical impact of concomitant use of
these medications among older postmenopausal women.

Chapter 1

1.0 INTRODUCTION
1.1 Overview of the document
This dissertation describes a pharmacoepidemiologic study to (1) describe the concomitant
utilization pattern of selective serotonin reuptake inhibitors (SSRIs) and serotonin
norepinephrine reuptake inhibitors (SNRIs) and bisphosphonates, examine (2) the increased risk
of osteoporotic-related fractures associated with the concomitant use of SSRIs with
bisphosphonate therapy, and (3) whether the risk of osteoporotic-related fractures is related to the
role of serotonin in bone rather than the disease (depression). This chapter provides background
on the basic understanding of osteoporosis and osteoporotic fractures and the associated risk
factors, epidemiology, prevention and treatment of the disease, bisphosphonate therapy, and a
brief statement on the safety concerns with simultaneous use of bisphosphonate therapy and
SSRIs or SNRIs in postmenopausal women. Chapter 2 provides a more in depth overview of the
literature of concomitant use of drugs and adverse drug events, concomitant use of drugs with
bisphosphonates and risk of fractures, SSRIs or SNRIs and bone health, and
pharmacoepidemiologic study design considerations. Chapter 3 provides details on a preliminary
descriptive study to assess the utilization of these medications both separately and concomitantly
using nationally-representative survey data in order to determine to what extent these
medications are prescribed among women. Chapter 4 describes the methods used for this
pharmacoepidemiologic study, whereas Chapter 5, Chapter 6, and Chapter 7 describe the results,
and discussion and conclusions from the study, respectively.
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1.2 Osteoporosis and osteoporotic-related fractures
1.2.1 Basic understanding
Bone is a highly specialized living supportive tissue with major functions of providing
support for the body, protection of vital organs, providing an environment for marrow, and acts
as a mineral reservoir for calcium homeostasis in the body. Bone is comprised of bone cells, an
organic matrix of collagen and noncollagenous proteins (osteoid), and inorganic mineral matrix.
Bone cells which include osteoblasts, osteocytes, and osteoclasts are concerned with the
production, maintenance and modeling of osteoid (Figure 1.1).

Figure 1.1. Bone cells
Source: www.iofbonehealth.org

Osteoblasts are bone-forming cells or they are the cells within bone that lay down the
extracellular matrix and regulate its mineralization. Osteoclasts are bone degrading (resorption)
cells at sites called Howship’s lacunae. Osteocytes, smaller in size than osteoblasts, are mature
osteoblasts which eventually become calcified bone. Osteocytes are the most abundant cells in
bone (or are the principal cell in adult bone) and are thought to be important in responding to
changes in physical forces upon bone and to transducer messages to the osteoblastic cells on the
bone surface, directing them to initiate resorption or formation responses.1,2
Osteoporosis is a bone health disease characterized by the loss of bone mass (low bone
mineral density) and strength that leads to an increased risk of fracture. Osteoporosis results from
2

the imbalance created in the process of bone remodeling, which is the major activity of bone
cells in the adults skeleton.3 Bone remodeling is a process by which old bone is continuously
replaced by new tissue through resorption and formation, balanced at an equilibrium, so that the
bone adapts to mechanical load and strain.4 Diagnosis of osteoporosis is based on the World
Health Organization (WHO) criteria for bone mineral density (BMD). Osteoporosis corresponds
to BMD T-score of -2.5 or less compared to a normal, young adult population of the same gender
(reference population) BMD T-score of -1.0 or higher. A T-score is useful to express BMD in a
postmenopausal population and is expressed as standard deviation (SD) units.5 Factors associated
with osteoporosis (or low BMD) and increased risk of fractures included in a new Fracture Risk
Assessment Tool (FRAX®) for evaluating fracture risk are listed in Table 1.1. FRAX® was
developed by the WHO to evaluate a patient’s 10-year probability of hip fracture and major
osteoporotic fracture (i.e., clinical spine, forearm, hip, or shoulder fracture). Previously,
clinicians could only estimate a 5-year fracture risk.6

Table 1.1. Risk factors for osteoporotic fracture used in FRAX®












Age (50 to 90 years)
Sex
Body mass index
Low femoral neck BMD
Prior fragility fracture
Parental fragility fracture
Current tobacco smoking
Long-term use of glucocorticoids
Rheumatoid arthritis
Other causes of secondary osteoporosis (e.g., medications and medical conditions)
Alcohol intake of more than two drinks per day

Adapted from the North American Menopause Society, 2010.6
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Figure 1.2. The human skeletal system highlighting common osteoporotic fracture sites.

In healthy postmenopausal women, BMD of both the entire skeleton and single
anatomical sites have been shown to decrease progressively after the onset of menopause
because of hormonal changes.7 Specifically, the rapid bone loss in postmenopausal women
results from low estrogen production.8 Although postmenopausal osteoporosis affects the whole
skeleton, vertebral fractures, hip fractures, and Colles’ (wrist/forearm) fractures are the most
common osteoporotic fractures.9 Other osteoporotic fractures include pelvic, humeral, and other
femoral fractures.10 A schematic diagram of the human skeletal system is shown in Figure 1.2
highlighting the most common osteoporotic fracture sites.
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1.2.2 Epidemiology
Osteoporosis and its resulting problem of fractures among older adults are a major public
health concern in the United States.11 The proportion of osteoporosis is significantly higher in
postmenopausal women compared with men of the same age.12 The U.S. Preventive Services
Task Force (USPSTF) recommends that women ≥65 years of age be screened routinely for
osteoporosis, but there is no recommendation for or against routine osteoporosis screening in
postmenopausal women who are younger than 60 years of age or in women 60 to 64 years of age
who are not at increased risk for osteoporotic fractures.13 The prevalence of osteoporosis rises
from 4% in women ages 50 to 59 years to 52% in women age 80 years and older.14 Thus,
osteoporosis and osteoporotic fractures increases with age. This is further supported by the
findings in a study of over 200,000 postmenopausal women. In this study, relative to women
aged 50-54 years, the odds of having osteoporosis were found to be 5.9-fold higher in women
aged 65-69 and 14.3-fold higher in women aged 75-79 years.15 This information suggests that
older postmenopausal women are more prone to suffer from osteoporosis and thus are at
increased risk of osteoporotic fractures in their lifetime.
Roughly 4 in 10 white women age 50 years or older in the U.S. will experience a hip,
vertebral, or wrist fracture sometime during the remainder of their lives and 13% of white men
will suffer a similar fate. The estimated remaining lifetime risks after age 50 for hip, vertebral,
and wrist/forearm fractures in women are 17.5%, 15.6%, and 16.0%, respectively.10 In the U.S.,
the rates of osteoporosis and/or osteoporotic fractures are higher among white women compared
with Asian or African American women.16 It is estimated that 90% of all hip and vertebral
fractures in white American women aged between 65 and 85 years old are attributed to
osteoporosis.17
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Of the most common osteoporotic fractures, hip and vertebral fractures are associated with
pronounced burden on society and individuals in terms of clinical consequences and economic
burden emphasizing the need for intervention in women at high risk.18 Specific burdens include
chronic pain, disability, depression, loss of independence or functional ability and psychosocial
difficulty, increased mortality, and increased healthcare costs.19 In 2005, osteoporosis-related
fractures were responsible for an estimated $19 billion in costs in the U.S. By 2025, predictions
show that these costs will rise to approximately $25.3 billion.20 It has been estimated, assuming
there will be no changes over a long period of time, that hip fractures, the most prevalent in older
adults, are projected to increase progressively to 2.6 million by 2025 and to 4.5 million by 2050
worldwide.21 The current annual cost to the U.S. health care system for patients with hip
fractures is more than $12.6 billion (an average of $37,000 per patient). Only 25% of hip fracture
patients will make a full recovery; 40% will require nursing home care; 50% will need a cane or
walker; and 24% of those over age 50 will die within 12 months, hence, the future post-fracture
cost may even be greater.22
As the U.S. population of older adults is projected to increase in the coming decades, a high
prevalence of osteoporosis and/or osteoporotic-related fracture burden is expected. In fact,
according to the U.S. Census Bureau, it is projected that by 2030, 20% of Americans will be
aged 65 years and older and by 2050, the age group is projected to increase to 88.5 million from
38.7 million in 2008. Similarly, the 85 years and older population is expected to increase to 19
million by 2050 from 5.4 million in 2008.23 Moreover, among older adults, the current
proportion of females in the U.S and other countries is greater than males and will still remain so
in the future. The United Nations suggests that, “in many cases, the difference is so large that
concerns of the older population should in fact be viewed primarily as the concerns of older
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women”. The difference in this ratio is generally driven by the fact that average life expectancy
is greater for females than for males.24,25
1.2.3 Prevention and treatment of disease
1.2.3.1 Background
Patients with osteoporosis and osteoporotic (or prevalent) fractures are offered
opportunities for prevention (medication given to individuals with no prior fractures to prevent
the onset of osteoporosis (i.e., further lowering of bone density and/or a first fracture) and
treatment of disease (i.e., the person begins pharmacotherapy after having sustained fractures) to
reduce the risk of new fractures. These opportunities involve both nonpharmacological and
pharmacological therapy interventions.26
Nonpharmacological interventions involve measures such as falls prevention. Falls are
defined as events which result in persons inadvertently coming to rest on the floor or ground or
other lower level, excluding intentional change in position to rest in furniture, wall or other
objects.27 Risk factors for falls among older adults include medications (e.g., antidepressants,
hypnotics and anxiolytics, any central nervous system drug, analgesics, any cardiovascular drug,
any endocrine system drug, any respiratory system drug), chronic diseases (coronary heart
disease, any circulatory disease, diabetes, thyroid disease, chronic obstructive pulmonary
disease, depression, eye disease, arthritis),28 and physical function in terms of one or more
impairments of self-reported difficulty on five Instrumental Activities of Daily Living (IADLs,
range 0-5) including walking two to three blocks, climbing up ten steps, preparing meals, doing
heavy household chores, and shopping.29
Falls are a common and serious public health concern among older adults 65 years and
older. It is estimated that one in every three adults 65 years and older fall each year.30 Falls can

7

be especially injurious for this age group. About 20-30% of older people who fall suffer
moderate to severe injuries (e.g., bruises, hip fractures, traumatic brain injuries, and upper limb
injuries).31,32 Injurious falls can lead to hospitalizations, disability and loss of independence,
functional decline, reduced quality of life, and even premature death.31-35 For example regarding
hospitalization, a Statistical Brief presenting data from the Healthcare Cost and Utilization
Project Nationwide Emergency Department Sample on emergency department (ED) visits among
older adults in 2006 reported that of the more than 2.1 million visits to the ED for injurious falls,
29.6% of visits resulted in hospital admission. The most common injuries related to falls were
fractures, which accounted for 41% of injurious fall-related ED visits.33 Consistent with these
findings, data from the National Center for Health Statistics showed that in 2007, there were
264,000 fall-related hip fractures and the rate for women was almost three times the rate for
men.36
The preceding information further illuminates the fact that osteoporosis and osteoporotic
fractures are a result of multifactorial factors (i.e., component causes for a sufficient cause).37 In
other words, any single approach to optimal bone health is not thought to be adequate to prevent
the disease from occurring. In addition to the appropriate pharmacologic therapy, clinicians are
urged to educate patients about the use of nonpharmacologic interventions/measures (e.g., fall
prevention, use of hip protectors) to assist patients at risk of osteoporotic fractures.38 A fall is
neither necessary nor a sufficient cause of fracture.39 Osteoporotic fractures (e.g., spine fractures)
which are pathologic can occur spontaneously,40 but a fall is considered the strongest single risk
factor for fracture in an older adult.38 Thus, of the nonpharmacologic interventions for
osteoporosis, fall prevention represents the foundation of prevention and management of disease,
without which patients are unlikely to achieve the full benefit of pharmacologic therapy.41 The
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Centers for Disease Control and Prevention recommends steps or interventions to reduce the risk
of falling for older adults 65 years or older and these include using muscle strengthening
exercise, being mindful of medications, keeping vision sharp, and eliminating hazards at
home.42
With regards to pharmacologic therapy, the decision to intervene or selection of patients
for treatment is based on the patient’s level of fracture risk profile and skeletal health assessment
involving clinical judgment, not just on BMD assessment and the efficacy and side-effects of
drugs likely to be prescribed.43,44 The National Osteoporosis Foundation recommends initiating
therapy in postmenopausal women age 50 years and older presenting with a hip or vertebral
(clinical or morphometric) fracture, BMD tests of T-score ≤-2.5 at the femoral neck or spine
after appropriate evaluation to exclude secondary risk factors, T-score between -1.0 and -2.5 at
the femoral neck or spine and a 10-year probability of a hip fracture ≥3% or a 10-year
probability of a major osteoporosis-related ≥ 20% based on the U.S.-adapted WHO algorithm.45

1.2.3.2 Pharmacologic therapy options
Of the current U.S. Food and Drug Administration (FDA)-approved pharmacologic
therapy options, bisphosphonates are widely prescribed46 and recommended by the North
American Menopause Society as first-line pharmacologic treatments in the management of
osteoporosis for postmenopausal women.6 The American College of Rheumatology recommends
bisphosphonates as first-line therapy in medication-induced osteoporosis (e.g., in long-term users
of glucocorticoids or oral corticocosteroids).47 Other pharmacologic options include the selective
estrogen-receptor modulator (SERM; also known as estrogen agonist/antagonist) raloxifene
(marketed as Evista® oral tablets), parathyroid hormone (PTH) or its analogues such as
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teriparatide (recombinant human PTH 1-34) (marketed as Forteo®), estrogens, calcitonin, and
denosumab (marketed as Prolia®).

1.3 Bisphosphonates: FDA-approved
The current FDA-approved bisphosphonates in the management of osteoporosis for
postmenopausal women in U.S. include alendronate (Fosamax®), ibandronate (Boniva®),
risedronate (Actonel®), and zoledronic acid (Reclast®). Table 1.2 and Table 1.3 provide a list
of these bisphosphonates with some additional information. It is unclear whether any of these
drugs is more effective than any other. This is because there are no head-to-head clinical trials of
bisphosphonates for the prevention of fractures.48

Table 1.2. List and dosage of FDA-approved bisphosphonates in the U.S.
Generic name

Brand name

Dosage, dosing interval, and formulation (s)

Alendronate

Fosamax® or
Fosamax Plus D®

Risedronate

Actonel®

Ibandronate

Boniva®

Zoledronic acid

Reclast®

Prevention (oral tablet of 5 mg daily or 35 mg
weekly) and treatment (oral tablet of 10 mg
daily or 70 mg weekly)
Oral tablet doses of 5 mg daily, 35 mg
weekly, 75 mg on 2 consecutive days once a
month, or 150 mg monthly
2.5 mg oral tablet daily, 150 mg tablet
monthly (for prevention and treatment), or
intravenous injection of 3 mg every 3-months
(for treatment)
5 mg intravenous injection yearly for
treatment
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Original FDA
approval year
1995
1998
2003

2007

Table 1.3. List and description of FDA-approved bisphosphonates in the U.S.
Drug product
Fosamax®
(Alendronate
sodium)

Indications
Treatment and prevention of
osteoporosis in
postmenopausal women,
glucocorticoid-induced
osteoporosis, and Paget’s
disease of bone

Contraindications
- Abnormalities of the esophagus
(e.g., stricture or achalasia)-upper
gastrointestinal adverse reactions
- Severe renal impairment

Geriatric use
®
Fosamax -treated
patients were at least
65 years of age in
postmenopausal
osteoporosis studies

Actonel®
(Risedronate
sodium)

Prevention of postmenopausal
osteoporosis, treatment and
prevention of glucocorticoidinduced osteoporosis, and
Paget’s disease

Actonel -treated
patients were at least
65 years of age in
postmenopausal
osteoporosis studies

Boniva®
(Ibandronate
sodium)

Treatment and prevention of
postmenopausal osteoporosis

- Abnormalities of the esophagus
(e.g., stricture or achalasia)-upper
gastrointestinal adverse reactions
- Hypocalcemia (mineral
metabolism)
- Severe renal impairment
- Upper gastrointestinal adverse
reactions
- Severe renal impairment

Reclast®
(Zoledronic acid
Injection)

Treatment of postmenopausal
osteoporosis, and Paget’s
disease of bone

- Severe renal impairment
- Hypocalcemia (mineral
metabolism)

®

®

Boniva -treated
patients were at least
65 years of age in
postmenopausal
osteoporosis studies
®
Reclast -treated
patients were at least
65 years of age in
postmenopausal
osteoporosis studies

1.3.1 Bisphosphonates: Efficacy
Several studies have shown bisphosphonates to have beneficial clinical effects in reducing
bone loss and the risk of fracture in older women.49-51 However, a recent report based on research
conducted by the Southern California Evidence-based Practice Center under contract to the
Agency for Healthcare Research and Quality found that comparative benefits in fracture risk
reduction among the treatments for low bone density vary. The strength of evidence is high for
reducing vertebral fractures, non-vertebral fractures, and hip fractures among postmenopausal
women with osteoporosis. In contrast, the evidence for treatments of wrist fractures is low. A
summary of strength of evidence and conclusions from various studies is presented in Table
1.4.48
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Table 1.4. Summary of comparative benefits of bisphosphonates in fracture reduction.48
Strength of
evidence
High

Study design

Conclusion

Randomized clinical trials
(RCTs)

High

RCTs

High

RCTs

Vertebral fractures: alendronate, risedronate, ibandronate, and
zoledronic acid reduce the risk of vertebral fractures among
postmenopausal women with osteoporosis
Non-vertebral fractures: alendronate, risedronate, and zoledronic
acid reduce the risk of nonvertebral fractures among
postmenopausal women with osteoporosis
Hip fractures: alendronate, risedronate, and zoledronic acid reduce
the risk of hip fractures among postmenopausal women with
osteoporosis. The effect of ibandronate is unclear, since hip fracture
risk reduction was not a separately reported outcome in trials
reporting nonvertebral fractures.
Wrist: alendronate reduces the risk of wrist fractures among
postmenopausal women with osteoporosis. Risedronate in a pooled
analysis of two trials was associated with a lower risk of wrist
fractures, but did not quite reach the conventional level of
statistical significance.
Data are insufficient from head-to-head trials of bisphosphonates to
prove or disprove superiority for prevention of fractures for any
agent

Low

Insufficient

Head-to-head trials

Table 1.5. Adherence to bisphosphonate therapy and fracture rates in osteoporosis.
RR reduction in adjusted OR (%)
Compliant cohort
Total fractures
Vertebral fractures
Hip fractures
Wrist fractures
Persistent cohort
Total fractures
Vertebral fractures
Hip fractures
Wrist fractures

21.1
37.2
37.3
9.2
29.3
40.0
44.5
22.5

Adapted from Siris, 200651

It is important to note that compliance and persistence to these medications is an
important factor in order to achieve the expected benefits. For example, a study to characterize
the relationships between adherence (compliance and persistence) to bisphosphonate
(alendronate or risedronate) therapy and risk of fracture types in 35,537 postmenopausal women
using 2 claims databases from 45 employers and 100 health plans in the continental U.S., showed
12

that adherence to bisphosphonate therapy was associated with significantly fewer fractures at 24
months (See Table 1.5).51
Also beneficial clinical effects have been shown in medication-induced osteoporosis (i.e.,
long-term users of glucocorticoids and/or oral corticosteroids) 52,53 and in those supplemented
with vitamin D and calcium.54 The American College of Rheumatology 2010 recommendations
indicate pharmacologic treatment with bisphosphonates in postmenopausal women and men age
≥50 years with glucocorticoid treatment with an anticipated duration of ≥3 months, or prevalent
glucocorticoid therapy of a duration of at least 3 months.47 Glucocorticoid use is considered the
most prevalent secondary risk factor for osteoporosis.52
1.3.2 Bisphosphonates: Structure and pharmacology
To appreciate the clinical benefits of bisphosphonates in osteoporosis and osteoporotic
fractures, one needs to understand the molecular structure and mechanism of action at the
molecular level. Bisphosphonates are characterized by their affinity for bone mineral because
they bind to hydroxyapatite crystals,55 and inhibitory effects on osteoclasts.56 Bisphosphonates
inhibit the aggregation of crystals and the crystal dissolution thereby inhibiting calcification. The
attachment of bisphosphonates to crystalline hydroxyapatite is related to their structure. There
are, however, differences among molecules in terms of configuration and the associated
affinities. These molecules are ranked with respect to their affinities from lowest to highest as
risedronate, ibandronate, alendronate, and zoledronic acid.58 It is important to note that the four
molecules are classified as nitrogen-containing bisphosphonates that act specifically by
inhibiting the enzyme farneslypyrophosphate synthase (FPP)57 within osteoclasts.
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Figure 1.3. General structure of a bisphosphonate.
The general structure of a bisphosphonate is shown in Figure 1.3. The R1 side chain is
usually a hydroxyl, and R2 side-chain contains the nitrogen group that is responsible for potency.
In relation to potency, the following schematic representation (Figure 1.4)58 summarizes the
correlation between moieties and the potency, while Table 1.6 shows the structure-activity
relationship of the FDA-approved bisphosphonates in the US and bisphosphonate concentration
that gives 50% inhibition (IC50) for each compound.59 As can be seen from the table, the
antiresorptive relative potencies for osteoclast inhibition (from lowest to highest) are:
alendronate, ibandronate, risedronate, and zoledronic acid.

14

The R2 side-chain varies widely
and is responsible for
differences in potency

The P-C-P group is
essential for biological
activity

The P-C-P acts as
“Bone Hook” and is essential
for binding to hydroxyapatite

R1 is usually a OH Group
and this enhances binding
to hydroxyapatite

Figure 1.4. Bisphosphonate structure moieties and their role in potency for osteoclast inhibition.
Table 1.6. US-approved bisphosphonates and their structures with IC50 values for the inhibition
of FPP synthase.59
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic acid

R1
-OH
-OH
-OH
-OH

R2
-(CH2)3NH2
-CH2-3-pyridine
-CH2CH2N(CH3)(pentyl)
-CH2-imidazole

initial IC50 (nM)
2249±180
452.9±16.6
1052±55.1
475.3±18.3

final IC50 (nM)
260.0±19.6
5.7±0.54
25.4±1.57
4.1±0.22

Both bisphosphonates’ affinities for crystalline hydroxyapatite and inhibitory effects on
osteoclasts are important pharmacological features. The high affinity for bone mineral allows
bisphosphonates to achieve a high local concentration throughout the entire skeleton. Suppressed
bone resorption after bisphosphonate initiation suggests bisphosphonate efficacy and potency in
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promoting the apoptosis of osteoclasts actively engaged in degradation of mineral on the bone
surface. Thus, bisphosphonates have become the primary therapy for managing skeletal
conditions characterized by increased osteoclast-mediated bone resorption60 (i.e., osteoporosis
and/or osteoporotic fractures). Overall, these studies clearly demonstrate that bisphosphonates
(nitrogen-containing bisphosphonates) produce their beneficial clinical effect through the mode
of osteoclast inhibition. The half-life of bisphosphonates ranges between 5 and 10 years.61
Whether the potential differences in molecular structure and clinical efficacy factors are
related to safety issues of bisphosphonate use remains to be determined. For example alendronate
(second highest in affinity but with lowest relative potency) has a stronger prophylactic effect
against fractures than risedronate (lowest affinity but high potency) in rheumatoid arthritis
patients on long-term corticosteroid therapy.53 In depth investigations of these differences and
the safety of bisphosphonates with differences in molecular structures and potency are not the
scope of this present study. However, the findings of this study suggest potential attenuating or
negating effects of corticosteroid therapy (drug associated with increased risk of fracture) and the
effects can be thought to be greater on risedronate than on alendronate therapy. Therefore, drugs
that interfere with bone remodeling and associated with increased risk of fracture, and
concomitant use of these drugs with bisphosphonates may alter the beneficial clinical effect of
bisphosphonates and instead put the patients at increased risk of fracture. These are potential
safety concerns that warrant further understanding and investigation.
1.4 Problem statement
Ideally, optimal efficacy of bisphosphonate therapy is expected to be achieved even in the
presence of competing risk factors (e.g., medications) for osteoporosis and osteoporotic fractures
(Table 1.1). There are two possible scenarios: 1) best case scenario: bisphosphonate therapy
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supersedes the competing negative effects of risk factors for osteoporotic fractures and therefore
treatment effects are beneficial, or 2) worst case scenario: the beneficial effects of
bisphosphonate therapy are attenuated by the negative effects of risk factors for osteoporotic
fractures and instead result in increased risk of new fracture. The second phenomenon is a
serious safety issue and can be the case when bisphosphonate therapy is given concomitantly or
simultaneously with medications that induce secondary osteoporosis such as SSRIs and SNRIs.
Given that bone cell types possess a functional serotonin (5-HT) signal transduction mechanism
(5-HT receptors and the serotonin transporters [5-HTT]) for both responding to and regulating
the uptake of 5-HT suggest the involvement of 5-HT and 5-HTT in bone metabolism,62,63 the
safety of these agents is of particular interest for individuals with osteoporosis and/or
osteoporotic fractures.

1.5 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake
Inhibitors: Use and Clinical Pharmacology
1.5.1 SSRIs
The first SSRI to be used clinically was fluoxetine (Prozac®) which was approved by the
FDA in 1987.64 Several other SSRIs have since become available including paroxetine (Paxil®),
sertraline (Zoloft®), fluvoxamine (Luvox®), citalopram (Celexa®), and escitalopram (Lexapro®).
Table 1.7 provides a list of these SSRIs with some additional information.
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Table 1.7. List and description of FDA-approved SSRIs in the U.S.
Drug product
®
Lexapro
(Escitalopram)

Indications
-Acute and
maintenance
treatment of Major
Depressive Disorder
(MDD)
-Acute treatment of
generalized anxiety
disorder

Contraindications
-****Serotonin Syndrome especially when
co-administered with other serotonergic
agents (including triptans, TCAs, fentanyl,
lithium, tramadol, tryptophan, buspirone
and St. John’s Wort) or using of MAOIs
such as linezolid or intravenous methylene
blue
-Concomitant use of pimozide

®

Treatment of
depression

-**** (see Lexapro )
-Concomitant use of pimozide

®

-Maintenance
treatment of MDD
-Treatment of
Obsessive
Compulsive Disorder
(OCD)
-Acute treatment of
panic disorder
Treatment of OCD

-**** (see Lexapro )
-Coadministration of pimozide,
thioridazine due to QTc prolongation
-Concomitant use of olanzapine

Celexa
(Citalopram)

Prozac
(Fluoxetine)

®

Luvox
(Fluvoxamine)

®

Paxil
(Paroxetine)

®

Zoloft
(Sertraline)

-MDD
-OCD
-Panic Disorder
-Social Anxiety
Disorder
-Generalized Anxiety
Disorder
-Posttraumatic Stress
Disorder
-MDD
-OCD
-Panic Disorder
-Posttraumatic Stress
Disorder
-Social anxiety
disorder

®

®

®

-**** (see Lexapro )
-Coadministration of tizanidine,
thioridazine, alosetron, pimozide
®

-**** (see Lexapro )
-Concomitant use with thioridazineproduces prolongation of the QTc intervalassociated with ventricular arrythmias
-Concomitant use of pimozide

®

-**** (see Lexapro )
-Concomitant use of pimozide
®
-with ANTABUSE (disulfiram) due to
the alcohol content of the concentrate

Geriatric use
The number of elderly
patients in controlled trials
®
of Lexapro in MDD was
insufficient to adequately
assess for possible
differential efficacy and
safety measures on the basis
of age (approximately 6% of
the 1144 patients were 60
years of age or older)
-No overall differences in
safety or effectiveness were
observed between older
subjects and younger
subjects
-Precautions-Hyponatremia
No overall differences in
safety were observed
between geriatric and
younger patients (approved
for use)

No overall differences in
safety were observed
between geriatric and
younger patients (approved
for use)
Premarketing clinical trials
®
with Paxil (17% of patients
®
treated with Paxil were 65
years of age or older). No
overall differences in the
adverse event profile and
effectiveness between
elderly and younger subjects
-No overall differences in
pattern of adverse reactions
and efficacy were observed
in the U.S. geriatric clinical
trial subjects relative to
younger subjects

For over a decade now, SSRIs have been the most popular psychotropic medications in
treating depression65 with a better safety and tolerability profile than older agents of
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antidepressants (e.g., tricyclic antidepressants [TCAs], monoamine oxidase inhibitors
[MAOIs]).66 SSRIs are considered first-line drug treatment in older patients,67 especially in
relieving depression in women.68 In addition, SSRIs are useful in a variety of other medical
conditions which include possible management of chronic painful rheumatologic conditions such
as fibromyalgia,69 diabetic peripheral neuropathic pain,70 anxiety and panic disorders,71 and
treatment of vasomotor symptoms such as hot flashes.72-74 Hot flashes have been reported to be
persistent into the late postmenopausal years.75
The clinical benefit of SSRIs is believed to derive from increasing the synaptic levels of 5HT by antagonizing the 5-HTT to block neuronal 5-HT reuptake from the extracellular space and
thereby prolonging 5-HT receptor activation.76 Despite the better safety profile and tolerability of
SSRI use, they are not completely devoid of adverse effects. Examples of adverse effects
include, but are not limited, to bleeding, serotonin syndrome, hyponatremia, sleep disturbances,
nausea, diarrhea, and bone loss (or osteoporosis)- a risk factor for osteoporotic-related
fractures.77,78

1.5.2 SNRIs
Serotonin norepinephrine reuptake inhibitors have been associated with bone loss (or
bone resorption) thus potentially increasing the risk of fracture in older adults.71,79 SNRIs are
dual action antidepressants that inhibit both 5-HT and norepinephrine (NE) transporters. The
FDA-approved SNRIs include venlafaxine (Effexor®), duloxetine (Cymbalta®), desvenlafaxine
(Pristiq®), which is an active metabolite of venlafaxine, and levomilnacipran (Fetzima®).64
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1.6 Significance
Increased risk of osteoporotic fractures associated with use of SSRIs, and potentially
SNRIs, introduces additional clinical consequences of concern about bone health in
postmenopausal women. Concomitant SSRIs or SNRIs with bisphosphonate (BP) utilization may
continue to rise in postmenopausal women because of the projected future increase in the
population of older adults. Therefore, results from this study could add to the gap in the current
body of literature and be useful for physicians treating osteoporosis and/or osteoporotic fractures
by highlighting possible safety concerns that may be important to consider when optimizing
patient care. Currently, there are no specific guidelines for the management of bone loss
observed with antidepressants, yet considerable evidence suggests SSRIs and SNRIs have an
effect on bone health. Results from this study may provide useful information to be integrated
into the monitoring of the routine care for osteoporosis and/or osteoporotic-related fractures in
the same way that other drug-related risk factors for osteoporosis (e.g., glucocorticoids)47 are
monitored. Also these results might be relevant to policymakers concerned with meeting the
needs of aging Americans, especially the health of older women.
1.7 Objectives of the study
There are three specific aims for this study:
1. To describe the concomitant utilization pattern of SSRIs and SNRIs with BPs.
2. To assess the risk of osteoporotic-related fractures associated with the concomitant use of BPs
and SSRIs.
3. To assess the increased risk of osteoporotic-related fractures associated with the concomitant
use of BPs and SNRIs and whether the risk of osteoporotic-related fractures is related to the
role of 5-HT in bone rather than the disease (depression).
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1.8 Hypotheses
The following null hypotheses are being tested in this study:
H0(1) Concomitant use of SSRIs with BPs will have no effect on the risk of fractures compared to
use of BPs alone (i.e., HR=1)
H0(2): Concomitant use of SNRIs with BPs will have no effect on the risk of fractures compared
to use of BPs alone (i.e., HR=1)
Like many observational studies, confounding is a common threat in this study. Confounding
will be controlled at the design stage using propensity score matching. Propensity score is
defined as the probability of receiving treatment rather than the control for a patient conditional
on observed baseline covariates.80 Details of motivation to use propensity score method in the
design of a pharmacoepidemiologic study are provided in Section 2.8 of Chapter 2.

1.9 Summary
Osteoporosis and osteoporotic-related fractures are serious public health burdens in
postmenopausal women. The burden is expected to rise due to the projected future increase in the
population of older adults. Pharmacologic therapy using BPs in prevention and treatment is
currently a popular option. However, SSRIs and, potentially SNRIs, are associated with
increased risk of fracture and might potentially attenuate the beneficial effects of bisphosphonate
therapy. These serious safety concerns have not been investigated yet.

21

List of References
1. International Osteoporosis Foundation. Basic Bone Biology. International Osteoporosis
Foundation. Available at: http://www.iofbonehealth.org/introduction-bone-biology-allabout-our-bones. Accessed September 13, 2011.
2. Sommerfeldt DW, Rubin CT. Biology of Bone and How it Orchestrates the Form and
Function of the Skeleton. Eur Spine J 2001;10:S86-S95.
3. Raisz LG. Pathogenesis of Osteoporosis: Concepts, Conflicts, and Prospects. J Clin
Invest. 2005;115:3318-3325.
4. Frost HM. Skeletal Structural Adaptations to Mechanical Usage (SATMU):2. Redefining
Wolff’s Law: The Modeling Problem. Anat. Rec. 1990;226:414-422.
5. National Institute of Health. Osteoporosis Prevention, Diagnosis, and Therapy. JAMA
2001;285:785-795.
6. The North American Menopause Society. Management of Osteoporosis in
Postmenopausal Women: 2010 Position Statement of the North American Menopause
Society. Menopause 2010;17:25-54.
7. Nuti R, and Martini G. Effects of Age and Menopause on Bone Density of Entire
Skeleton in Healthy and Osteoporotic Women. Osteoporosis Int. 1993;3:59-65.
8. Riggs BL, Khosla S, Melton LJ III. A Unitary Model for Involutional Osteoporosis:
Estrogen Deficiency Cause both Type I and Type II Osteoporosis in Postmenopausal
Women and Contributes to Bone Loss in Aging Men. J Bone Miner Res 1998;13:763773.
9. Cummings SR, Melton LJ. Epidemiology and Outcomes of Osteoporotic Fractures.
Lancet 2002; 359:1761-1767.
10. Johnell O, Kanis J. Epidemiology of Osteoporotic Fractures. Osteoporos Int. 2005; 16
Suppl. 2: S3-7.
11. Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon
General. Office of the Surgeon General (US). Rockville (MD): 2004.
12. Guggenbuhl P. Osteoporosis in Males and Females: Is There Really a Difference? Joint
Bone Spine 2009;76:595-601.
13. United States Preventive Services Task Force. Screening for Osteoporosis in
Postmenopausal Women: Recommendations and Rationale. Ann Intern Med.
2002;137:526-528.
14. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of Low Femoral Bone Density
in Older U.S. Adults from NHANES III. J Bone Miner Res 1997;12:1761-1768.
22

15. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and Fracture Outcomes of
Undiagnosed low Bone Mineral density in Postmenopausal Women: Results from the
National Osteoporosis Risk Assessment. JAMA 2001;286:2815-2822.
16. Barrett-Connor E, Wehren LE, Siris ES, et al. Osteoporosis and Fracture Risk in Women
of Different Ethnic Groups. J Bone Miner Res 2005;20:185-194.
17. Melton LJ III, Thamer M, Ray NF, et al. Fractures attributable to Osteoporosis: Report
from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:16-23.
18. Lane NE. Epidemiology, Etiology, and Diagnosis of Osteoporosis. Am J Obstetrics and
Gynecology. 2006;194:S3-11.
19. Melton LJ III. Adverse outcomes of osteoporotic fractures in the general population. J
Bone Miner Res 2003;18:1139-1141.
20. Burge R, Dawson-Hughes B, Solomon DH et al. Incidence and Economic Burden of
Osteoporosis-Related Fractures in the United States, 2005-2025. J Bone Miner Res
2007;22:465-475.
21. Gullberg BOJ, Kanis JA. World-wide Projections for Hip Fracture. Osteoporos Int
1997;7:7.
22. American Academy of Orthopedic Surgeons. Hip Fractures. American Academy of
Orthopedic Surgeons. Available at: www.orthoinfo.aaos.org. Accessed April 30, 2010.
23. U.S. Census Bureau. 2008 National Projections of the U.S. Resident Population by Age,
Sex, Race, and Hispanic Origin. U.S. Census Bureau. Available at:
http://www.census.gov. Accessed April 30,2010.
24. Humes K. The Population 65 Years and Older: Aging in America. Demographics. The
Book the States 2005. Pages 464-468. Available at:
http://www.csg.org/knowledgecenter/docs/BOS2005-AgingInAmerica.pdf. Accessed
April 30, 2010.
25. United Nations Department of Economic and Social Affairs Population Division. Major
Developments and Trends in Population Ageing. United Nations, New York. Briefing
Paper. February 7-9, 2007.
26. Levine JP, Pharmacologic and Nonpharmacologic Management of Osteoporosis. Clin
Cornerstone 2006; 8:40-53.
27. WHO Global Report on Falls Prevention in Older Age, World Health Organization.
Available at: www.who.int/ageing/publications/Falls_prevention7March.pdf. Accessed
July 1, 2012.
28. Lawlor DA, Patel R, Ebrahim S. Association between Falls in Elderly Women and
Chronic Diseases and Drug Use: Cross Sectional Study. BMJ 2003;327:712.
23

29. Faulkener KA, Cauley JA, Studenski SA et al. Lifestyle Predicts Falls Independent of
Physical Risk Factors. Osteporos Int 2009;20:2025-2034.
30. Hausdorff JM, Rios DA, Edelber HK. Gait Variability and Fall Risk in Communityliving Older Adults: A 1-Year Prospective Study. Archives of Physical Medicine and
Rehabilitation 2001;82:1050-1056.
31. Alexander BH, Rivara FP, Wolf ME. The Cost and Frequency of Hospitalization for Fallrelated Injuries in Older Adults. Am J Public Health 1992;82:1020-1023.
32. Scuffham P, Chaplin S, Legood R. Incidence and Costs of Unintentional Falls in Older
People in the United Kingdom. J Epidemiol Community Health 2003;57:740-744.
33. Owens PL. (AHRQ), Russo CA (Thomson Reuters), Spector W (AHRQ) and Mutter R
(AHRQ). Emergency department visits for injurious falls among the elderly, 2006. HCUP
Statistical Brief #80. October 2009. Agency for Healthcare Research and Quality,
Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb80.pdf.
34. Rubenstein LZ. Preventing Falls in the Nursing Home. JAMA 1997;278:595-596.
35. Stevens JA, Corso PS, Finkelstein EA, Miller TR. The Costs of Fatal and Non-fatal Falls
among Older Adults. Injury Prevention 2006; 12: 290-295.
36. National Hospital Discharge Survey (NHDS), National Center for Health Statistics.
Available at: www.cdc.gov/nchs/hdi.htm. Accessed July 1, 2012.
37. Aschengrau A, Seage III GR. Essentials of Epidemiology in Public Health. 2nd ed.
Sudbury, MA: Jones and Bartlett Publishers, 2008.
38. Kessenich CR. Nonpharmacological Prevention of Osteoporotic Fractures. Clin Interv
Aging 2007;2:263-266.
39. Rothman KJ, Greenland S. Causation and Causal Inference in Epidemiology. Am J
Public Health 2005;95(Suppl 1):S144-S150.
40. Curtis JR, Taylor AJ, Matthews RS, et al. “Pathologic” Fractures: Should these be
Included in Epidemiologic Studies of Osteoporotic Fractures? Osteoporos Int
2009:20:1969-1972. [Curtis, 2009]
41. Lewiecki EM. Management of Osteoporosis. Clinical and Molecular Allergy 2004;2:9.
42. Centers for Disease Control and Prevention. National Center for Health Statistics. Falls
among Older Adults: An Overview. Available at:
www.cdc.gov/HomeandRecreationalSafety/Falls/adultfalls.html. Accessed July 1, 2012.
43. Jeannette E. Osteoporosis: Part II. Nonpharacologic and PharmacologicTreatment. Am
Fam Physician 2001;63:1121-1128.

24

44. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-2026.
45. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of
Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010.
46. Gehlbach SH, Avrunin JS, Puleo E, Spaeth R. Fracture Risk and Antiresorptive
Medication Use in Older Women in the USA. Osteoporos Int 2007;18:805-810.
47. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010
Recommendations for the Prevention and Treatment of Glucocorticoid-Induced
Osteoporosis. Arthritis Care & Research 2010;62:1515-1526.
48. Crandall CC, Newberry SJ, Gellad WG, et al. Treatment to Prevent Fractures in Men and
Women with Low Bone Mineral Density or Osteoporosis: Update of a 2007 Report.
Comparative Effectiveness Review No. 53. (Prepared by Southern California Evidencebased Practice Center under contract No. HHSA-290-2007-10062-I.) Rockville, MD:
Agency for Healthcare Research and Quality: March 2012.
www.effectivehealthcare.ahrq.gov/reports/final.cfm.
49. Siris ES, Pasquale MK, Wang Y, Watts NB. Estimating Bisphosphonate Use and
Fracture Reduction among US Women Age 45 and Older, 2001-2008. J Bone Miner Res
2010. Doi 10.1002/jbmr.189.2010
50. Harris ST, Reginster J,-Y, Harley C, et al. Risk of Fracture in Women Treated with
Monthly Oral Ibandronate or Weekly Bisphosphonates: The eValuation of Ibandronate
Efficacy (VIBE) Database Fracture Study. Bone 2009;44:758-765.
51. Siris ES, Harris ST, Rosen CJ et al. Adherence to Bisphosphonate Therapy and Fracture
Rates in Osteoporotic Women: Relationship to Vertebral and Nonvertebral Fractures
from 2 U.S. Claims Databases. Mayo Clin Proc 2006;81:1013-1022.
52. Devogelaer J-P. Glucocorticoids-Induced Osteoporosis: Mechanisms and Therapeutic
Approach. Rheum Dis Clin N Am 2006;32:733-757.
53. Katayama K, Matsuno T. Effects of Bisphosphonates on Fracture Incidence and Bone
Metabolism in Rheumatoid Arthritis Patients in General Practice Taking Long-Term
Corticosteroid Therapy. Clin Drug Invest 2008;28:149-158.
54. Newman ED, Matzko CK, Olenginski TP, et al. Glucocorticoid-Induced Osteoporosis
Program (GIOP): A Novel, Comprehensive, and Highly Successful Care Program with
Improved Outcomes at 1 Year. Osteoporos Int 2006;17:1428-1434.
55. Roux C. Potential Effects of Bisphosphonates on Bone Ultrastructure. Osteoporos Int
2009;20:1093-1095.
56. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of Osteocyte and Osteoblast
Apoptosis by Bisphosphonates and Calcitonin. J Clin Invest. 1999;104(10):1363-1374.

25

57. Dunford JE, Thompson K, Coxon FP, et al. Structure-Activity Relationships for
Inhibition of Farnesyl Diphosphate Synthase In vitro and Inhibition of Bone Resorption
In vivo by Nitrogen-Containing Bisphosphonates. J Pharmacol Exp Ther 2001;296:235242.
58. Abdou WA, Shaddy AA. The Development of Bisphosphonates for Therapeutic Uses,
and Bisphosphonate Structure-Activity Consideration. ARKIVOC 2009;5:143-182.
59. Dunford JE, Kwaasi AA, Rogers MJ, et al.Structure-Activity Relationships Among the
Nitrogen Containing Bisphosphonates in Clinical Use and Other Analogues: Time
Dependent Inhibition of Human Farnesyl Pyrophosphate Synthase. J. Med. Chem.
2008;51:2187-2195.
60. Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of Action and Role in
Clinical Practice. Mayo Clin Proc. 2008;83(9): 1032-1045.
61. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and Biochemical Responses to
Intravenous Alendronate in Postmenopausal Osteoporosis. J Bone Miner Res.
1997;12:1700-1707.
62. Bliziotes MM, Eshleman AJ, Zhang XW, et al. Neurotransmitter Action in Osteoblasts:
Expression of a Functional System for Serotonin Receptor Activation and Reuptake.
Bone 2001;29:477-486.
63. Bliziotes M, Eshleman A, Burt-Pichat B, et al. Serotonin Transporter and Receptor
Expression in Osteocytic MLO-Y4 Cells. Bone 2006;39:1313-1321.
64. U.S. Department of Health & Human Services. U.S. Food and Drug Administration Web
site. http://www.accessdata.fda.gov. Accessed November 18, 2010.
65. National Institute of Mental Health (NIMH). Women and Depression: Discovering Hope.
Available at: http://www.nimh.nih.gov. Accessed November 18, 2010.
66. Draper B, Berman K. Tolerability of Selective Serotonin Reuptake Inhibitors. Drugs
Aging 2008;25:501-519.
67. Montano CB. Primary Care Issues Related to the Treatment of Depression in Elderly
Patients. J Clin Psychiatry 1999;60 (suppl 20):7.
68. Soares CN, Poitras JR, Prouty J, et al. Efficacy of Citalopram as a Monotherapy or as an
Adjunctive Treatment to Estrogen Therapy for Perimenopausal and Postmenopausal
Women with Depression and Vasomotor Symptoms. J Clin Psychiatry 2003;64:473-479.
69. Perrot S, Javier RM, Marty M, et al. Antidepressant Use in Painful Rheumatic
Conditions. Rheum Dis Clin North Am. 2008;34:433-453.
70. Yee-Chi L, Phoon-Ping C. A Review of SSRIs and SNRIs in Neuropathic Pain. Expert
Opin. Pharmacother. 2010;11(17):2813-2825.
26

71. Brown CS. Depression and Anxiety Disorders. Obstet. Gynecol. Clin. North Am.
2001;28(2):241-268.
72. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, Placebo-Controlled Trial of Three
Doses of Citalopram for the Treatment of Hot Flashes: NCCTG Trial N05C9. J Clin
Oncol 2010;28:3278-3283.
73. Soares CN, Joffe H, Viguera AC, et al. Paroxetine for Women in Midlife after Hormone
Therapy Discontinuation. Am J Med. 2008;121:159-162.
74. Cubeddu A, Giannini A, Bucci F, et al. Paroxetine Increases Brain-derived Neurotrophic
Factor in Postmenopausal Women. Menopause 2010;17:338-343.
75. Huang AJ, Grady D, Jacoby VL, et al. Persistent Hot Flashes in Older Postmenopausal
Women. Arch Intern Med. 2008;168:840-846.
76. Williams DA and Lemke TL (eds.). Foye’s Principles of Medicinal Chemistry. 5th Ed.
Philadelphia, PA; Lippincott Williams & Wilkins, 2002.
77. Sussman N. Medical Complications of SSRI and SNRI Treatment. Primary Psychiatry
2008; 15:37-41.
78. Ensrud KE, Blackwell TL, Ancoli-Israel S, et al. Use of Selective Serotonin Reuptake
Inhibitors and Sleep Disturbances in Community-dwelling Older Women. J Am Geriatr
Soc 2006;54:1508-1515.
79. Shea MLO, Garfield LD, Teitelbaum S, et al. Serotonin Norepinephrine Reuptake
Inhibitor Therapy in Late-life Depression is Associated with Increased Marker of Bone
Resorption. Osteoporosis Int. 2013: DOI 10.1007/s00198-012-2170-z.
80. Rosenbaum PR, Rubin DB. The Central Role of Propensity Score in Observational
Studies for Causal Effects. Biometrika 1983;70: 41-55.

27

Chapter 2

2.0 LITERATURE REVIEW
2.0.1 Overview
This chapter will provide 1) a brief understanding of the motivation to concomitant drug use and
adverse drug events as a consequence, 2) a detailed literature review of concomitant use of
specific drugs with BPs and potential adverse drug events such as increased risk of fracture, 3)
description of concomitant use of SSRIs with bisphosphonates and increased risk of fracture and
suggested supporting evidence, 4) the description to determine the role of depression versus 5HT in bone health, and 5) pharmacoepidemiologic study design considerations.
2.1 Concomitant Use of Osteoporosis-Inducing Medications with Bisphosphonates and
Increased Risk of Fracture
2.1.1 Introduction
The number of older Americans suffering with multiple chronic health conditions
(multimorbidity)1 is large and growing over time. Estimates have shown that 68.4% of Medicare
beneficiaries have two or more chronic conditions and 36.4% have four or more chronic
conditions. Moreover, these multiple chronic conditions (MCCs) increase with age and are more
prevalent among women than men across all age groups.2 For example, in 2010, in a study of
Medicare fee for service beneficiaries, over 70% of women had two or more chronic conditions
compared with 65% of men.3 The 15 common chronic conditions (and their proportions) that are
available in the 2010 CMS Chronic Condition Warehouse research files include
hypertension/high blood pressure (58%), high cholesterol (45%), ischemic heart disease (31%),
arthritis (29%), diabetes (28%), heart failure (16%), chronic kidney disease (15%), depression
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(14%), chronic obstructive pulmonary disease (12%), Alzheimer’s disease (11%), atrial
fibrillation (8%), cancer (8%), osteoporosis (7%), asthma (5%), and stroke (4%).3 This list
corresponds with a list of chronic conditions used to define MCCs by the Department of Health
and Human Services Strategic Framework on Multiple Conditions.4
With regard to the trend of MCCs, findings from the 1998, 2004, and 2008 waves of the
Health and Retirement Study (a nationally representative survey of older adults over 50 years in
the U.S.) showed that the proportion reporting one or more chronic diseases increased from
86.9% in 1998, to 91.2% in 2004, and 92.2% in 2008.5 Similarly, recent estimates using data
from the National Health Interview Survey found that the percentage of adults aged 45 years and
over with two or more of nine self-reported chronic conditions increased from the 1999/2000
collection period to the 2009/2010. During that 10-year period, the percentage of adults aged 4564 years who had been diagnosed with two or more chronic conditions rose from 16% to 21%,
and rose from 37% to 45% among adults aged 65 years or older.6 The increasing prevalence of
MCCs has significant impact for the aging population. People with MCCs are particularly
vulnerable to suboptimal quality care, have more physician contacts, fill more prescription drugs,
and are more likely to be hospitalized each year than those with only one chronic condition.7,8
Therefore, care management of MCCs requires heightened coordination of complex medical and
longitudinal psychosocial care, and management of prescribed drugs.6
Medication management of MCCs is a challenging task. As the number of chronic
conditions increases, the number of medications prescribed also increases. According to the
National Center for Health Statistics, the percentage of persons who used two or more
prescription drugs (concomitant use) increased from 25% in 1999-2000 to 31% in 2007-2008.9
Women use more prescriptions than men, and this increases with age suggesting that women are
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at a greater likelihood of experiencing an adverse drug event (ADE).10,11 It is important to note,
however, that the association of ADEs and age is a complex issue that can, in part, be explained
by pharmacokinetic and pharmacodynamic changes, patient-specific physiologic and functional
characteristics that occur with aging, and pharmacoeconomics rather than simple chronologic
age.12,13
Medication management of postmenopausal osteoporosis is the particular focus of this
review. Postmenopausal osteoporosis is a result of reduced production of estrogen after
menopause and increases the risk of fracture.14 The National Osteoporosis Foundation reports
that about 80% of the estimated 10 million Americans with osteoporosis are women. In addition,
approximately one in two women age 50 years and older will break a bone because of
osteoporosis.15 Bisphosphonates are widely prescribed16 and recommended by the North
American Menopause Society as first-line pharmacologic treatment in the management of
osteoporosis for postmenopausal women.17 Bisphosphonates are characterized by their affinity
for bone mineral through binding to hydroxyapatite crystals18 and inhibitory effects on
osteoclasts.19
Examples of chronic conditions that can exist in osteoporotic postmenopausal women older
than 50 years of age include diabetes, depression, chronic inflammatory joint disease, chronic
inflammatory bowel disease, and breast cancer. These chronic conditions may increase the
severity of osteoporosis and often affect the management of osteoporosis by increasing the risk
of fracture.20 Other factors include medications such as glucocorticoids (GCs) for the treatment
of chronic inflammatory joint disease. Management of both osteoporosis and chronic
inflammatory joint disease is an example of management for MCCs that requires concomitant
use of medications and could also affect the management of osteoporosis. This is of concern
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because concomitant uses of medications have the potential for clinically important interactions
that may result in ADEs leading to patient harm.
In a study using the 2000-2002 National Ambulatory Medical Care Survey to examine 25
clinically important drug-drug interactions, Aparasu et al. found that patients over 44 years of
age, especially older adults, Medicare beneficiaries, and those prescribed multiple medications,
were at risk of receiving concomitant medications with the potential for a clinically important
drug-drug interaction when compared to patients less than 25 years of age. Moreover, the study
showed that the annualized visit rates involving interacting medications were high among
persons over 64 years vs. less than 64 years, females vs. males, and whites vs. others.
Interestingly, of the examined potentially interacting medications, none of the combinations
included osteoporosis treatment agents such as bisphosphonates.21 The U.S. Department of
Human Services framework to address the population with MCCs highlights that recognizing
drug-drug interactions and potential ADEs from complex medication regimens is one of the
strategies for medication management.22
Drug-drug interactions occur when one therapeutic agent alters the absorption, distribution,
metabolism, and/or excretion of another drug (pharmacokinetic interactions) or the biological
effect of another agent (pharmacodynamic interactions). In the case of pharmacodynamic
interactions, the two drugs act at the same or interrelated receptor sites and may behave in an
additive, synergistic, or antagonistic fashion.23 Pharmacokinetic interactions often occur via the
cytochrome P-450 (CYP450) enzymes, which is the most common pathway for drug-drug
interactions.24 Transporter-based interactions (analogous to drug interactions mediated by P450
enzymes) have also been documented in recent years. Transporters can play a role in drug
absorption, distribution, metabolism (in concert with metabolizing enzymes), and excretion.25
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With regard to osteoporosis treatment agents, Table 2.1 outlines drug-drug interactions
involving BPs and the potential outcomes sourced from the FDA prescribing and labeling
information; however, there is evidence in the literature of additional possible interactions that
are not documented in the product label. For example, within the past 10 years, studies have
suggested that medications associated with increased risk of fracture (see Table 2.2), such as
proton pump inhibitors (PPIs), might attenuate the beneficial effects of BPs when used
concomitantly. Drug-drug interactions between BPs and medications, which result in negative
effect on bone strength leading to increased risk of fracture, have been hypothesized to be a
pharmacodynamic interaction.26 In support of this hypothesis, an explanation follows.

Table 2.1. Bisphosphonate-drug interactions and ADEs from the FDA prescribing and labeling
information.
Bisphosphonate drug
Co-administered drug (s) Outcome
Interference with absorption
Fosamax® (alendronate sodium), Calcium
supplements/Antacids
of drugs
Boniva® (ibandronate sodium),
Actonel® (risedronate sodium)
Fosamax® (alendronate sodium), Aspirin/ Nonsteroidal anti- May worsen gastrointestinal
inflammatory drugs
irritation
Boniva® (ibandronate sodium),
(NSAIDS)
Actonel® (risedronate sodium)
H2 blockers and PPIs
May affect oral
Boniva® (ibandronate sodium),
bioavailability, but
Actonel® (risedronate sodium)
interactions are not considered
to be clinically relevant
Nephrotoxic drugs
Renal failure
Reclast® (zoledronic acid)
Aminoglycosides
May have additive effect to
Reclast® (zoledronic acid)
lower serum calcium for
prolonged periods
Loop diuretics
May increase risk of
Reclast® (zoledronic acid)
hypocalcemia
Pharmacologic actions of bisphosphonates are osteoclast-mediated. Bisphosphonates inhibit
bone resorption by preventing osteoclast recruitment, differentiation and activity, and inducing
osteoclast apoptosis.19 Therefore, suppression of osteoclast bone resorption is the
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pharmacodynamic effect of bisphosphonates. On the other hand, medications associated with
osteoporosis and increased risk of fracture such as GCs and PPIs affect bone by inhibiting
osteoblast differentiation and activity, bone formation, and/or increasing bone resorption.27,28 In
this case, concomitant GC/PPI and bisphosphonate use may increase the risk of
osteoporosis/bone loss through the antagonizing or attenuating effects of GC/PPI on any
beneficial effects of bisphosphonates. The pharmacodynamic interaction of these combinations
would result in attenuation of bisphosphonate effects, hence increasing the risk of fracture for the
patient.
Table 2.2. Medications associated with increased risk of fracture in older people.
Medication class
Generic drug examples
Hydrocortisone, prednisone, dexamethasone
Oral GCs
Letrozole, anastrozole
Aromatase inhibitors
Citalopram, fluoxetine, paroxetine
SSRIs
Esomeprazole, omeprazole, lansoprazole
PPIs (acid suppressive drug).
Rosiglitazone, pioglitazone
Thiazolidinediones
Levothyroxine
Thyroid hormones
Heparin, warfarin
Anticoagulants
Phenobarbital, oxcarbazepine, valproic acid
Anticonvulsants
Lorazepam, triazolam
Benzodiazepines
Olanzapine, quetiapine, risperidone
Atypical antipsychotics
Hydrocodone, oxycodone, morphine
Opioid analgesics
Furosemide, bumetanide
Loop diuretics
Methotrexate
Methotrexate
Although Table 2.2 includes a number of medications associated with osteoporosis
and/or increased risk of fracture in older people, this review focuses only on five selected
medication classes (GCs, PPIs, SSRIs, aromatase inhibitors, and thiazolidinediones) and one
medication (levothyroxine). The rationale for the selection is because there is supportive
evidence in the literature suggesting that the biological mechanisms of these drug effects can
influence bone metabolism and increase the risk of fracture (i.e., have negative effects on normal
bone remodeling process). Medications that were not reviewed are those with poorly understood
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pharmacological actions on bone (e.g., anticonvulsants)29 and/or that the pharmacodynamic
effect of increased risk of fracture may be explained primarily through increased risk of falls
(e.g., anticonvulsants30 and benzodiazepines31). Similar to these drug examples, it is worth
mentioning that the association between SSRIs and increased risk of fractures can be fall-related,
for example through sedating effects of SSRIs.32 However, SSRIs have been included for review
because there is sufficient evidence that the biological mechanisms of these drug effects can
influence drug metabolism. We review the literature and outline the results of the clinical
outcomes of concomitant use of these agents with BPs and increased risk of fracture through
potential attenuation of BPs. Furthermore, we summarize the pharmacology of these agents and
potential harm on the bone and suggest future areas of research.
2.1.2 Literature search strategy
We performed a Medline search for articles published from January 2003 to January 2013. The
following medical subject headings (MeSH) terms were used: bisphosphonates (formerly termed
diphosphonates) OR bone density conservation agents OR glucocorticoids OR acid-suppressive
drugs/proton pump inhibitors OR levothyroxine OR thiazolidinediones OR aromatase inhibitors
OR selective serotonin uptake inhibitors AND bone fractures. CINAHL and PsychINFO
databases were also searched for any additional relevant publications. The abstracts of all
potential articles were reviewed for relevancy. Other references were obtained from citations
from retrieved articles. Studies were included if they specifically reported results of concomitant
use of any of these medications with bisphosphonates and risk of fractures, focused on women,
and were published in the English language. Articles that focused generally on use of one of the
listed medications and fractures without particular emphasis on use with bisphosphonates and
potential antifracture efficacy or attenuation of bisphosphonates were excluded. There were no
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studies of concurrent use in the literature to review thiazolidinediones, aromatase inhibitors, and
SSRIs and therefore studies suitable for conducting this review only focused on acid-suppressive
drugs, GCs, and levothyrozine. Following is a review of these medications in more detail.
2.1.2.1 Proton pump inhibitors
Acid-suppressive drugs, such as PPIs, may be associated with increased risk of fractures.
In a pooled analysis of PPI use, Kwok et al. showed significant risk for spine fractures (4 studies,
OR:1.50; 95% CI, 1.32-1.72) and hip fractures (10 studies, OR:1.23; 95% CI, 1.11-1.36). Where
duration of follow up was reported, this ranged from a median of 6.5 weeks to a mean of 7.8
years. Longer duration of exposure (typically >3 years, pooled result of 6 studies) was associated
with higher increased risk of fracture (OR:1.40; 95% CI, 1.14-1.72) when compared with the
increased risk of fracture (OR:1.23; 95% CI, 1.19-1.27) at shorter duration of exposure (<12
months, pooled result of 5 studies).33 PPIs are the most effective pharmacological option for
managing gastrointestinal disorders such as gastroesophageal reflux disease (GERD).34 BP drugs
have been shown to cause upper gastrointestinal adverse events such as GERD,35 thus resulting
in the concomitant use of BPs and PPIs. Concomitant use of PPIs with BPs may increase the risk
of fracture by reducing the antifracture efficacy of bisphosphonates. With regard to this
hypothesis, three studies were identified.
De Vries et al. conducted a retrospective cohort study using the UK General Practice
Research Database in patients who started either acid-suppressive medication (PPIs or H2
receptor blockers) or BP therapy (alendronate, risedronate, ibandronate, or etidronate) between
1988 and 2007. The primary objective was to assess the association between concomitant use of
BPs and acid suppressants and attenuated fracture risk in patients aged 40 years and older.
Concomitant use of acid suppressants was defined as a prescription within 6 months before start
35

of 3 month-long BP episodes. The periods of follow-up (defined from the first BP or acidsuppressive medication prescription) was divided into periods of current (the period from the
prescribing date up to 91 days after the estimated end of the prescription) and past exposure for
BPs and acid suppressive medication. In the BP cohort, the findings indicated a significant
association between current concomitant use of H2 receptor blockers and BPs and risk of
vertebral fracture (ARR: 1.56; 95% CI, 1.24-1.96); concomitant use of PPIs and BPs and
increased risk of any fracture (ARR:1.08; 95% CI, 1.01-1.16) and hip fracture (ARR:1.24; 95%
CI, 1.08-1.42), when compared with current users of BP alone (i.e., patients who never used acid
suppressants or who stopped taking acid suppressants for at least 6 months before the start of the
BPs). Further investigations on these data showed that the risk of fracture was observed to be
dose-dependent with fracture risk increasing as daily dose increased. The authors concluded that
these findings suggest that BP use does not counteract the increased risk of fracture seen with
acid-suppressive medication use.36
In a cohort study using Danish national health care data from 38,088 people from 1996 to
2005, Abrahamsen et al. found that concomitant PPI use with alendronate was associated with a
dose-dependent attenuation of risk reduction against hip fracture in patients aged 70 years and
older. Based on theoretically complete (100%) refill compliance, the risk reduction in PPI users
was not significant (19%; HR: 0.81; 95% CI, 0.64-1.01), but there was a 39% risk reduction
(HR: 0.61; 95% CI, 0.52-0.71) in patients who were not PPI users. The attenuation of the risk
reduction depended on the cumulative PPI dose. A cumulative PPI dose of 1 to 359 defined daily
doses (DDDs) had no impact on the treatment response at the hip, but the authors demonstrated
no risk reduction with alendronate in patients exposed to more than 360 DDDs of a PPI. No
such effects were observed with concomitant histamine H2 receptor blockers.37 A previous case-
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control study also showed that PPIs (calculated as cumulative DDDs) were found to be
associated with an increase in fracture risk while H2 receptor blockers were not, but the reasons
were unclear.38 Both H2 receptor blockers and PPIs are potent antisecretory agents39 and this
would seem to suggest that acid suppression is not the mechanism for the effects on bone. Yang
et al. have proposed that the increased risk associated with PPIs may be linked to a decreased in
calcium absorption.28
In contrast to the preceding studies, Roux et al. found that concomitant PPI use did not
demonstrate canceling effects of anti-fracture efficacy of BPs. This study was a recent post hoc
analysis of a subset of patients who had participated in three prospective, randomized, placebocontrolled clinical trials (Vertebral Efficacy with Risedronate Trial-MultiNational, Vertebral
Efficacy with Risedronate Trial-North America, and the risedronate Hip Intervention Program)
with durations of up to 3 years. In this post hoc analysis, it was found that concomitant PPI use
with risedronate was not associated with incident vertebral fractures, when compared to PPI nonusers. The vertebral fracture rate was similar among PPI users (16.1%) and PPI non-users
(16.9%). Overall findings from this study showed that risedronate reduced fracture risk of new
vertebral fractures in PPI users (RR:0.43; 95% CI,0.23-0.81) and PPI non-users (RR:0.62; 95%
CI, 0.52-0.73).40
The evidence on concomitant use of PPIs and bisphosphonates and antifracture efficacy
of bisphosphonates is conflicting. Two cohort studies indicated a significant antifracture efficacy
of bisphosphonates with concomitant PPIs and bisphosphonates use, but the randomized clinical
trial (RCT) did not indicate significant association. Although the cohort studies were of good
quality (e.g., sample size, generalizability of the databases, and follow-up periods long enough to
capture the outcomes being evaluated) and controlled for measurable confounders, the studies
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are subject to selection bias making it difficult to determine if the attenuation of BPs are because
of PPIs or some source of bias. On the other hand, the RCT by Roux et al. may reflect a true
causal-relationship of non-significant attenuation of BPs due to PPIs because they eliminate
selection bias.41 From an methodological standpoint, RCTs are superior to observational studies,
such as cohort studies, and are thus considered a gold standard for determining causal
relationships.42 This is because in observational studies participants are not randomized to a
treatment or control group, but differences in outcomes (between participants with varying
characteristics) are observed after treatment decisions. In contrast, in RCTs, participants are
randomly assigned to a treatment or control group, thus participants under study are expected to
have the same characteristics. Findings from the RCT above would be considered “stronger”
than findings from the two cohort studies. However, two important concerns about this particular
RCT are noted. First, the trials included relatively healthy postmenopausal women with
osteoporosis or radiographically identified vertebral fractures and had no recent use of drugs
known to affect bone (e.g., BPs), and had no major illness. Applying these exclusion and
inclusion criteria limits the generalizability of the findings from RCT populations as they are not
representative of broader populations included in observational studies. Second, the Roux et al.
study was a post hoc analysis of a subset of patients who had participated in prospective RCTs.
The initial hypothesis in these RCTs was not PPI effects on bisphosphonates. In such case one
could argue that all of the methodological benefits of an RCT do not necessarily apply. Both of
these reasons could explain why the RCT and the two cohort studies did not arrive at the same
conclusions. Given this conflicting evidence and the methodological challenges, it is premature
to conclude one way or the other based on these few studies. Additional well-designed studies
are needed to help determine valid conclusions.
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2.1.2.2 Glucocorticoids
Glucocorticoids (GC) (also called corticosteroids) used in the management of many
inflammatory conditions are considered the most prevalent secondary risk factor for
osteoporosis.43 Van Staa et al. in a prospective study using data from two large, prospective,
randomized, controlled trials, showed that postmenopausal oral GC users have considerably
higher fracture risk compared to nonusers (adjusted RR:5.67; 95% CI, 2.57-12.54) at similar
baseline levels of bone mineral density (BMD).44 Chronic treatment with GC in postmenopausal
women can independently result in significant reduction in BMD.45
In a population-based, case-control study using a hospital discharge registry in Denmark,
Vestergaard et al. found an association between cumulative GC use (more than an average dose
of approximately 71 mcg prednisolone per day) and increased risk of hip fracture compared with
never users.46 Using the same database in a large community-based sample in Denmark,
Vestergaard et al. later conducted a case-control study to examine the risk of fractures in subjects
exposed to systemic and topical GCs and found an increased risk of fracture among oral GC
users at dosages higher than 2.5 mg prednisolone equivalents per day (adjusted OR:1.15; 95%
CI, 1.09-1.22 for dosages of 2.5-7.49 mg/day, and adjusted OR:1.59; 95% CI, 1.49-1.70 for
dosages of ≥7.5 mg/day).47 Manuel et al. conducted a cross-sectional study of 513 men and
women in Spain and found that the use of oral GCs over a 3-month period at doses higher than
7.5 mg/day of prednisone or equivalent was associated with risk of non-vertebral fractures (a
prevalence of 28.3%).48 In a case-control study using patients within the Dutch PHARMO-RLS
database, De Vries et al. found that current use of oral GCs was associated with an increased risk
of hip/femur fracture (adjusted OR:1.43; 95% CI, 1.22-1.67) in patients 50 years and older,
especially at higher daily dosages.49
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It is evident that oral GCs used for a longer duration are associated with increased risk of
fracture and the risk is dose dependent. Bisphosphonates are recommended as first-line therapy
in these patients.50 This is in agreement with the current guidelines and recommendations
developed by the American College of Rheumatology. In addition, the American College of
Rheumatology recommends calcium and vitamin D supplementation counseling for all patients
beginning GC therapy.51 Bisphosphonates have been shown to be beneficial in medicationinduced osteoporosis such as in long term users of oral GCs43,52 and in those supplemented with
vitamin D and calcium.53 Maintenance of sufficient calcium and vitamin D is needed for optimal
benefits of bisphosphonates.54
Concomitant use of GCs with BPs has been reported. A recent descriptive study using the
1999-2008 U.S. National Health and Nutrition Examination Survey found that the prevalence of
GC use in the U.S. general population 20 years and older is 1.2% (95% CI, 1.1-1.4),
corresponding to 2,513,259 persons, but the prevalence rate increases with age. Women (53.3%,
95% CI, 47.2-59.4) represented a larger proportion of oral GC users than men. Oral GC users
reported concomitant use of BPs (8.6%), hormone replacement therapy (5.9%), calcium (22.7%),
vitamin D (18.5%), and other medications (37.9%). Women reported greater concomitant use of
all antiosteoporosis pharmaceutical interventions.55 Despite the current recommendations for BPs
use in GC-induced osteoporosis and the prevalent concomitant use, the potential for GCs to
attenuate the effects of BPs and any resulting increased risk of fracture remains unclear in the
literature.
A review of case series and case reports conducted by a taskforce of the American
Society for Bone Mineral Research to assess reports of atypical femoral fractures in patients
receiving long-term BPs suggests that concomitant use of medications such as GCs might be an
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important risk factor for these atypical femoral fractures. The taskforce recommended that
assessment of concomitant use of GCs is one of the key areas for the evidence when evaluating
the long-term use of BPs and atypical femoral fractures.56,57 Similarly, Giusti et al. conducted a
systematic literature review of postmenopausal women treated with BPs who sustained
subtrochanteric/diaphyseal fractures and found that concomitant use of GC therapy might be an
important risk factor.58 Evidence from case series and reports may constitute only a small
percentage of the total number of cases that exist. Larger studies have yet to be conducted to
examine this potential attenuating effect of GC on BPs and increased risk of fracture.
Considering that oral GCs are widely accepted risk factors for fracture, it is not our
intention to suggest that large studies on oral GCs and their contribution to the increased risk of
fracture are lacking in the current literature; however, through our review we found that none of
the large studies we identified and reviewed that demonstrate strength of association between
oral GCs and fractures investigated an interaction with bisphosphonates. In other words,
concomitant use of oral GCs and bisphosphonates was not investigated as an independent risk
factor. Instead, bisphosphonate use was either not assessed at baseline44,47-49 or was only adjusted
for as a potential confounder.46
2.1.2.3 Levothyroxine
The prevalence of thyroid diseases (i.e., hyperthyroidism and hypothyroidism) increase
with age and is more common among older women than men. Women are five times more likely
than men to have thyroid problems.(www.thyroid.org) A recent review of studies from Europe,
Japan, and the U.S. shows that the prevalence ranges between 0.6 and 12 per 1000 in women and
between 1.3 and 4.0 per 1000 in men.59 Levothyroxine (LT4) replacement therapy is the
treatment of choice for hypothyroidism in postmenopausal women. The goal of LT4 treatment is
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to normalize serum thyroid stimulating hormone (TSH) values.60 Both hyperthyroidism, defined
as suppressed TSH, and suppressive T4 treatment are associated with a reduction in BMD and an
increased risk of fracture in postmenopausal women and in men aged 50 years and older.61 It is
worth noting that the effects of thyroid hormone on bone are related to the dose. Excess thyroid
hormone increases the risk of fracture, therefore it is recommended that the lowest possible dose
of thyroid hormone be used to correct the medical problem being addressed.62 The patient fact
sheet provided by the American College of Rheumatology also recognizes excess thyroid
hormone replacement in those taking medications for low thyroid or hypothyroidism as an
important risk factor for osteoporosis. One of the steps suggested to prevent, treat, or manage
osteoporosis and/or increased risk of fracture is to use bisphosphonates.63 The important
question, however, is whether anti-fracture efficacy of BPs can be counteracted when
levothyroxine is given concomitantly with BPs. Two relevant articles were available in the
current literature for review.
Panico et al. conducted a prospective cohort study involving seventy four
postmenopausal women aged 52-65 years with low BMD (T-score ≤ -2.5) and thyroid carcinoma
using long-term LT4 therapy (3-9 years) versus non-users. Effectiveness of alendronate on BMD
in this study was observed to be worsened as the duration of LT4 treatment increased when
measured at 12 and 24 months.64 Specifically, changes in BMD were significantly less in
alendronate-treated osteoporotic women who had been on TSH-suppression therapy for 9 years
than those receiving therapy for 3 years or those who had not been taking LT4 (i.e., controls).
Patients treated for 3 years showed an increase of BMD at the lumbar level by 7.88%, those
treated for 6 years by 4.63%, and those treated for 9 years by 0.86% from their baseline BMD
measurements. Similarly, the increase of BMD at the femoral level was 4.62% in those treated
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for 3 years, 3.01% in those treated for 6 years, and 0.95% in those treated for 9 years.64 In the
control group (women who had not been taking LT4 and were treated with BPs) BMD increased
8.2%. These findings suggest that LT4 may have attenuated the beneficial effects of alendronate
and potentially other BPs when the two agents are co-administered.
Turner et al. conducted a nested case-control study consisting of 213,511 adults aged 70
and over prescribed LT4 between April 2002 and March 2007 and followed them for fractures
until March 2008. Descriptive results showed that a total of 22,236 (10.4%) people sustained at
least one fracture and of these cases 20,514 (92.3%) were current users of LT4 at the index date
(the date of admission to hospital for the first fracture). Of particular interest, the authors
reported that cases were more likely than controls to have a diagnosis of osteoporosis (27% vs.
22%) and to use BP (28% vs. 23%). Despite this, the association between concomitant LT4 and
BP use and increased risk of fracture was not examined. Bisphosphonate use was adjusted for as
a potential confounder. Nevertheless, when the association between LT4 and increased risk of
fracture was examined, current use (if the duration of their prescription encompassed the index
date) of LT4 when compared with remote use (if the prescription ended more than 180 days
before the index date) was associated with a higher risk of fracture in women (adjusted OR:1.98;
CI, 1.80-2.19) than men (adjusted OR:1.42; CI, 1.15-1.76). Among current users, high
cumulative doses of LT4 (>0.093 mg/day) were associated with an increased risk of fractures
(adjusted OR:3.45; CI, 3.27-3.65) compared with low doses (<0.044 mg/day).65

2.2 Selected medications and pharmacology on bone
The mechanisms of action of medications associated with increased risk of fracture are
via their impact on osteoblasts and osteoclasts. These effects have an overall influence on the
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balance of the bone remodeling process. As pointed out in this review, there is some clinically
significant evidence in the literature suggesting possible attenuating effects of PPIs, oral GCs, or
LT4 on BPs. This interaction might also be clinically significant between SSRIs, aromatase
inhibitors, or thiazolidinediones and BPs. Currently there is a lack of evidence in the literature on
these latter medications with regard to these potential interactions. To provide insight into the
potentially similar pharmacodynamic interaction of attenuation of BPs and increased risk of
fractures when these medications are co-administered with BPs, we briefly outline the proposed
mechanisms of action on bone for PPIs, GCs, LT4, SSRIs, aromatase inhibitors, and
thiazolidinediones in Table 2.3.
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Table 2.3. Medications likely to be prescribed concomitantly with bisphosphonates that can influence
bone metabolism and increase the risk of fracture.
Medication type
Proposed mechanism
Reference
Gastric acid suppression can result in hypergastrinemia and
Yang Y-X, et al.
PPIs
may cause malabsorption of calcium and vitamin B12.
2010.28
2+
Decreased calcium absorption leads to decreased plasma Ca
concentration leading to elevated levels of parathyroid
hormone, followed by increased bone resorption, decreased
volumetric BMD, and consequently decreased bone strength.
Vitamin B12 is involved in osteoblast activity and bone
formation. Deficiency of vitamin B12 can result in a sequence
of events which includes decreased osteoblastic activity,
decreased bone formation, and decreased volumetric BMD
that finally results in decreased bone strength. Another
potential pathway to decreased bone strength is that
deficiency of Vitamin B12 can induce homocysteinemia by
interfering with collagen cross-linking. Decreased bone
strength leads to increased risk of fracture.
Rauch, et al.,
The GC effect is mediated via the GR. GR is present in
GCs
2010.27
osteoblasts and is required for inhibition of bone formation
and, consequently, bone loss. Suppression of osteoblast
differentiation and inhibition of bone formation may be
central to the association between GC and increased risk of
fractures.
Physiological variation in normal thyroid status is related to
Murphy et al.
LT4
BMD, with hyperthyroid status resulting in decreased BMD
2010.66
(increased bone resorption), and leading to increased risk of
fractures.
Bliziotes et al.
Osteocytes and osteoblasts possess a functional 5-HT signal
SSRIs
transduction mechanism (5-HT receptors and the 5-HTT) for 2001, Takeda et al.
both responding to and regulating the uptake of serotonin. 5- 2002, Karsenty
HT uses one predominant receptor, Htr1b, to affect osteoblast 2006.67-69
biology. Brain-derived high levels of 5-HT binds to 5-HT
receptors on osteoblasts which in turn negatively controls
osteoblast proliferation via molecular clock Cyclin (Cyc D1)
gene cascade leading to decreased bone formation. The
binding of 5-HT also positively regulates bone resorption via
activation of a protein kinase A/ATF4-dependent pathway,
leading to increased synthesis of RANKL, an activator of
osteoclast differentiation and function.

45

Table 2.3. …..CONTINUED
Medication type
Aromatase
inhibitors (AIs)

Proposed mechanism
Reference
AIs act by blocking the peripheral conversion of estrogen
Gaillard et al.
from androgen precursors and thus lowering tissue and
2011.70
circulating estrogen levels. Estrogen deficiency leads to the
development of osteoporosis and increased risk of fracture.
Estrogen receptors and aromatase are both expressed in
bone. Normally, estrogen has suppressive, antiresorptive
effects on osteoclasts during remodeling by stimulating the
expression of antiresorptive factors such as osteoprotegerin.
This results in the attenuation of RANK and RANKL
signaling, leading to inhibition of osteoclastogenesis and
decreased bone resorption. Therefore, the presence of AIs
leads to estrogen deficiency, which in turn leads to increased
synthesis of RANKL.
Bruedigam et al.
Thiazolidinediones Users of TZDs are at increased risk of low BMD and
fractures which result from bone marrow AG. Bone marrow 2010.71
(TZDs)
AG is stimulated from the switch of mesenchymal stem cells
into the fat lineage via activation of PPAR-γ and this leads
indirectly to suppression of osteogenesis. TZD-mediated
activation of PPAR-γ accelerates osteoblast differentiation
and is ultimately followed by increased osteoblast apoptosis.
This concept builds the molecular basis for clinically
observed bone marrow AG, diminished bone formation, and
increased fracture rate in TZD-treated patients.
Abbreviations: GR, glucocorticoid receptor; 5-HT, serotonin; 5-HTT, serotonin transporters; ATF4, activation transcription factor protein 4; RANKL, receptor activator of nuclear factor kappa B
ligand; RANK, nuclear factor kappa B receptor; AG, adipogenesis; PPAR-γ, peroxisome proliferatoractivated receptor γ.

2.3 Conclusions and recommendations
Available literature suggests that concomitant PPIs, GCs, or LT4 with BPs could lead to
increased risk of fracture through the attenuation of beneficial effects of BPs. This attenuation
could be because of the negative/antagonistic pharmacodynamic interaction. Although we did
not find sufficient evidence in the literature to suggest that SSRIs, AIs, or TZDs might attenuate
the effects of BPs when given concomitantly, we hypothesize the possibility of this phenomenon.
Potentially, there may be a common underlying mechanism for attenuation effects. What these
drugs have in common is that they result in bone loss and increased risk of fracture via inhibition

46

of osteoblastic activity and bone formation and/or increased bone resorption caused by increased
osteoclast differentiation and function. This similarity of negative effects on bone might suggest
analogous evidence (and may have a biologic rationale) to demonstrate a potentially clinically
important association between concomitant use of SSRIs, AIs, or TZDs with BPs and attenuation
of antifracture effects of BPs.
The Bradford Hill criterion of analogy72 can be useful in evaluating causal associations in
pharmacoepidemiology.73 The criteria may be applied in this situation because all the listed
medications in Table 2.3 have similar pharmacological actions on bone and are associated with
increased risk of bone loss and fracture in patients. Therefore, given the analogy to
pharmacological actions of drugs such as PPIs, it is plausible to suppose that the phenomenon of
attenuation of BPs might exist among concomitant users of medications associated with
increased risk of fracture with BPs for the treatment of postmenopausal osteoporosis. This is an
important drug safety issue concerning prescribing and use of BPs that has not been addressed in
clinical guidelines commonly used by clinicians.
Recommendations developed in the current Clinician’s Guide to Prevention and
Treatment of Osteoporosis on the drug safety issues of BPs include side effects of BPs (e.g.,
atrial fibrillation), contraindications in certain patients, osteonecrosis of the jaw, and atypical
femoral fractures associated with long-term use of bisphosphonates.74 Furthermore, currently
there are no ongoing or documented safety review reports of concomitant use of PPIs, GCs,
TZDs, AIs, SSRIs, or LT4 with BPs and potential increased risk of fracture by the FDA. With
this gap in the current clinical guidelines, and lack of ongoing drug safety reviews by the FDA
regarding the concomitant use of BPs with any of the aforementioned drugs, it calls for more
research to investigate this hypothesis by conducting pharmacoepidemiologic studies to
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investigate which pharmacodynamic interactions might be clinically important and have the
potential for harm on the bone, and if necessary, prompt further prospective pharmacodynamic
studies of these drug combinations. These future research efforts add to prescribers’ knowledge
of potential safety issues during the process of medication management of MCCs, especially,
comorbid osteoporosis. This current study focuses on concomitant use of SSRIs or SNRIs with
BPs and increased risk of fracture. This phenomenon has not been reported yet.
2.4 SSRIs Use and Icreased Risk of Fractures in Postmeopausal Women
2.4.1 Literature review results
A number of prospective studies and studies based on administrative databases have
demonstrated the association between SSRIs use and increased risk of fracture, especially among
postmenopausal women. The results are discussed as follows.
In a large United Kingdom (UK) case-control and case series study using data from the UK
General Practice Research Database involving 16,341 cases, 79% women of mean age 79 years
old with a recorded diagnosis of hip fracture or fractured neck of femur, analysis of the data
showed a strong association of prior SSRI exposure and hip fracture (OR=1.42; 95% CI 1.281.58). However, the authors noted that the results were probably overestimated because of
selection and indication bias. The case-series design ascertained the true adverse impact of
antidepressants on hip fracture risk through removing the influence of factors that varied
between individuals, such as frailty and severity of depression.75
Bolton et al. performed a case-control study involving 15,792 cases (70.3% females) of
persons aged 50 years and older using a population based administrative health data in Canada
aimed at determining the effects of individual psychotropic medications (SSRIs, other
monoamine antidepressants, lithium, typical antipsychotics, atypical antipsychotics, or
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benzodiazepines) and increased risk of osteoporotic fractures. The findings showed that of the
current psychotropic medications used, SSRIs had the strongest positive association with
fractures (OR=1.45; 95% CI 1.32-1.59; p<0.01) in a multivariable model and showed a
significant trend of increasing fracture with increasing dose.76 These two studies based on
administrative database are in agreement with other prospective studies.
Ensrud and colleagues77 conducted a prospective Study of Osteoporotic Fractures from
August 4, 1992 to July 31, 1994 involving 9,704 women 65 years and older who were CNS
active medication users. Among the antidepressant users, 103 (21%) were SSRIs users
(fluoxetine, paroxetine, and sertraline). Findings from the study showed women using SSRIs had
moderate increased risk of hip fracture (multivariable HR= 1.54; 95% CI, 0.62-3.82) compared
with central nervous system (CNS) medication nonusers. However, the results were not
statistically significant38 possibly because of the small sample size.
Diem et al.78 in a prospective Study of Osteoporotic Fractures involving 9,704 women aged
65 years and older (of whom 198 [7.3%] were SSRI users), found that women taking SSRIs
experienced a higher age-adjusted rate of bone loss at the total hip than nonusers (-0.77% vs 0.49% per year; p=0.005) and the results were not significantly altered in a multivariable model.
Overall, the authors concluded that at any of the sites (hip, femoral neck, or trochanter), the
adjusted rate of bone loss among SSRI users was at least 1.6-fold higher than that among
nonusers of antidepressants.78
Similar results by Williams et al. in a retrospective cohort study have been reported. The
study aimed at investigating the effect of SSRIs use on BMD among older women with a lifetime
history of depressive disorder. The results showed that BMD among SSRIs users was 5.6%
lower at the femoral neck (p=0.03), 6.2% lower at the trochanter (p=0.04), and 4.4% lower at the
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mid-forearm (p=0.03) sites compared with nonusers.79 Loss of BMD has been associated with
increased risk of hip and spine fracture incidence in postmenopausal women.80
Richards et al.81 found that postmenopausal women on SSRIs exhibited bone loss and had a
two-fold increase in the risk of fragility fracture. The study involved a prospective cohort of
5008 community-dwelling adults 50 years and older aimed at investigating the effect of daily
SSRI use on the incidence of clinical fragility fracture. Daily SSRI use was associated with
increased risk of fragility fracture (adjusted hazard ratio [HR], 2.1; 95% CI 1.3-3.4). A dose
effect of SSRIs on clinical fragility fracture was also noted (HR, 1.5; 95% CI 1.1-2.1). The
clinically relevant sites were 40% forearm, 21% ankle and foot, 13% hip, 13% rib, 9% femur,
and 4% back. Furthermore, daily SSRI users demonstrated decreased fracture-free survival
compared with nonusers.81
Spangler et al. in a prospective cohort study of 93,676 postmenopausal women, found that
compared with women using other types of antidepressants, women using SSRIs had increased
adjusted risk of any fracture (HR=1.30; 95% CI 1.20-1.41), clinical spine (HR=1.25;95% CI
0.96-1.63), wrist (HR=1.29; 95% CI 1.07-1.56), and fractures at other sites (HR=1.32;95% CI
1.21-1.45). Statistical significance was not achieved at the hip (HR=1.33; 95% CI 0.95-1.86).
Also, it can be seen that the confidence intervals for clinical spine included 1.0, but the authors
did not mention whether this was an issue for their findings. This was probably because
antidepressants were associated with increased risk of clinical spine fracture (HR=1.36; 95% CI
1.14-1.63) and the study was primarily looking at antidepressant use or depressive symptoms as
primary exposures.82
Diem et al.83 in a recent study based on a 10-year follow-up medication-use data involving
the same population of 9,704 women aged 65 years and older recruited in the prospective Study
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of Osteoporotic Fractures, showed that of these women 2,809 experienced an incident nonspine
fracture over the follow-up period, including 936 with a hip fracture and 582 with a wrist
fracture. Women taking SSRIs experienced a higher age-adjusted risk of nonspine fracture
compared with nonusers (HR=1.36, 95% CI 1.11-1.67) and was not substantially altered after
adjusting for other covariates (HR=1.38, 95% CI 1.10-1.72) in a multivariable model. The risk of
wrist fracture was HR=1.54 (95% CI 1.01-2.36) for SSRIs users compared with nonusers. The
risk of hip fracture was close to 1.0 (HR=1.01, 95% CI 0.71-1.44) for SSRIs users compared
with nonusers secondary to potential confounding factors.83
The results provided above are from single studies. In order to provide reliable and a more
generalizable summary of the results, meta-analysis becomes useful for reviewing and
combining research results. Meta-analyses keeps researchers from relying on the results of a
single study in attempting to understand a phenomenon. Thus, meta-analysis helps us to see the
similarities and differences among the methodologies and the results of multiple studies.84 It is in
this effort that studies aimed at understanding the phenomenon of SSRIs and fracture risk have
demonstrated more reliable evidence though meta-analysis. Summary of the results of the three
most recent meta-analyses are presented as follows.
The Wu et al. results showed that overall, SSRIs use was associated with a significantly
increased risk of fracture (RR=1.72;95% CI, 1.51-1.95, p<0.001).85 Eom et al. in a meta-analysis
based on 12-observational studies showed that the overall risk of fracture was higher among
people using SSRIs (adjusted OR=1.69, 95% CI 1.51-1.90).86 Rabenda et al., based on a total of
34 studies, found that use of SSRIs showed systematically a higher increase in the risk of
fractures of all types, non-vertebral, and hip fractures than studies investigating TCA use.87
Clearly, evidence from the meta-analyses adds more weight to the literature from single studies
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discussed in this section. To the best of our knowledge, based on this evidence, we can conclude
that indeed SSRIs may be associated with increased risk of fracture.
2.5 Serotonin System and Bone Health and Potential Attenuating Effects of SSRIs
on Bisphosphonates
2.5.1

Serotonin and bone health

The link between SSRIs and bone health is based on the adverse effects of 5-HT on the
bone remodeling process. The bone is comprised of bone cells, an organic matrix of collagen and
noncollagenous proteins (osteoid), and inorganic mineral matrix. Of particular interest in this
study is that bone cells (i.e., osteocytes, osteoblasts, and osteoclasts) possess a functional 5-HT
signal transduction mechanism (5-HT receptors and the 5-HTT) for both responding to and
regulating the uptake of 5-HT.67,88
Preclinical in vitro and in vivo studies support the potential for direct skeletal effects of
SSRIs through 5-HTT inhibition.89 In an earlier study by Warden and colleagues, the authors
showed that inhibition of 5-HTT has significant detrimental effects on bone mineral accrual in
the mouse skeleton. This study aimed to investigate the impact of 5-HTT inhibition on bone
mineral accrual in the growing mouse skeleton. The study was achieved by assessing: 1) mice
with a null mutation in the gene encoding for the 5-HTT, and 2) normal growing mice treated
with a SSRI. The findings showed that the null mutation of the gene encoding for 5-HTT
resulted in a consistent skeletal phenotype of reduced mass, altered architecture, and inferior
mechanical properties. Moreover, inhibition of 5-HTT using SSRI resulted in reduced bone
mineral accrual during growth.90
Similar findings on the effects of SSRI on mouse skeleton were later reported in another
study by Warden and colleagues. The study involved adult female mice. Findings showed that
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daily introduction of fluoxetine hydrochloride 5 and 20 mg/kg/d, equivalent with the standard
(20 mg/d) and maximum (40-80 mg/d) recommended fluoxetine doses used to treat depression in
humans, for four weeks reduced gains in lower extremity and vertebral BMD and negatively
altered trabecular architecture within both the distal femur and L5 vertebra, independent of
estrogen deficiency. The authors further suggested that these findings might support clinical data
demonstrating SSRI use to be associated with decreased bone loss after menopause.91 Further
studies have demonstrated that the negative skeletal effects associated with pharmacological 5HTT inhibition are independent of drug effects on animal physical activity levels and not
supposedly altered skeletal loading.92 Although there are still inconsistencies between some
reported animal studies, most animal studies have reported convincing data to demonstrate
skeletal effects of SSRIs.93
Since 5-HTT is a transporter, 5-HT needs to be present locally within the skeleton for the
5-HTT to influence bone cell activity.89 5-HT acts through binding on the 5-HT receptors. There
are 14 genetically, pharmacologically, and functionally distinct 5-HT receptors belonging to
seven families termed 5-HT1 through 5-HT7. 5-HT receptors belong to the G-protein coupled
receptor (GPCR) family, with the exception of the 5-HT3 receptor, which is a ligand-gated ion
channel.94 A number of these receptors have been located in bone cells. Three serotonin
receptors: 5-Htr1b, 5-Htr2a, and 5-Htr2b, are expressed in osteoblasts.88
In a study by Westbroek et al., the presence of 5-Htrb receptors was reported in fetal
chicken bone tissue and isolated bone cells (i.e., osteocytes, osteoblasts, and periosteal
fibroblasts [a population containing osteoblast precursor cells]).95 It has been demonstrated that
5-HT via 5-Htrb receptors is a peripheral modulator of osteoblast recruitment in bone formation
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in aging mice.96 These studies suggest that 5-HT and 5-HTT may be involved in bone
metabolism and the potential consequences on bone health.
5-HT uses one predominant receptor Htr1b, to affect osteoblast biology. In gut-derived 5HT on osteoblasts, binding of 5-HT to 5-Htr1b, which is linked to the Gαi protein, inhibits
adenylyl cyclase which in turn inhibits second-messenger cAMP production and protein kinase
A (PKA)-mediated cAMP response element-binding (CREB) phosphorylation. Most of the
actions of cyclic AMP are carried out by protein kinase A, which phosphorylates specific sites on
downstream effector processes. This process leads to decreased expression of Cyclin (Cyc D1)
genes and decreased osteoblast proliferation. As a result, bone formation is slowed down.68 In
other words, higher 5-HT levels secondary to inhibition of 5-HTT by SSRI, contributes to the
decrease in bone formation.
In brain-derived 5-HT on osteoblast, serotonergic neurons of the dorsal raphe signal to
ventromedial hypothalamic nuclei neurons via the Htr2c receptor to inhibit the synthesis of
epinephrine and thereby decrease sympathetic tone. This decrease is relayed in osteoblasts by
decreased signaling via the β2 adrenergic receptor (Adrβ2), which negatively controls osteoblast
proliferation via molecular clock gene (Cyc D1) cascade and positively regulates bone resorption
via activation of a PKA/ATF4-dependent pathway (ATF-4: a transcription factor protein),
leading to increased synthesis of receptor activator of nuclear factor kappa B ligand (Rankl), an
activator of osteoclast differentiation and function.69 In other words, 5-HT activation can also
directly produce RANKL in addition to the RANKL produced during normal bone remodeling
process. In normal bone remodeling in healthy physiologic systems, bone stromal cells,
including cells of the osteoblast lineage, provide a limited amount of RANKL, which leads to
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osteoclast differentiation, survival, and activation and subsequent bone resorption. Resorption is
balanced by osteoblast-dependent new bone formation.97
Treatment of homozygous oim/oim mice (the oim/oim mouse is an established model of
moderate to severe osteoporosis) with either a bisphosphonate (alendronate) or Rankl inhibitor
(Rank-Fc) causes similar decreases in fracture incidence.98 This data suggests a link between
SSRIs-Rankl-bisphosphonates. Similarly, Sutherland et al. in an in vitro study using rabbit
osteoclasts treated with 100 µM clodronate or alendronate for up to 48 hours in the absence or
presence of 100ng/mL RANKL found that RANKL significantly attenuated (or antagonized) the
ability of both clodronate (CLO) and alendronate (ALN) to induce osteoclast apoptosis and
inhibit bone resorption (Figure 2.1). The number of apoptotic rabbit osteoclasts was significantly
lower in cultures treated for 48 hrs with ALN or CLO in the presence of RANKL than in cultures
treated with the bisphosphonates alone. The authors conclude that RANKL protects osteoclasts
from the apoptosis-inducing and anti-resorptive effects of bisphosphonates in vitro. 99
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Figure 2.1. The percentage of non-apoptotic and apoptotic osteoclasts. Data are expressed as the mean ±
SEM (n = 3 replicates). ***P = 0.001 compared with ALN or CLO alone (analysis of variance).
#Treatment with ALN or CLO alone caused a significant decrease in osteoclast number compared with
control (CTL) cultures (P = 0.01) and a significant increase in osteoclast apoptosis compared with control
cultures (P = 0.001).99 (Disclaimer: This is an open access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited)

2.5.2

Potential attenuating effects of SSRIs on bisphosphonates

Based on Bradford Hill causal criteria of plausibility (refers to the biological plausibility
of the hypothesis) and the evidence from laboratory experiments on animals,72 SSRIs and
skeletal effect association can be considered to be causal. However, Rothman and coworker100
warns that, “evidence from human experiments, however, is seldom available for most
epidemiologic research questions, and animal evidence relates to different species and usually to
levels of exposure very different from those humans experience.” Despite this limitation, he adds
that, “logically, however, experimental evidence is not a criterion but a test of the causal
hypothesis, a test that is simply unavailable in most circumstances.”35 This underscores our
hypothesis and provides a plausible reasoning to conduct this current study. Steps in which
SSRIs might negate the beneficial effects of bisphosphonate therapies are given in Figure 2.2.
56

Figure 2.2. Schematic representation of the proposed model tested in this study.
2.6 Role of Depression versus Serotonin System on Bone Health
2.6.1

Depression and increased risk of fracture

Although the preceding discussion demonstrates that SSRIs, commonly used for the
treatment of depression, increases the risk of fracture through the 5-HT transporter inhibition, it
is still unclear whether the ADE of increased risk of fracture is associated with burden of the
disease (depression) or the serotonin transporter system.
Depression is thought to be an independent risk factor for osteoporosis or decreased BMD,
with depressed women, particularly those who are postmenopausal, showing a higher risk than
men.101 Diem and colleagues have shown that depressive symptoms are associated with higher
bone loss, leading to low BMD, in older women with Geriatric Depression Scale score (GDS) of
at least 6 independent of antidepressants.79 Silverman et al. found that postmenopausal women
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with prevalent vertebral fracture reported more symptoms as assessed by the GDS than women
without prevalent vertebral fracture (1.54 vs 1.26; p=0.001).102 Tolea et al. found that high
depressive symptoms were associated with increased risk of osteoporosis (OR=1.39, 95% CI,
1.02-1.91) and new fractures (OR=1.39, 95% CI, 1.01-1.95) among Mexican American women
aged 65 years and older.103
In contrast to these findings, Spangler and colleagues in a cohort study of 93,676
postmenopausal women found no statistical significant association between depressive
symptoms and mean change in 3-year BMD at the hip or spine. Similarly, no significant
association was found between the use of antidepressants and 3-year changes in hip, spine, or
whole body BMD. Moreover, depressive symptoms were not associated with increased risk for
hip, spine, or wrist fracture, but were only associated with minimal increased risk for any
fracture.83 Therefore, not only is the association between depression and osteoporosis and/or
fractures uncertain, but also the causal relationship has not been fully elucidated.68 This presents
challenges in need of further investigations.
To investigate this dilemma, we compare the association of concomitant SNRIs with
bisphosphonates users and concomitant SSRIs with bisphosphonates users and increased risk of
fracture. Selective serotonin reuptake inhibitors and, possibly SNRIs, are associated with
osteoporosis and increased risk of fracture.104 Currently there are no specific studies on the
association between SNRIs and fracture.105 However, studies on antidepressants other than
SSRIs and fracture might implicate SNRIs. Vestergaard et al. found that venlafaxine (an example
of a SNRI) was associated with statistically significant increased risk of forearm fracture at a
dose of >0.5 DDD/day (OR=1.54 95% CI 1.12-2.12) and spine fracture at a dose of ≤0.25
DDD/day (OR=1.97; 95% CI 1.18-3.29). There were no statistically significant results for hip or
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any fracture or at other drug doses.106 (One DDD is the dose thata person on average uses of the
drug in 1 day. The amount of DDD was calculated from the number of prescriptions, the number
of tablets prescribed, and the dose of the pills in the actual
prescription).[www.whocc.no/atcddd/] Vardel et al. found that non-SSRI/non-TCA
antidepressants drugs (including venlafaxine) were associated with osteoporotic fracture
(OR=1.40; 95% CI 1.06-1.85).107 Why the comparison? This is because of the binding
characteristics and selective nature of SNRIs on 5-HT receptors.
2.6.2

Selective nature of SNRIs and bone health

Serotonin norepinephrine reuptake inhibitors are dual action antidepressants that inhibit
both serotonin (5-HT) and norepinephrine (NE) transporters. The FDA-approved SNRIs include
venlafaxine (Effexor®), duloxetine (Cymbalta®), and desvenlafaxine (Pristiq®) which is an active
metabolite of venlafaxine, and levomilnacipran (Fetzima®).108 The ability of these drugs to block
5-HT and NE transporters in vitro and in vivo has been reported.
Duloxetine potently inhibits binding to the human 5-HT (Ki=0.8 nM) and NE transporters
(Ki=7.5 nM). Venlafaxine, however, inhibiting binding to the human 5-HT was 106 times less
potent (Ki=82 nM) than duloxetine and also inhibits binding to NE transporters (Ki=2480 nM).
Thus venlafaxine binds to NE transporter with 331 times lower affinity than duloxetine. Results
from in vitro studies showed that duloxetine inhibited 5-HT (Ki=4.6 nM) and NE (Ki=16),
whereas venlafaxine inhibited 5-HT and NE with 17- and 34-fold lower potency. Furthermore,
duloxetine blocked ex vivo 5-HT and NE transporter binding with ED50 values of 0.03 and 0.7
mg/kg subcutaneous (s.c). Venlafaxine was 67 and 77-fold less potent than duloxetine at
inhibiting 5-HT and NE ex vivo transporter binding. These findings indicate that higher doses of
venlafaxine were needed to block the NE transporter.109
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Desvenlafaxine has higher affinity for the human 5-HT transporter (Ki=40.2 nM)
compared with NE transporter (Ki=3385 nM). In addition, assays indicate that desvenlafaxine is
approximately 10-fold more potent at inhibiting 5-HT uptake (IC50=47.3) than NE uptake
(IC50=531.3).110 Despite the findings from different assays, the findings suggest that the relative
potencies for 5-HT transporter inhibition relative to NE transporter inhibition is in the order (low
to high): venlafaxine, desvenlafaxine, duloxetine, and levomilnacipran.
Of particular interest is that venlafaxine acts as a SSRI at lower doses (75 mg/day, FDA
labeling recommended starting dose), and a SNRI at higher doses (150-225 mg/day).111 This
mode of action might also be observed with desvenlafaxine and duloxetine in relation to the
relative potencies. Higher doses of venlafaxine for the treatment of a severe depressive episode
are well tolerated.112 The recommended therapeutic dosage for desvenlafaxine is 50 mg/day for
MDD patients and higher doses (50-400 mg/day) are well tolerated.113 On the other hand, the
recommended and with demonstrated efficacy dose for duloxetine in the treatment of MDD is 60
mg/day and higher doses can be tolerated up to 120 mg/day.114
The important question is whether the selectivity of SNRIs on 5-HT vs. NE transporters
is clinically relevant as drug doses are increased with respect to the effects of SNRIs115 and
increased risk of osteoporotic fracture. A dose-dependent effect of SSRI use on fracture cases
has been observed. Vestergaard et al. has shown that users of SSRIs reported an increased risk of
any fracture (OR from 1.1 at doses <0.15 daily defined dose (DDD)/day to 1.4 at doses ≥0.75
DDD).106 This dose-effect (in the opposite direction than what might be expected) may or may
not be observed with SNRIs use. We hypothesize that if the risk of fracture is the same between
SSRIs vs. SNRIs, then the increased risk of fracture may be related to the role of depression. In
contrast, if the risk of fracture differs, and is greater among SSRIs users compared to SNRIs
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users, then there is a higher likelihood of 5-HT playing a role but, not depression, in increased
risk of fracture. Findings from this investigation can add new knowledge to understand the role
of depression as an important risk factor for fracture as opposed to 5-HTT.
2.7 Summary
Bisphosphonates are effective in the prevention and treatment of osteoporosis and/or
osteoporotic fractures in postmenopausal women. However, safety concerns of potential
attenuation of BPs with concomitant use of medications with skeletal effects (e.g., SSRIs) and
increased risk of fracture have been raised. Literature review has demonstrated the association of
SSRI use with increased risk of fracture among postmenopausal women. However, these studies
did not report fracture outcome comparisons between concomitant SSRIs with bisphosphonate
users and nonusers (BP alone users). Most studies investigating the effect of SSRIs on bone in
postmenopausal women exclude users of BP medications or BP use was not examined as a
specific risk factor/ exposure of interest. Instead, it was just adjusted for,75-83 thus missing the
opportunity to investigate this potential event of possible attenuation of BPs by SSRIs and
eventual increased risk of fracture.
Since BPs are considered a mainstay of pharmacologic therapy for the prevention and
treatment of osteoporosis and/or osteoporotic-related fractures, it is highly likely that
postmenopausal women prescribed BPs would be using SSRIs as well, if needed. A descriptive
study using a large U.S. claims database (from 1999 to 2004) of women aged ≥50 years has
shown that concomitant medications are used by women receiving daily or weekly BP therapy
and this increased with age. The study did not include monthly or yearly BP therapies.
Furthermore, of the medications that were concomitantly used with BPs, SSRIs or SNRIs were
not described, highlighting a gap in the literature.116 Descriptive concomitant use of
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SSRIs/SNRIs with bisphosphonates is explored and results are provided in Chapter 3 and
Chapter 5. In order to assess the association between concomitant use (section VI) and the role of
5-HT in bone (section VII), a pharmacoepidemiologic study was conducted and results and
discussion are presented in Chapter 6 and Chapter 7, respectively.
2.8 Study design considerations
2.8.1

Background

This study focuses on the effects of concomitant SSRIs/SNRIs with bisphosphonates in large
numbers of patients, which is the definition of pharmacoepidemiology, a discipline that applies
epidemiological principles and methods. Pharmacoepidemiological studies are often conducted
after approval for drug marketing has been granted. These studies are classified as observational
in nature.117 Observational research involves the direct observation of individuals (rather than
manipulated [e.g., through randomization]) in their natural setting.118 For example, studies using
Medicare claims data are observational because the investigator is observing the subjects’ health
care utilization without any contact or involvement with the subjects.118 Unlike clinical trials
where individuals are randomized to receive an intervention or not, in observational studies,
receiving an intervention or not is determined by individual preferences, practice patterns, or
policy decisions.119
The most commonly used study design types for observational pharmacoepidemiologic
studies include cohort studies, case-control studies, crossover studies,120 and nested case-control
studies121. In order to attribute a particular effect to the use of a drug, one of the key components
to consider is the study design. Studies designed to minimize confounding bias (e.g.,
experimental designs), provide the most convincing evidence for a causal relationship between
exposure and outcome of interest.117 Confounding bias is of particular concern in observational
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epidemiologic studies of drug effects.122 In observational designs, the researcher must identify
and measure potentially confounding variables, or the internal validity of the study will be
undermined. As a consequence of lacking internal validity, conclusions about relationships are
incorrect, and any generalization, regardless of the level of external validity, is meaningless.123
Therefore, it is important to identify and handle confounding in observational studies.
2.8.2

Identification of confounders

Confounding is defined as the mixing effects between an exposure (X), an outcome (Y),
and a third extraneous variable known as a confounder. As such, confounders are factors
(exposures, interventions, treatments, etc.) that explain or produce all or part of the difference
between the measure of association and the measure of effect that would be obtained with a
counterfactual ideal.100 The ideal comparison group in a cohort study consists of exactly the
same individuals in the exposed group had they not been exposed. The ideal comparison would
help to answer the question of what would have happened to those who did receive treatment, if
they had not received treatment. Practically, this ideal comparison is unobservable and only an
estimate of them can be created. Thus, the ideal comparison is referred to as counterfactual
ideal.100
There are three criteria that must be met in order for a variable to be considered a
confounder: 1) that the variable must be associated with the exposure in the population that
produces the cases, 2) the variable must be an independent cause or predictor of the disease, and
3) the variable cannot be an intermediate step in the causal pathway between the exposure and
disease. Figure 2.3 depicts the relationship between the confounder, the exposure, and the
disease and Figure 2.4 depicts a variable that is a step in the causal pathway between exposure
and a disease.124
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Figure 2.3. Schematic representation of the association between the confounder with both the
exposure and disease.

Exposure

Variable

Disease

Figure 2.4. Schematic representation of the variable that is a step in the causal pathway between
the exposure and the disease.

With regards to osteoporotic fractures, Table 2.4 shows potential risk factors associated
with osteoporosis (or low BMD) and increased risk of fractures included in a new Fracture Risk
Assessment Tool (FRAX®) for evaluating fracture risk. FRAX® was developed by the WHO to
evaluate a patient’s 10-year probability of hip fracture and major osteoporotic fracture (i.e.,
clinical spine, forearm, hip, or shoulder fracture).17 Assuming one of the risk factors is
considered an exposure (X), then the remainder of the risk factors are considered as the third
extraneous variables known as confounders.
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Table 2.4. Risk factors for osteoporotic fracture used in FRAX®.












Age (50 to 90 years)
Sex
Body mass index
Low femoral neck BMD
Prior fragility fracture
Parental fragility fracture
Current tobacco smoking
Long-term use of glucocorticoids
Rheumatoid arthritis
Other causes of secondary osteoporosis (e.g., medications and medical conditions)
Alcohol intake of more than two units daily

Adapted from The North American Menopause Society, 2010.17

2.8.3

Handling confounding
2.8.3.1 Background

The central target of most health sciences research studies is the elucidation of causeeffect relationships among variables of interest and outcomes.125 In epidemiology, variables of
interest are commonly referred as exposure or treatment. When a statistical association is
reported in an epidemiology study, it is stated with the hope of using the association measures to
give insight into a causal-effect relationship.126 Confounding is termed a “causal concept”125 and
thus can be an impediment to elucidation about true causal effects. In other words, recognizing
confounding, one ought to understand what is meant by causal effect. A causal-effect can be
defined as the effect due to a certain treatment or exposure.126
For illustration, suppose Ya=1 is the outcome variable that would have been observed
under exposure value a=1, and Ya=0 the outcome variable that would have been observed under
the exposure value a=0. The exposure has a causal effect in the population if Pr[Ya=1=1] ≠
Pr[Ya=0=1], where the probability Pr[Ya=1] is the proportion of subjects that would have
developed the outcome Y had all the subjects in the population of interest received exposure
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value a. Note that the risk Pr[Ya=1] is computed using all subjects of the population had they
received the counterfactual exposure a (that is, it is an unconditional or marginal probability).127
On the other hand, exposure or treatment and outcome are associated if Pr[Y=1|A=1] ≠
Pr[Y=1|A=0]. Where the probability Pr[Y=1|A=a] is the proportion of subjects that developed
the outcome Y among those subjects in the population of interest that happened to receive
exposure value a (that is, it is a conditional probability). In other words, the distribution of Y
conditional on variable A is defined as examining the distribution of Y within levels of variable
A. The symbol “|” denotes conditional relations. Therefore, the definition of association involves
two disjoint subsets of the population determined by subjects’ actual exposure value, whereas
causation involves the same subset (for example, the entire population) under two potential
exposure values. Hence the cliché “association is not causation.” In ideal randomized
experiments (assuming no loss to follow-up, full compliance with assigned treatment, and blind
assignment), association is causation.127
In non-randomized (e.g., observational) studies association is not necessarily causation
because of the potential lack of exchangeability of exposed and unexposed subjects.
Exchangeability means that the risk under the potential exposure value a among the exposed,
equals the risk under the potential exposure value a among the unexposed.127 Therefore,
pharmacoepidemiologic research aimed at assessing cause-effect relationships would prefer
randomized experiments as the gold standard method of design. Unfortunately, randomized
experiments are not always feasible because of cost, ethical, or practical reasons.128,129 Therefore,
even though exchangeability is not guaranteed, conducting observational studies is the only
option available to pharmacoepidemiologists to identify associations or relationships and
determine causal-effect relationships using observational data and statistical analyses.
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Correlation, regression, risk ratio, and odds ratio are examples of associational concepts whereas
confounding and randomization are examples of causal concepts. Bias or confounding exists
when an association measure differs from the corresponding effect measure that would prevail
under ideal experimental conditions and this is the case with non-randomized (observational
studies).125 This highlights the challenges pharmacoepidemiologists face when they draw
conclusions about effects of drugs in large populations. How do we explain this challenge?
The fundamental problem of addressing a causal-effect research question is how to
reconstruct outcomes that are not observed (counterfactuals or potential outcomes) because they
are not what happened. The outcome can be observed only (or more precisely, at most) under
one, and not under both conditions. Hence, reconstructing the counterfactuals is crucial to
estimate unbiased causal-effects. The treatment that an individual actually does not receive is
called counterfactual treatment.130 How can we address this problem? One approach would be to
reconstruct counterfactuals using propensity score method (PSM).
2.8.3.2 Propensity score method
PSM allows researchers to reconstruct counterfactuals using observational data, a
situation similar to random assignment, albeit only with respect to observed variables.131
Propensity score method does this by reducing the bias due to the measured confounders.132 The
strategy does not control for hidden biases.131 Using PSM it is possible to duplicate one crucial
feature of randomized experiment of designing an observational study without access to the
outcome data. In experiments design, the way data will be collected is decided before observing
the outcome data which is a tremendous stimulus for “honesty” in experiments and can be in
well-designed observational studies as well.133
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Propensity score method was introduced by Rosenbaum and Rubin and was defined as
the probability of treatment assignment conditional on observed baseline covariates:
ei=Pr(Zi=1|Xi), where Z=1 for treated and Z=0 for control. The propensity score (ei) exists in both
randomized experiments and in observational studies. Like all probabilities, a propensity score
ranges from 0 to 1. In randomized experiments, the propensity score is known and is defined by
the study, whereas in an observational study, it must be estimated from the data on indicator for
received treatment (treated and controls) and observed covariates. The propensity is most often
estimated using a logistic regression model.134
Given random assignment to treatment or control in randomized experiments (e.g.,
tossing a coin), each person has a 50% chance of being in treatment. Thus, each person has a true
propensity score of 0.5. In non-randomized quasi experimental studies where the investigators
have no control over the treatment assignment, the probabilities of receiving treatment (ei) are a
function of individual characteristics and are likely to vary from 0.50. For example, consider
treatment assignments Z=1 and Z=0, then ei above 0.50 would mean the person was more likely
to select into treatment than control, and score below 0.50 would mean the opposite.135
In observational studies, propensity scores are used primarily to reduce bias and increase
precision. There are four different PSMs researchers can use for removing the effects of
confounding when estimating the effects of treatment on outcomes which involve balancing of
nonequivalent groups. These include propensity score matching, stratification on the propensity
score, covariance adjustment, or inverse probability of treatment weighting using the propensity
score.136 In this research project, the focus was on propensity score matching. Propensity score
matching is the commonly used in the medical literature.137 Furthermore, previous research has
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demonstrated that matching on propensity score can result in a greater reduction in treatment
selection bias than stratification on propensity score.138
2.8.3.3 Propensity score matching
The propensity score (PS) is a potential matching variable because it does not depend on
response information that will be collected after matching.134,139 Propensity score matching refers
to pairing of treatment and control subjects, to form matched sets, with similar values (or
distribution) of PS so that treated subjects are similar to the control subjects with respect to
background variables (or covariates) measured on all subjects, just like in a randomized
experiment. Thus, two matched subjects (one in treated and one in control group), with the same
propensity score, are imagined to be ‘randomly’ assigned to each group in the sense of being
equally likely to be treated or control. It is important to note that PS achieves balance in observed
covariates whereas randomization in experimental studies achieves balance in all covariates
(observed and unobserved).134,136,139
The implication of the balancing property of the propensity score in all observed
covariates is that, when matching on PS, any differences in outcomes between treated and
control subjects cannot be due to observed covariates. In other words, matching on PS tends to
produce unbiased estimates of the treatment effects when treatment is strongly ignorable.
Treatment assignment is considered strongly ignorable if the treatment assignment, Z, and the
response, Y, are known to be conditionally independent given the covariates, X. Moreover, these
design efforts, which result in more balanced distributions of covariates across treatment groups,
make subsequent model-based adjustments (e.g., covariance adjustments, instrumental variables)
more reliable.133,134
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There are advantages for designing this pharmacoepidemiologic study using the PS
matching strategy. First, a matched data set allows for simple, transparent analysis. Second, a
matched analysis based on a well-formulated propensity score has the advantage of deleting from
analysis those subjects with measurable contra-indications (or absolute indications) for treatment
who have no available treated (or untreated) comparison subject. Confounding by indication is
often the main challenge to validity in pharmacoepidemiology and the PS focuses directly on the
indications for use and non-use of the drug under study.140 For example, Zoledronic acid
(Reclast®) is contraindicated in patients with severe renal impairment (i.e., creatinine clearance
less than 35 ml/min) or in patients with evidence of acute renal impairment. A complete list of
indications, contraindications, and geriatric use information for BPs is shown in Table 1.7 in
Chapter 1. Third, matched or stratified analyses do not make strong assumptions of linearity in
the relationship of propensity with the outcome which is the assumption made when PS is
included in a multivariate model together with actual treatment.140 The estimated treatment
effects can be biased if this assumption does not hold.134
The most common approach to PS matching is 1:1 matching and this research project
used 1:1 matching strategy, where each treatment subject is matched to its 1 nearest neighbor.
Matching at ratios of 1:n can increase statistical efficiency in case-control141 and cohort
studies.142 However, it should be noted that 1:n matching increases bias because it is likely that
less similar cases are matched with increasing number of matches.142 Upon matching, balance of
the covariates is assessed and then the treatment effect is estimated directly comparing outcomes
between treatment and control groups in the matched sample.
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2.8.3.4 Sensitivity test
The sensitivity test is the final step used to investigate whether causal effect estimated
from PSM is susceptible to the influence of unobserved covariates. There are three approaches
for conducting a sensitivity test: 1) changing the specification in the equation, 2) using the
instrumental variable, and 3) use of Rosenbaum Bounding approach.126

2.9

Summary

Concomitant uses of medications are associated with ADEs. Literature shows that
concomitant use of medications known to induce osteoporosis (e.g., GCs, PPIs, or LT4) with BPs
have potential attenuating effects of BPs resulting in increased risk of fracture. SSRIs are
associated with increased risk of fracture and might also have potential attenuating effects. Also,
the role of depression versus 5-HT on bone is unclear. Both of these latter hypotheses will be
investigated in this study. To ensure internal validity of estimated effects, confounding bias of
observed covariates will be handled using the PSM.
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Chapter 3
3.0 Preliminary study
3.1 Abstract
Title: Utilization patterns of bisphosphonates and selective serotonin reuptake inhibitors from
2004 to 2008 among women
Introduction: Comorbid osteoporosis and/or fractures and depression is prevalent in older
postmenopausal women in the United States. Both conditions might require pharmacologic
therapy. The most popularly used are antidepressants of the SSRIs or SNRIs and BPs. SSRIs and
SNRIs have been associated with increased risk of osteoporosis and/or osteoporotic fractures.
SSRI, SNRIs, and BPs utilization has become more common over time among women. The
potential for attenuation of the effect of BPs by SSRIs/SNRIs and increased risk of fracture has
not been investigated yet. Before the investigations, it was important to explore the extent to
which these medications are prescribed concomitantly.
Specific aims: 1) to examine the proportion of BP users who are also on SSRIs/SNRIs and
patterns of use over time, and 2) to explore the relationship between concomitant use and patient
age among women aged 45 years and older.
Methods: A cross-sectional analysis was performed using data from the 2004-2008 Medical
Expenditure Panel Survey (MEPS) to examine usage patterns of BPs and SSRIs/SNRIs for
women aged ≥45 years. Analyses were based on yearly consolidated data and prescribed
medicines files. Weighted descriptive statistics were used to evaluate patterns of medications use
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and proportions were reported. Age was categorized into four groups: 45-54, 55-64, 65-74, and
75-85 years old.
Results: Of the survey respondents, proportions of women 45-64 years old were higher
compared to those women 65-85 years old. Also, for each year about 80% of the respondents
were white women. In the timeframe examined, 8.9% of women in 2004, 9.9% in 2005, 10.3%
in 2006, 9.8% in 2007, and 10.0% in 2008 received bisphosphonates. In the same period, 13% of
women in 2004, 12.7% in 2005, 12.8% in 2006, 12.2% in 2007, and 11.9% in 2008 received
SSRIs. In addition, 2.7% of women in 2004, 3.3% in 2005, 3.0% in 2006, 3.9% in 2007, and
4.6% in 2008 received SNRIs. Concomitant use (BPs+SSRIs) was observed in 11.7% of women
in 2004, 12.1% in 2005, 13.3% in 2006, 14.1% in 2007, and 13.5% in 2008. Overall, the trend of
concomitant use of BPs+SSRIs increased across the five-year period (slope=0.56; p-value=0.04).
In the same timeframe examined, no statistically significant trend in concomitant use of
BPs+SNRIs was observed (slope=0.33; p-value>0.05). Furthermore, no structured odds ratios
were observed for the association of age and concomitant use of BPs+SSRIs.
Conclusion: Concomitant use of BPs and SSRIs in adult women ≥45 years is not uncommon
and might be higher in older postmenopausal women. The observed concomitant use presents
drug safety challenges surrounding the bone health of postmenopausal women. Studies are
needed to investigate the potential interactive effects of SSRIs on BP therapy.

3.2 Introduction
Osteoporosis and depression are known to coexist and it is still unclear the association
between these two chronic conditions.1 Also, these two conditions can exist together as
comorbidities of other diseases such in patients with chronic obstructive pulmonary disease.2
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Comorbid osteoporosis and depression is prevalent in patients 65 years and older.3 The
prevalence is higher in women (postmenopausal) than men.1 The interaction between
osteoporosis and depression is complex and as such single interventions are unlikely to be
effective in improving outcomes in patients with these coexisting conditions.4 Management of
both conditions often requires pharmacologic therapy interventions and these include
antiresorptives for osteoporosis and antidepressants for depression.
Of the current FDA-approved antiresorptives, BPs are recommended as first-line
pharmacologic therapy in the management of osteoporosis and/or fractures, especially in older
postmenopausal women.5 Bisphosphonates have become the primary therapy for managing
skeletal conditions characterized by increased osteoclast-mediated bone resorption6 such as
osteoporosis (or low bone mineral density). Bisphosphonates have been shown to reduce fracture
risk by 40-50% in patients with low BMD.7 The pharmacological features of BPs include a high
affinity for crystalline hydroxyapatite in the bone and inhibitory effects on osteoclasts. The high
affinity for bone mineral allows BPs to achieve a high local concentration throughout the entire
skeleton.6
The use of antiresorptive treatment (e.g., BPs) appears to be fairly common, with one
study reporting that 43% of premenopausal women (mean age 37± 8) have used BPs.8 Perreault
et al. in a study to determine use of antiresoptives (bone-specific drugs [BP, calcitonin, raloxifen]
and hormone replacement therapy) among older women who had an osteoporotic fracture or
were at risk of osteoporic fracture found that the use of these agents was reported to have
increased over time—from 1.9 per 100 person-years in 1995 to 31 per 100 person-years in 2000
among those with prior osteoporotic-related fracture and 0.5 per 100 person-years in 1995 to 11
in 2000 for controls.9 Gold et al. in a study using a large U.S. patient claims database accessed
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through Wolters Kluwer Health found that female BP recipients increased from 78,909 in 1999
to 250,286 in 2004.10 Also, other studies showed a significant reduction in hormone replacement
therapy (HRT) utilization and a corresponding increase in newer anti-osteoporosis medications
or nonhormonal therapy (e.g, BPs) after release of the Women’s Health Initiative study11 in 2002
that reported an association between HRT and increased risk of cardiovascular health disease and
breast cancer among postmenopausal women.12,13,14 Alternative medications to HRT for
postmenopausal symptoms include clonidine, SSRIs, SERMs, and BPs.15
On the other hand, with a better safety and tolerability profile than older classes of
antidepressants, SSRIs and SNRIs have become the most popular medications in treating
depression and are considered first-line drug treatment in older patients.16,17 An analysis of the
Medical Expenditure Panel Survey (MEPS) has reported that SSRI and SNRI use has become
more common (54.8% of antidepressant use in 1996 and 66.89% of antidepressant use in 2005)
over time. Use of newer agents which include SNRIs has also been shown to be common over
time (23.6% of antidepressant use in 1996 and 37.9% of antidepressant use in 2005). Of the
individuals in the MEPS analysis, general antidepressant use (rates per 100 persons treated) was
highest among those aged 50 years or older in women (7.62% in 1996 and 13.42% in 2005) than
men (3.96% in 1996 and 6.68% in 2005).18 In agreement, a recent Medicare Current Beneficiary
Survey by Akincigil et al. showed that use of SSRIs and SNRIs increased over a period of 10
years (between 2002-2005 compared to 1992-1995) and was higher in females.19
The studies discussed above demonstrate an increasing trend of utilization of BPs and
SSRIs /SNRIs. Whether this trend can also be observed for concomitant SSRIs or SNRIs with
BPs remains an open question. Because of comorbid osteoporosis and depression,1 BPs and
SSRIs or SNRIs could be prescribed together. In the study by Caughey et al., the authors
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determined the prevalence of potentially inappropriate medicines and treatment conflicts, for
older people dispensed an antidepressant. In this study, patients with comorbid osteoporosis
(already at-risk population for fractures), almost half were dispensed a SSRI and were at even
higher risk for decreased bone density over time and increased risk of fracture.3 Treatment for
osteoporosis was not addressed. To the best of our knowledge, no studies have been reported
describing the utilization pattern of concomitant SSRIs or SNRIs with BPs. Therefore, the
primary objective of this study was to examine the proportion and use over time of BP users who
are also on SSRIs or SNRIs and to explore the relationship between concomitant use and patient
age among women aged 45 years and older.

3.3 Methods
3.3.1 Data sources and patient population
Data from the 2004-2008 MEPS was used to examine usage patterns of BPs and
SSRI/SNRI antidepressants for women aged 45 years or older. MEPS, a survey cosponsored by
the Agency for Health Care Research and Quality (AHRQ) and the National Center for Health
Statistics (NCHS), is a relatively large, longitudinal study of health care use among the U.S.
civilian, non-institutionalized population (e.g., not in prisons or nursing homes). The survey is
conducted as a national probability survey using a complex stratified multistage area probability
design.20 The National Health Interview Survey (NHIS), another large ongoing Federal health
survey conducted by the National Center for Health Statistics of the Centers for Disease Control
and Prevention, U.S. Department of Health and Human Services, serves as the sampling frame
for MEPS.
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The MEPS household component collects information on demographic and socioeconomic characteristics, health care use, expenditures, respondent’s health status, sources of
payment, and health insurance coverage for all the members of the household. The survey is
designed such that certain groups, including racial minorities (Blacks, Hispanic, and Asian
individuals), and low-income households, are oversampled from the NHIS. Data from the MEPS
household participants are collected over a two and half year period. Each new MEPS annual
sample is referred to as a panel. The MEPS conducts the survey annually and employs an
overlapping panel design to collect data whereby each year a new panel of households is selected
from among those households that participated in the previous year’s NHIS. This design
provides data which can be combined and used for cross-sectional or longitudinal analysis.20,21
3.3.2 Identification of exposure
Concomitant use was defined as receipt of at least one prescription of a bisphosphonate
and a SSRI or SNRI antidepressant during a calendar year. The assigned Multum Lexicon Drug
Database values (Cerner Multum Inc., Denver, CO, USA; http://multum.com/Lexicon.htm) were
used to identify drug products in the MEPS survey. The Multum Therapeutic category values are
217 (BPs), 208 (SSRI antidepressants), and 308 (SNRI antidepressants).
3.3.3 Statistical analysis
Analyses were based on yearly consolidated data, and prescribed medicines files. The
demographic characteristics (including age, race, health insurance coverage, socio-economic
status, marital status, and education) and prescribed medicines information of the qualified
participants was obtained from the Full Year Consolidated Data, and the Prescribed Medicines
Files respectively of the 2004-2008 MEPS household components. Weighed descriptive statistics
were used to evaluate patterns of medication use and proportions were reported. Respondents
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who self-identified as “White” were categorized as “White” and also “Black” respondents were
classified as “Black”. However, respondents who self-identified as either “American
Indian/Alaskan Native” or “Asian” or “Native Hawaiian/Pacific Islander” or “Multiple races”
were re-classified as “Other”.
Based on age, and race, first, the proportions of women aged ≥45 years old who filled at
least one SSRI or SNRI antidepressants, and BPs, both separate were calculated. Second, the
analysis was limited to only women who were on BPs. The proportions of BP users who are also
on SSRI or SNRI antidepressants were calculated for each calendar year and these proportions
were further analyzed by age-groups: 45-54, 55-64, 65-74, and 75-85 years old. Age was defined
as age at the end of each calendar year. All estimates were calculated using the survey
procedures (PROCSURVEYFREQ) of the software SAS 9.3 version (SAS Institute, Cary, NC)
including variables for generating weighted national estimates and for use of the Taylor series
linearization method for variance estimation for complex survey designs. These variables are:
person-level weight (PERWT0xF); stratum (VARSTR); and cluster/psu (VARPSU).22,23
For trend analysis, the frequencies of overall utilization and utilization by age of SSRIs or
SNRIs with BPs were calculated for each year. Then, any change in these frequencies across the
5-year period were described and analyzed for statistical significance. A linear regression was
performed using the proportions of BP+SSRI/SNRI use from 2004 to 2008 to test for significant
linear trend across the 5 survey years for concomitant users.
Logistic regression was used to examine the relationship between increasing age and
utilization of BPs+SSRIs/SNRIs and whether the relationship was linear. The categorized age
groups (categorical variable) were thought of as ordered. Thus a Cochran-Armitage trend test
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was performed to test whether there was a linear relationship. Odds ratios were reported for the
age group categories in the model. For all analyses statistical significance was set at p<0.05.

3.4 Results
3.4.1 Summary descriptive statistics
In the time frame examined in this study, there were a total of 34,403 observations in 2004,
33,961 observations in 2005, 34,145 observations in 2006, 30,964 observations in 2007, and
33,066 observations in 2008. The demographic information of women ≥45 years are presented in
Table 3.1 for MEPS 2004-2008. In addition, the population patterns of these participants are
presented in Figure 3.1 which parallels the actual annual estimates from the U.S. Census Bureau
in Figure 3.2.24 The proportion of women ≥45 years during a calendar year increased gradually
and steadily, from 19.5 percent in 2004 to 20.4 percent in 2008 (Table 3.1 and Figure 3.1). Of
these participants, White women accounted for the largest proportions followed by African
American women and the rest were of other racial backgrounds.
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Table 3.1. Demographic information of U.S. women aged 45 years and older for MEPS 20042008.
Year
Total

2004
N (5846)

2005
N (5834)

2006
N (6113)

2007
N (5550)

2008
N (5574)

Characteristic

%

%

%

%

%

2058 (34.0)
1624 (28.8)
1098 (18.5)
1066 (18.6)

2088 (34.2)
1646 (29.2)
1030 (17.5)
1070 (19.2)

2168 (34.4)
1737 (29.2)
1103 (17.4)
1105 (19.0)

1941 (33.3)
1665 (30.4)
1001 (17.9)
943 (18.4)

2005 (33.4)
1690 (30.5)
1003 (18.0)
876 (18.1)

4626 (83.7)
874 (10.7)
365 (5.6)

4528 (83.5)
952 (10.6)
368 (5.9)

4704 (83.5)
1037 (10.6)
384 (5.9)

4240 (83.4)
919 (10.7)
407 (5.9)

3960 (83.1)
1124 (11.1)
517 (5.8)

2986 (54.5)
1160 (18.1)
1310 (21.5)
389 (5.8)

2988(55.1)
1172 (18.1)
1265 (20.8)
409 (6.0)

3184 (55.9)
1229 (18.2)
1256 (19.6)
444 (6.2)

3020 (55.7)
1110 (19.4)
1033 (18.5)
387 (6.2)

2994 (55.3)
1103 (19.0))
1021 (19.0)
456 (6.7)

2211 (29.4)
1633 (29.0)
2002 (41.6)

2245 (29.1)
1586 (28.5)
2003 (42.5)

2348 (28.3)
1673 (28.6)
2092 (43.1)

1975 (28.6)
1574 (27.7)
2001 (43.8)

1970 (29.6)
1653 (27.7)
1951 (42.7)

3617 (70.8)
1633 (22.0)
596 (7.2)

3553 (70.4)
1639 (22.0)
642 (7.6)

3690 (70.2)
1719 (21.4)
704 (8.4)

3418 (68.6)
1498 (22.9)
634 (8.6)

3370 (65.9)
1523 (25.0)
681 (9.2)

1542 (17.3)
2869 (53.2)
1435 (29.4)

1479 (16.8)
2878 (53.2)
1477 (30.0)

1548 (17.1)
2941 (51.2)
1624 (31.6)

1292 (16.3)
2689 (50.9)
1569 (32.8)

1293 (15.5)
2680 (52.2)
1601 (32.3)

Age
45-54
55-64
65-74
75-85
Race
White
Black
Other
Marital status
Married
Divorced/Separated
Widowed
Never Married
Family income
Low income or below
Middle income
High income
Insurance type
Private
Public
Uninsured
Education
<High school
High school
>4 years college+
20.6

20.4

20.4

20.2

Frequency (%)

20.2
20

19.8

19.9

19.8
19.6

19.5

19.4
19.2
19
2004

2005

2006

2007

2008

Year

Figure 3.1. Plot of population patterns of US women aged 45 years and older, MEPS 2004-2008.
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38.5
37.9%

38
Frequency (%)

37.5%
37.5

37.2%

37
36.5

36.7%
36.3%

36
35.5
2004

2005

2006

2007

2008

Year

Figure 3.2. Annual estimates of the U.S. resident population of women aged 45-85 years: July 1,
2004 to July 2008.24
Table 3.2 shows the proportions of those women 45 years or older reporting use of BPs,
SSRIs, SNRIs by year. According to the MEPS-HC for 2004-2008, 8.9 percent of women in
2004, 9.9 percent in 2005, 10.3 percent in 2006, 9.8 percent in 2007, and 10.0 percent in 2008
were using BPs. In the same period, 13.0 percent of women in 2004, 12.7 percent in 2005, 12.8
percent in 2006, 12.2 percent in 2007, and 11.9 percent in 2008 were using SSRI antidepressants.
2.7 percent of women in 2004, 3.3 percent in 2005, 3.0 percent in 2006, 3.9 percent in 2007, and
4.6 percent in 2008 were using SNRI antidepressants.
Table 3.2. Utilization patterns of bisphosphonates and SSRIs in U.S. women aged 45 years and
older for 2004-2008.
Year
Total

Medication use
Bisphosphonates (BPs)
SSRIs
SNRIs

2004
N (5846)
%
8.9
13.0
2.7

2005
N (5834)
%
9.9
12.7
3.3
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2006
N (6113)
%
10.3
12.8
3.0

2007
N (5550)
%
9.8
12.2
3.9

2008
N (5574)
%
10.0
11.9
4.6

3.4.2 Overall concomitant use of BPs and SSRIs or SNRIs
Among those women who were using BPs, concomitant SSRIs with BPs use was
observed in 11.7 percent of women in 2004, 12.1 percent in 2005, 13.3 percent in 2006, 14.1
percent in 2007, and 13.5 percent in 2008 (Table 3.3). Graphic representations of these findings
are shown in Figure 3.3. A steady increase in BPs+SSRIs concomitant use was observed
between 2004 and 2007 and then decreased slightly in 2008 (Table 3.3 and Figure 3.3).
Whereas, for BPs+SNRIs utilization, an increase in concomitant use was observed from 2004 to
2005, followed by a downward utilization trend in 2006 and then a steady upward trend in 2007
and 2008 (Table 3.4 and Figure 3.3). Overall, between 2004 and 2008, the utilization rate of
BPs+SSRIs increased (from 117 to 135 concomitant use per 1000 persons) and this increase had
a significant linear trend (slope=0.56;p=.04). When weighted, this increase represented an
increase of 0.66 million BPs+SSRIs users in 2004 to 0.86 million in 2008. On the other hand, a
non significant increase in utilization rate (from 25 in 2004 to 43 concomitant use per 1000
persons in 2008) was observed for concomitant BPs+SNRIs (slope=0.33; p>0.05).
Table 3.3. Utilization patterns of concomitant use of bisphosphonates and SSRIs by age in U.S.
women aged 45 years and older for MEPS 2004-2008.
Year
Total
BPs+SSRIs use
45-54 years, n (%)
55-64 years, n (%)
65-74 years, n (%)
75-85 years, n (%)
All, n (%)

2004
N=497

2005
N=519

2006
N=556

2007
N=496

2008
N=466

6 (12.6)
20 (18.4)
12 (7.5)
14 (8.8)
52 (11.7)

10 (16.5)
24 (19.4)
11 (6.6)
17 (9.5)
62 (12.1)

8 (16.2)
20 (9.8)
25 (16.2)
27 (13.4)
80 (13.3)

5 (10.8)
23 (13.3)
19 (13.0)
26 (16.6)
73 (14.1)

11 (26.9)
9 (7.3)
15 (12.3)
27 (15.9)
62 (13.5)
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BPs+SSRIs use

14

BPs+SNRIs use

Frequency

12
10
8
6
4
2
0
2003

2004

2005

2006

2007

2008

2009

Year

Figure 3.3. A plot of utilization patterns for concomitant use of BPs+SSRIs, and BPs+SNRIs in
U.S. women aged ≥45 years, MEPS 2004 to 2008.
Table 3.4. Utilization patterns of concomitant use of bisphosphonates and SNRIs by age in U.S.
women aged 45 years and older for MEPS 2004-2008.
Year
Total
BPs+SNRIs use
45-54 years, n (%)
55-64 years, n (%)
65-74 years, n (%)
75-85 years, n (%)
All, n (%)

2004
N=497

2005
N=519

2006
N=556

2007
N=496

2008
N=466

1 (5.5)
3 (3.0)
2 (1.6)
3 (1.9)
9 (2.5)

4 (12.1)
4 (4.0)
6 (4.0)
1 (1.1)
15 (3.8)

1 (2.3)
4 (3.3)
3 (1.5)
3 (1.7)
11 (2.2)

1 (3.0)
10 (5.9)
0 (0)
6 (3.8)
17 (3.5)

4 (11.5)
6 (5.1)
5 (4.8)
2 (2.1)
17 (4.3)

3.4.3 Concomitant use of BPs and SSRIs/SNRIs by age and year
When concomitant use of SSRIs with BPs use was examined by age group in each
calendar year (Table 3.5 and Figure 3.4), we observed a significant linear trend (slope=2.1;
p=0.01) of concomitant use among women aged between 75-85 years which increased steadily
between 2004 and 2008. Although a similar upward trend was observed among women aged 6574 years, the linear trend was nonsignificant (slope=1.6; p>0.05). In the group aged 65-74 years,
utilization decreased between 2004 and 2005, increased sharply in 2006, and then decreased in
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2007 and 2008. Of the qualified participants in this study, interesting findings were observed
among women aged 55-64 years. Among women of this age group, unstable (“zigzag”)
downward, but nonsignificant, trend (slope=-2.8; p=0.06) was observed from 2004 to 2008. A
look at year to year utilization pattern shows an increase from 2004 to 2005 then decreased
sharply in 2006, increased sharply in 2007 and then decreased in 2008. Finally, a non significant
overall upward utilization trend (slope=2.3; p>0.05) was observed among women aged 45-54
years old. In this age group, the utilization trend increased upward from 2004 to 2005 then
remained almost unchanged in 2006, decreased in 2007, and then increased sharply in 2008.

30

Frequency (%)

25
20

45‐54 Years
55‐64 Years

15

65‐74 Years

10

75‐85 Years

5
0
2003

All

2004

2005

2006

2007

2008

2009

Year

Figure 3.4. Plot of utilization patterns of concomitant BPs+SSRIs use by age of U.S. women age
≥45 years and older, MEPS 2004-2008.
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Table 3.5. Trend analysis for concomitant SSRIs use with BPs.
Year
Total
BPs + SSRIs
use
45-54 (%)
55-64 (%)
65-74 (%)
75-85 (%)
All, n (%)

2004
N=467

2005
N=519

2006
N=556

2007
N=496

2008
N=466

Slope; p-value

12.6
(7.04-18.24)
18.4
(16.01-20.87)
7.5
(2.57-12.41)
8.8
(7.53-10.00)
11.7
(8.67-14.74)

16.5
(15.81-17.11)
19.4
(14.53-24.26)
6.6
(4.12-9.10)
9.5
(6.33-12.59)
12.1
(9.56-14.73)

16.2
(14.10-18.22)
9.8
(7.21-12.30)
16.2
(12.85-19.52)
13.4
(8.69-18.06)
13.3
(10.57-16.01)

10.8

26.9
(0.16-53.59)
7.3
(3.46-11.04)
12.3
(8.67-16.02)
15.9
(12.03-19.78)
13.5
(10.37-16.56)

2.3; p>0.05

13.3
(10.31-16.26)
13.0
(10.66-15.32)
16.6
(12.47-20.81)
14.1
(11.57-16.72)

-2.8; p>0.05
1.6; p>0.05
2.1; p=0.01
0.56; p=0.04

Note: The denominator for age categories is the total number of women in that particular age
group and for that particular year, whereas the denominator for “All” is the “Total” number of
women in that year.
When concomitant use of BPs+SNRIs was examined by age group in each calendar year
(Table 3.6 and Figure 3.5), we observed a positive, but nonsignificant linear trend across all age
groups of concomitant use between 2004 and 2008 (slope range=+0.24 to +0.61; p >0.05).
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Frequency (%)

12
10
45‐54 Years

8

55‐64 Years
6

65‐74 Years

4

75‐85 Years

2

All

0
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Figure 3.5. Plot of utilization patterns of concomitant BPs+SNRIs use by age of U.S. women
age ≥45 years, MEPS 2004-2008.
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Table 3.6. Trend analysis for concomitant SNRIs use with BPs.
Year

2004

2005

2006

2007

2008

Total
BPs+SNRIs
use
45-54 (%)

N=467

N=519

N=556

N=496

N=466

5.5
(5.21-5.78)
3.0
(1.37-4.56)
1.6
(0-4.23)
1.9
(1.72-2.06)
2.5
(0.76-4.26)

12.1
(11.67-12.63)
4.0
(1.05-6.90)
4.0
(1.85-6.20)
1.1
(0-3.24)
3.8
(1.87-5.76)

2.3
(1.98-2.55)
3.3
(1.58-4.99)
1.5
(0.20-2.85)
1.7
(0-3.68)
2.2
(1.05-3.29)

3.0

11.5
(5.79-17.24)
5.1
(1.14-9.13)
4.8
(2.67-6.93)
2.1
(1.96-2.23)
4.3
(1.55-7.05)

55-64 (%)
65-74 (%)
75-85 (%)
All, n (%)

5.9
(4.44-7.41)
0
3.8
(1.24-6.42)
3.5
(2.38-4.71)

Slope;
value

0.29p>0.05
0.61;p>0.05
0.24;p>0.05
0.31;p>0.05
0.33;p>0.05

Note: See Table 3.5
3.4.4 Relationship between concomitant use of BPs+SSRIs and age
The findings from examining whether age is associated with utilization pattern of
concomitant use of BPs+SSRIs (Table 3.7) shows no structured pattern of odds ratios, overall.
However, we noticed the highest odds of concomitant use with increasing age in the year 2007
(odds ratios ranging from 1.24 to 1.66). Also, we observed that the pattern of odds ratios were
similar in the years 2005 and 2008 which might suggest a need for further investigations.
A time-trend analysis of the age effect shows a statistically non significant decreasing
probability trend for BPs+SSRIs concomitant use in 2004 (p>0.05) and a statistically significant
decreasing trend in 2005 (p<0.05), a statistically non significant increasing trends in 2006 to
2008 (p>0.05). See Table 3.8.
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Table 3.7. BPs+SSRIs concomitant utilization odds ratio (and 95% confidence interval) for age,
by year; MEPS 2004-2008.
Year
Total
BPs+SSRIs
use
Age
45-54
55-64
65-74
75-85

2004
N=467

2005
N=519

2006
N=556

2007
N=496

2008
N=466

1.00
1.56 (0.76, 3.20)
0.56 (0.22, 1.43)
0.66 (0.32, 1.39)

1.00
1.22 (0.59, 2.54)
0.36 (0.14, 0.90)
0.53 (0.24, 1.16)

1.00
0.56 (0.26, 1.24)
1.00 (0.48, 2.11)
0.80 (0.35, 1.85)

1.00
1.27 (0.46, 3.55)
1.24 (0.46, 3.35)
1.66 (0.63, 4.36)

1.00
0.21 (0.07, 0.62)
0.38 (0.16, 0.94)
0.52 (0.25, 1.08)

Table 3.8. Cochran-Armitage Trend test of concomitant use of BPs+SSRIs for age, by year; MEPS
2004-2008.
Year

2004

2005

2006

2007

2008

Statistic (Z)
0ne-sided p-value
Trend (‘1’)

1.438
0.075
decrease

2.547
0.005
decrease

-0.229
0.410
increase

-0.699
0.242
increase

-0.319
0.375
increase

3.5 Discussion
This study described national estimates across five-year period of concomitant SSRIs/SNRIs
with BPs and the trend over time. We also screened the effects of age on utilization patterns in
order to provide information that might be useful in supporting the need for further detailed
investigations. Both overall utilization patterns of concomitant use as well as utilization for four
age categories were presented.
3.5.1

Overall utilization and trends of concomitant use
We found that overall concomitant SSRIs with BPs use is prevalent and increased

slightly across the five-year period among the study population. Although we observed
concomitant SNRIs with BPs use, based on the National Center for Health Statistics minimum
standard for reliability of estimates,25 overall patterns of use across the five-year period were
98

considered too small for any meaningful interpretations and therefore concomitant SNRIs with
BPs use findings are not discussed further. The low cell sizes can be attributed to the fact that
SSRIs are widely used than SNRIs. Although SSRIs and SNRIs are both most popular
antidepressants with comparable efficacy,26 all SSRIs (citalopram, fluoxetine, fluvoxamine,
paroxetine, and sertraline) but only one SNRI (venlafaxine) are the most commonly used
medications for depression. This was according to the 2000 American Psychiatric Association
practice guideline for the treatment of patients with major depressive disorder. These
medications are likely to be optimal in terms of the patient’s acceptance of side effects, safety,
and quantity and quality of clinical data.27 Also, the 2001 expert consensus panel recommended
venlafaxine as an alternative to SSRIs as a first-line treatment for depression in older adults.28
With regards to the overall increasing trend of concomitant SSRI with BP use, it is
unclear why the simultaneous use of these agents increased across the five-year period and what
might explain the effects of age on patterns of use. Since this present study did not intend to
determine the predictive factors influencing the patterns of use, we explored the literature in an
effort to suggest explanations for our findings. Three suggested explanations are provided and
these include, 1) increasing population of women in the US and demographic factors, 2)
increasing diagnosis of osteoporosis or fractures and/or depression, 3) side effects associated
with HRT use and the influence on alternative therapies, and 4) newer indications for both BPs
and SSRIs in women.
Population increase is an important factor to consider when assessing changes in trend of
drug utilization, and in the present study concomitant SSRIs with BPs use. In our study we
observed that overall the female population increased in numbers from 2004 (36%) to 2008
(40%) (see Figure 3.2).24 Utilization can increase if the chances that more females begin taking
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medications increases. This can be supported by the fact that females are more likely to visit
their healthcare providers than males and this has an overall influence on medication
utilization.29 Furthermore, of the women surveyed, we observed a large number of white women
compared to other races across the five year period. The old National Osteoporosis Foundation
Guide, last updated in 2005, applied only to postmenopausal white women30 and this might have
influenced both the patient preference and physician prescribing habits in shared decisionmaking.
Another perspective related to population increase might be the increase in the incidence
of osteoporosis or fractures and/or depression. This is an important factor that could result in an
overall increased demand for prescription drugs. The incidence of osteoporosis and risk of
fractures in postmenopausal women continues to increase over time. It is estimated that 10
million individuals in the United States have osteoporosis, eight million are women and two
million are men.31 According to estimated figures, osteoporosis was responsible for more than 2
million osteoporotic fractures in 2005. Due to specialized tests for diagnosis there has been a
five-fold increase in office visits for osteoporosis (from 1.3 to 6.3 million) based on data from
1996 to 2006. This data suggests that improved diagnosis can lead to therapeutic follow-up to
treat or prevent osteoporosis and/or risk of fractures through administering antiresorptives (e.g.,
bisphosphonates) and this will have an overall impact of increasing utilization of such
medications. Low BMD in combination with low-trauma fracture or fracture risk factors
(smoking and weight) remains the strongest predictor or drivers of BPs use in postmenopausal
women.32,33
The WHO suggests that major depression is the leading cause of burden of disease in the
Americas accounting for 7.5% of total disability-adjusted life years (DALYs) and is expected to
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be leading worldwide by year 2030 accounting for 6.2% of total DALYs. Moreover, the WHO
report indicates that depression is the leading cause of disease burden in young women (15-44
years).34 As with younger women, among older persons, the burden of depression is higher in
older women than older men, but is less common during the postmenopausal years.35,36 For
example in the study by Barry et al. it was found that among those who were non-depressed,
women were more likely to transition to a depressed state, with an adjusted odds ratio of 2.02
(95% CI;1.39-2.94).36 It is important to note that depression in older adults is not directly
associated with advancing age37, but rather is considered a disorder co-morbid with other
illnesses associated with aging.38
According to the Agency for Healthcare Research and Quality (AHRQ), about 60% of
depressed outpatients have at least one other chronic medical condition as well. The challenge of
treating depression is a big issue in older adults. AHRQ research comparing older adult patients
with and without depression in a primary care clinic found that the depressed patients had almost
1.5 more ambulatory care visits per year, over 12 percent more visits to the emergency
department, and 5% more hospitalizations.39 Despite the complexity of treatment of patients with
comorbidity, patients with cormobid disorders continue to receive treatment to improve the
quality of care.40 With the high prevalence of depression in postmenopausal women attributed to
improved diagnosis through increased contacts with the healthcare system, antidepressant
prescriptions are likely to be driven up as result in order to meet the desired goal of improving
the quality of care for patients with depression. This is in agreement with previous literature
which found that guideline concordance (guideline of the 1999 Canadian Network for Mood and
Anxiety Treatments) increased prescribing physician visits in the year following diagnosis. In
this study 2,742 patients (mean age 42 years; 64% female patients) met the study criteria. Of the
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beneficiaries to whom psychoactive medication was dispensed, 2,047 (75%) received an
antidepressant as the initial starting drug and 1958 (71%) received a recommended first-line
antidepressant. In a multivariable model, recommended first-line medication (z=6.17, df 11,
p=0.001), starting dose (z=5.70, df 11, p=0.001), and duration (z=9.49, p=0.001) were associated
with more visits to prescribing physicians.41
Another factor that might have influenced use of bisphosphonates and/or SSRIs/SNRIs is
the study by the Women’s Health Initiative (WHI) about the adverse effects of estrogen in
women. In 2002, data from a WHI study was published highlighting the side effects (breast
cancer and cardiovascular disease) of estrogen plus progestin in healthy postmenopausal
women.42 In response to these concerns, use of alternative therapies increased. This is evident
from the reported increase in nonhormonal options as alternatives to estrogen, given with and
without progestin (or HRT), for postmenopausal symptoms such as osteoporosis and hot flushes
that respond only to prescription medications following WHI study. The North American
Menopause Society released a position statement in 2003 recommending options for women with
concerns or contraindications relating to estrogens. The nonhormonal options included
antidepressants such as venlafaxine (SNRI), paroxetine, and fluoxetine (both of which are
SSRIs). This statement in now retired.43 Huot et al. showed a decrease in HRT and increase in
bisphosphonate prescriptions from 2004 to 2006 in women aged 50 years and older.44 Vegter et
al. showed that those who stopped HRT received more nonhormonal therapies for menopausal
symptoms from 2002 to 2006 compared to those who continued hormonal therapy; incidence
risk ratio (IRR) of bisphosphonates was significant (IRR=2.54, 95% CI 1.16-5.55) and overall
IRR of antidepressants was not statistically significant (IRR=1.34, 95% CI 0.97-1.86).
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Antidepressant use was increased for both tricyclic antidepressants and SSRIs, but not for other
types of antidepressants (including SNRIs).45
Another way through which side effects of HRT use may influence alternative therapy
choices could be to increase healthcare costs. The long-term safety concerns of breast cancer
associated with HRT use increases management costs for HRT users because women are more
likely to get excess rates of resource utilization for uterine- and breast-related diagnostic and
treatment procedures, thus, increasing the healthcare cost pressures.46 Considering that the
current US Preventive Service Task Force guidelines recommend alternatives such as
bisphosphonates for osteoporosis therapy,47 these recommendations plus the induced additional
healthcare-related cost pressures might have reinforced the need to consider therapeutic
alternatives to HRT.
Consensus guidance recommendations support new indications for BPs or SSRIs and the
new indications may contribute to expanded utilization of either or both drugs. Additional
indications for bisphosphonate use include reducing skeletal complications of many
malignancies, including multiple myeloma, breast and prostate cancer, and other solid tumors,
and palliation of cancer-associated bone pain.48 Data from the Surveillance, Epidemiology, and
End Results from 2004-2008 showed that the trend of cancer incidence for females of all races
remained stable with an annual percentage change of 0.4%. (www.seer.cancer.gov) In addition,
data from the Centers for Disease Control (2004-2008) indicate that the site with the highest
incidence rate (about 120 per 100,000 population) was of the female breast followed by the lung.
The highest death rate among females was from lung cancer (www.apps.nccd.cdc.gov). Other
indications for SSRIs include, generalized anxiety disorder, social anxiety, panic disorder,
posttraumatic stress disorder, obsessive compulsive disorder, and eating disorder.(www.fda.gov)
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Given that some of the commonly associated health conditions in the postmenopausal
years include osteoporosis, depression, diabetes, and cancer (www.menopause.org), it is
plausible to suggest that coexistence of osteoporosis and depression or osteoporosis and other
indications for SSRIs or depression and other indications for BPs, or other indications for both
BPs and SSRIs are prevalent. Coexistence of any of these diseases can influence overall
expanded utilization of simultaneous SSRIs with BPs use.
3.5.2 Utilization patterns and trend of concomitant use with age
The main reason to further classify patients into age groups is that age-related
characteristics (e.g., clinical) are heterogeneous.49 As a result, age-related differences might
influence health services and medications utilization. The differences are especially significant
among women within the older age groups 65 years and older.50 In this present study, the
tabulated results by year for each age category showed increasing utilization of concomitant
SSRIs with bisphosphonates use among respondents 65 years and older across the five-year
period and the pattern might be time-dependent. This was further explained by looking at the
age-specific odds ratios. Although the odds ratios showed no structured pattern, the observed
highest odds ratios of older respondents with simultaneous use of BPs+SSRIs in 2007 is
probably because 90% of older adults 65 years and older had regular source of health care
regardless of other factors and the use of physician services was found to be high among this
population.51 The higher contact with healthcare providers could have had an overall influence in
medications use. In addition, major policy changes of year 2006 following the implementation of
The Medicare Modernization Act Prescription Drug Benefit (Part D)52 made it possible for older
adults 65 years or older to voluntarily subscribe to drug coverage which in turn resulted in
modest increase in average drug utilization.53 Another primary contributor to upward drug trend
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in this age group is the decline in unit costs of medications due to entry of lower-cost options
(generic drugs).54 Zoloft® (sertraline) was one of the generic drugs introduced in mid-2006.55
In 2005 and 2008 the similar low odds ratios observed suggested important factors that
might have impacted utilization of medications. In 2005 Gunnell et al. reported that SSRIs use
was associated with increased risk of suicidality in older adults.56 It is probably in response to
these concerns that SSRIs prescribing and hence utilization growth declined. In addition to the
implementation of Medicare Part D prescription drug coverage in 2006 which resulted in
increased drug utilization among older adults 65 years and older, the first generic
bisphosphonate, Fosamax® (alendronate), that is approved to treat osteoporosis was introduced
in 2008.57 As would be expected, the introduction of generic bisphosphonate into the
pharmaceutical market would decrease the unit costs of the most popular bisphosphonate drug.
Both the guaranteed prescription drug coverage and decreased unit costs were expected to further
drive the utilization of medications upwards and possible increased likelihood of simultaneous
SSRIs with BPs users. Instead, a decline in utilization was observed and there are two suggested
contributing factors: 1) the safety and effectiveness concerns related to medications for
postmenopausal osteoporosis published in 2007, and 2) the economic downturn-related factors in
2008.
Of the medications that have been proven to be effective in decreasing the risk of
osteoporotic-related fractures in postmenopausal women, bisphosphonates are the most popular.
Suboptimal compliance and persistence with bisphosphonate treatment was associated with
increased fracture risk. However, the benefits of oral bisphosphonates use over extended period
of time were unclear suggesting that decisions on optimal clinical effectiveness achieved during
indefinite use of bisphosphonates could not be supported.58 In a randomized, double-blind trial
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conducted at 10 U.S. clinical centers that participated in the Fracture Intervention Trial of
postmenopausal women using alendronate, findings showed that discontinuation of alendronate
for up 5 years does not appear to significantly increase fracture risk but therapy beyond 5 years
was recommended for women at high risk of clinical vertebral fractures.59 Considering that the
journal has a high impact factor, looking at the time of publication of this article (December
2006) the findings might have created confusion among physicians and patients as well during
the year 2007.
At about the same time of publication of the article by Black et al.59 a review by Briot et
al. which assessed optimal treatment duration of use of bisphosphonates determined that there
was no proof that these drugs prevented fractures after the first 4 to 5 years of treatment and so,
long-term use of these drugs was recommended for 4-5 years.60 Additional articles with
consistent conclusions have since been reported. During the year 2007, these findings were
widely publicized which also may have spilled over to 2008. As a result, it is plausible to
suppose that the negative impact on physician prescribing habits and patient preference was
unavoidable and, thus, had an overall influence in the decline in utilization of bisphosphonates.
As was mentioned earlier, the second suggested contributing factor to changes in
utilization of concomitant SSRIs with BPs was the impact of the economic crisis in 2008. The
economic crisis in 2008 was quite devastating for many families. Investments were devalued,
people lost jobs, and budget cuts were made in the government as well as the private sector and
this could strongly and negatively impact overall spending on basic needs including healthcarerelated utilization. A recent study by Piette et al.61 found that among chronically ill patients in
2008, rates of medication-cost problems associated with recent economic recession impacted all

106

age groups including those >65 years of age and eligible for Medicare Part D. Rates were
especially high among adults aged 40-64 years.

3.5.3

Relationship between concomitant SSRIs with BPs and age
The relationship between concomitant SSRIs with BP use and age was not consistent

across the five year-period. Overall, concomitant use decreased with age from 2004 to 2005 but
increased from 2006 to 2008. This can, in part, be explained by the confusion in age-related
treatment options driven by the age-dependent bone density change62 and safety of hormonal
treatments of menopause-related health outcomes.63 In younger postmenopausal women (after 50
years old), increase in bone loss (osteoporosis) is related to a sharp drop in estrogens and thus
hormonal therapy might be beneficial.62,63 Although HRT is associated with heart disease in
postmenopausal women, complications of therapy occur in women many years after the start of
menopause.64 In 2004, Anderson et al. released an updated interpretation of the WHI study (in
comparison to the previous 2002 WHI study) that was supportive of estrogen use in the younger
postmenopausal women below the age of 60 years.65 SERMs are considered first-line therapy in
younger postmenopausal women at lower risk for hip fracture.5 Use of SERMs results in a 55%
reduction in vertebral fractures but lacks advantage when looking at nonvertebral fractures.66 In
older postmenopausal years (65 years and older), there is accelerated bone loss beginning at 70
years old62 and bisphosphonates are the first-line therapy for osteoporosis.5 In reference to
SSRIs, the downward trend from 2004 to 2005 was probably due to a fall in utilization. For
example, Chen et al. in a study using Medicaid data found that the total number of antidepressant
prescriptions increased from 1991 to 2004 (from 6.8 million to 35 million scripts), but then fell
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in 2005 to 32.7 million prescriptions. SSRI prescriptions were 20.8 million in 2004 but fell to
19.5 million in 2005.67
The National Osteoporotic Foundation suggests age as one of the factors to consider
when choosing a treatment. The foundation states that “some medicines may be more appropriate
for younger postmenopausal women while others are more appropriate for older women.”68 This
statement is likely to have an overall influence on physician prescribing habits, patient
preferences, or healthcare systems. Under this confusion, some physicians might switch their
patients to a safer alternative, or some might use their clinical judgment and experiences to wait
and switch their patients later, patients’ preference might influence physician prescribing, or
healthcare systems might tailor their formularies. In summary, the factors discussed above might
be responsible to explain a downward (2004-2005) and upward (2006-2008) trend of
concomitant SSRIs with BPs use with age in our present study.
3.5.4 Strengths and limitations
There are strengths and limitations in this study. Strengths: First, MEPS consists of
patient-level data and is nationally representative of the U.S. civilian, non-institutionalized
population. It was therefore suitable to use this dataset to describe national estimates of
medication use. Secondly, self-reporting bias is minimal. This is because MEPS does seek
permission from the respondents to verify medications use from their respective pharmacies.
Limitations: Following age categorizations and medications use, all cell sizes for BPs+SSRIs use
were small (less than 30). According to the National Center for Health Statistics, estimates
determined to be statistically reliable are generally based on sample size (cell size greater than or
equal to 30) and relative standard error (less than 30%).25 Therefore, interpretations of data under
age categories is not representative of national estimates and caution is advised.
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3.6 Conclusions
We conclude that concomitant SSRIs with BPs use in adult women ≥45 years is not
uncommon and might be higher in older postmenopausal women. The trend of concomitant use
may be time-dependent and the utilization pattern over time may be influenced by patient-,
provider/physicians-, and health-care system-level factors that determine prescribing of
medications to particular patients. Unfortunately this study did not attempt to assess these factors
but only suggested possible explanations from literature. As such there is still need to further
investigate the impact of these factors on the utilization patterns of SSRIs with BPs using a large
sample size and longitudinal data. Moreover, the observed concomitant use presents drug safety
challenges surrounding the bone health of postmenopausal women. Studies are needed to
investigate the potential interactive effects of SSRIs on BP therapy.
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Chapter 4
4.0 METHODS
4.1 Study design
A nested case-control study was performed to examine 1) the association between concomitant
use of SSRIs or SNRIs with bisphosphonates and increased risk of osteoporotic-related fractures,
and 2) whether the risk of osteoporotic-related fractures is related to the role of serotonin in bone
rather than the disease (depression).
4.1.1 Rationale
One of the prime purposes of a pharmacoepidemiologic study is to determine whether
drug exposure causes an adverse drug event (health outcome). Typically, the sequence of
discovery of causal association between exposure and outcome using epidemiologic approaches
involves five steps which include the analytic methods such as nested-case control study design
(or the case-control in a cohort study).1 Nonetheless, many population-based case-control studies
can be thought of as nested within an enumerated source population.2 This design is based on a
sampling approach known as incidence density sampling or risk set sampling. In the nested-case
control study, cases of the outcome of interest that occur in a defined cohort are identified, a risk
set (i.e., that could become a case) corresponding to the cases is formed and, for each, a specified
number of matched controls is randomly selected for each risk set from among those in the
cohort who have not developed the outcome by the time of the outcome occurrence in the case.3
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By using this strategy, cases occurring later in the follow-up are eligible to be controls for earlier
cases.4
Strengths exist in support of this study design strategy. First, the design combines some
of the features and advantages of both cohort (i.e., limiting selection bias) and the efficiency of
case-control designs approach. The likelihood of selection bias tends to be diminished in
comparison with the traditional case-based case-control study. This is because cases and controls
are selected from the same (defined) source cohort and because (as in any traditional cohort
study) exposures are assessed before the disease occurs.4 In addition, this study approach can be
relatively quicker and less expensive than cohort or experimental studies, primarily because the
control group is a sample of the source population. Also, the design strategy involves potentially
less complex analysis. Second, when the outcome being studied occurs rarely and/or is suspected
to be a latent effect of the exposure, cohort studies become impractical and case-control studies
become a useful and efficient alternative. This is because fewer subjects are needed than for
cohort studies.2,5 Third, the likelihood of survival bias tends to be diminished in comparison with
the traditional case-based case control study. Survival bias is a potential problem in a case-based
case-control study carried out “cross-sectionally” because only cases with long survival after
diagnosis (best prognosis) are included in the case group.4 Fourth, the study design is better in
quantification of exposure with respect to time.3 Sampling is the equivalent of matching cases
and controls on duration of follow-up (or respect to time), thus if time is related to exposure, the
resulting data should be analyzed as matched data.2,4
4.2 Data sources
We used the random 5% sample data from the entire Medicare administrative claims data
(see Table 4.1 for a description of the data obtained) from 2008 to 2010. (Part A Medicare claims
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were of persons enrolled in fee-for-service because claims from these sources provide
information needed for research purposes.) These data are available back to January 2006, when
the program was implemented. The Centers for Medicare and Medicaid Services (CMS)
administer Medicare. All requests for CMS research-identifiable Medicare Part D data was
developed and reviewed with the assistance of the Research Data Assistance Center (ResDAC), a
CMS contractor that provides free assistance to academic, government and nonprofit
researchers.6
4.2.1 Rationale
Pharmacoepidemiologic research on the beneficial and adverse events of medications
among older adults has used databases such as Medicare Current Beneficiary Survey (MCBS) or
Medicare Expenditure Panel Survey (MEPS). However, these databases are limited by smaller
sample sizes, which can limit statistical power.7 MCBS is a continuous, multipurpose survey
(collected since 1991) of a representative sample of the Medicare population designed to aid the
CMS administration, monitoring and evaluation of the Medicare program.8 Unlike the databases
mentioned above, Medicaid database has a relatively large sample size of older adults and has
been used for drug safety related studies.9 The specific limitation of this database is its
generalizability. Those older adults who are not classified as of low income are not covered
under the Medicaid program and so are not represented in findings based on this database.
The use of Medicare Part D data, like other administrative databases such as Medicaid
data10 is faced with methodological challenges such as verifying data validity, confounding, and
logistic problems. A central limitation with many implications is that such databases are
collected for administrative rather than research purposes. These limitations are an important
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source of bias in the results of most studies. Based on this understanding, new methods relating
to data analysis approaches applicable to administrative claims data, such as Medicare Part D
data, have been suggested. These efforts are geared towards improving the usefulness of these
important data sources to evaluate drug safety and effectiveness.11 For example, recently,
Graham et al.12 determined the increased risk of cardiovascular events by rosiglitazone compared
with pioglitazone among 227,571 Medicare beneficiaries aged 65 years or older through a
Medicare Part D prescription drug plan from July 2006-June 2009. The results showed that the
prescription of rosiglitazone was associated with increased risk of cardiovascular events.12
This underscores the statement noted by Strom13 that “Medicare Part D is one potential
data source, which, when linked to other Medicare claims data, will be a unique resource on a
massive and stable population”.13 Thus the main advantage of using this source of data is its
large, nationally representative population of older adults. Also due the fact that out-of-pocket
spending was reduced with this plan among older adults, prescription drug use increased
significantly14 suggesting that Medicare Part D data potentially captures large numbers of users
of prescription drugs. Medicare Part D provided an opportunity for those beneficiaries who had
no drug coverage that were not poor and frail. Also, in a similar perspective, Platt and Ommaya15
noted that linked Medicare Part D data presents a valuable resource to assess drugs under reallife conditions, particularly in this vulnerable population, which is often excluded or
underrepresented in clinical trials. Therefore, use of information from Medicare administrative
claims data will be important because our preliminary studies using MEPS (see Chapter 3) have
been limited by smaller sample sizes and have not provided statistically reliable findings.
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Table 4.1. Description of CMS data files and key variables needed for analysis.
Study objective
To examine the association of
concomitant use of SSRIs/SNRIs,
glucocorticoids, or PPIs and
bisphosphonates and increased
risk
of
osteoporosis-related
fracture in adult women aged ≥65
years

Data variable (s)
Individual claims (e.g., fracture)
submitted for each inpatient stay at a
Medicare-approved facility (e.g.,
hospital)

CMS data file (s) needed
Medicare Part A (inpatient)

CCW Encrypted Part D Event
Number,
CCW
Encrypted
Beneficiary ID Number, Patient
Date of Birth, Gender, RX Service
Date (DOS), Encrypted Plan
Contract ID, Compound Code,
Quantity Dispensed, Days Supply,
Dispensing Status Code, Patient Pay
Amount, Medicare Part D formulary
tier identifier
CCW Encrypted Part D Event
Number,
CCW
Encrypted
Beneficiary ID Number, Brand
Name, Generic Name, Drug
Strength Description, Dosage Form
Code, and Dosage Form Code
Description
Provides a summary of the
beneficiary’s
use
of
various
Medicare categories and prior
history of various chronic conditions
(e.g.,
myocardial
infarction,
depression, etc.)
Provides
basic
beneficiary
demographic and geographic data, as
well as enrollment and eligibility
information

Medicare Part D (prescription drug
event)

Medicare
Part
characteristics file)

D

(drug

Beneficiary annual summary file

Beneficiary summary file

4.2.2 Data elements
The data elements from this database included a coded patient identifier (Medicare
patients have a unique personal identification number (PIN) through which all health system
encounters are tracked); patient demographics (age, race, and socioeconomic status);
procedure/diagnostic codes (or medical diagnoses); claim admission codes and dates, and
pharmacy claims details (National Drug Codes, drug names, date of drug dispensing, quantity
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dispensed, number of days supplied, and refill status).96 See Table 4.1 for a description of the
data variables obtained.
4.3 Study population
4.3.1 Inclusion criteria
Cases and controls were eligible for inclusion in the study if they were females and aged
65 years or older. Cases were defined as women with a first osteoporotic-related fracture
matching with the fracture index date. The fracture index date (date of experiencing a fracture)
was defined as the first documentation of an osteoporotic-related fracture during the study period
(January 2008 to December 2010) associated with hospitalization. Fracture identification was
based on the International Classification of Diseases, 9th revision; Clinical Modification (ICD-9CM) codes for fracture at six of the most common fracture sites from inpatient encounters: hip,
spine, distal radius/ulna, tibia/fibula or ankle, and humerus from inpatient encounters (Table
4.2). Only patients using bisphosphonates were included in the study.
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Table 4.2. Description of osteoporotic fracture sites included in the study.
Fracture site
Hip or pelvis
fracture

Fracture type
Closed

Femur

Closed

Vertebral (without
spinal cord injury)

Closed

Radius / ulna or
wrist

Closed

Humerus

Closed

Tibia/fibula or ankle

Closed

ICD-9-CM
Pathologic
Transcervical
Pertrochanteric
Unspecified hip
Acetabulum
Pubis
Other specified
Unspecified
Pathologic
Shaft/unspecified
Lower end
Pathologic
Cervical
Thoracic/Dorsal
Lumbar
Sacrum & coccyx
Unspecified
Pathologic
Upper end
Shaft
Lower end
Unspecified
Pathologic
Upper end
Shaft/unspecified
Lower end

733.14
820.0x
820.2x
820.8x
808.0x
808.2x
808.4x
808.8x
733.15
821.0x
821.2x
733.13
805.0x, 806.0x
805.2x, 806.2x
805.4x, 806.4x
805.6x, 806.6x
805.8x, 806.8x
733.12
813.0x
813.2x
813.4x
813.8x
733.11
812.0x
812.2x
812.4x
823.0x, 823.2x, 823.4x
823.8x, 824.0x, 824.2x
824.4x, 824.6x, 733.16

4.3.2 Exclusion criteria
Cases and controls were excluded if they had a history of prior fracture. History of prior
fracture was defined by any fracture in the first 6 months of observation if multiple fracture
events are noted during the study period, only the first event was included in the study. Women
with any fracture that was listed as “open” (e.g., 813.1x: fracture of radius/ulna, upper end, open)
was excluded since open fractures are more likely the result of a major trauma rather than
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osteoporosis. The complete list of open fractures is as follows: those with open fractures of the
hip, ICD-9-CM codes: 820.1x (transcervical), 820.3x (pertrochanteric), and 820.9x (unspecified
part of neck of femur); open wrist or radius/ulna fracture, ICD-9-CM codes: 813.1x (upper end),
813.3x (shaft), 813.5x (lower end), and 813.9x (unspecified part of radius/ulna), and open
vertebrae fracture with or without spinal code injury, ICD-9-CM codes: 805.1x, 806.1x
(cervical), 805.3x, 806.3x (thoracic), 805.5x, 806.5x (lumbar), 805.7x, 806.7x (sacrum &
coccyx), and 805.9x, 806.9x (unspecified part). Other exclusions were those women taking
calcitonin (Miacalcin), parathyroid hormone teriparatide (Forteo), selective estrogen-receptor
modulators (Evista), and also those women with diagnosis of Paget’s disease, or disabled people
under 65 years of age. These patients are at a much higher risk for adverse bone health.
4.4 Exposure to concomitant use
Assessments of the drug exposure as identified by their brand or generic names were as
follows. The primary exposure variable was the concomitant use of SSRIs or SNRIs with
bisphosphonates and was defined as having received at least one prescription for a
bisphosphonate and a SSRI or SNRI (with no dispensing medication gap for a SSRI or SNRI of
more than 90 days whereas users of bisphosphonates were those patients who were exposed for
at least 180 days in the 360 day period). SSRI users were defined as women reporting SSRI use
but no other antidepressants at a given visit. Likewise, SNRI users were defined as women
reporting SNRI use but no other antidepressants at a given visit.16 Information on SSRI or SNRI
use was classified as either ‘current’, ‘recent’, or ‘past’ users. A schematic representation is
shown in Figure 4.1. Current users were defined as those individuals with a total of 90 day
supply for a SSRI or SNRI and within 90 days (1 to 90) prior to the index date of sustained
fracture. Recent users were defined as those individuals with a total of 90 day supply for a SSRI
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or SNRI and within 91 days and 180 days prior to the index date of sustained fracture. Past
users-those individuals who were not current users or recent users and had a supply for a SSRI or
SNRI dispensed more than 180 days in the 360 day period prior to the index date of sustained
fracture. These definitions have been used in a previous study to assess the association between
antidepressants and risk of fracture of the hip or femur. In this study, compared with individuals
who had never used an SSRI, the risk of hip/femur fracture increased with current use of SSRIs
(adjusted OR=2.35, 95% CI 1.94-2.84), recent use (adjusted OR=1.48; 95% CI 1.14-1.93), and
past use (adjusted OR=1.23; 95% CI 1.07-1.42).17

Figure 4.1. Timing of SSRI or SNRI use.

4.5 Regulatory approval
This study was reviewed and approved by the Institutional Review Board (IRB) at Virginia
Commonwealth University.
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4.6 Statistical plan
4.6.1 Selection of subjects:
Flow charts for the selection of subjects eligible for analysis are shown in Figure 4.2
(Specific Aim 1) and Figure 4.3 (Specific Aim 2).
4.6.2 Dependent and independent variables:
Dependent (or response) variable: increased risk of osteoporotic-related fractures
Independent (treatment or explanatory) variables: Concomitant use of SSRIs or SNRIs and
bisphosphonates.
4.7 Strategic framework to control for confounding
A multivariable logistic regression model was developed to calculate the propensity score of
individual patients. (Refer to more information on propensity score method in Chapter 2 Section
IX). Propensity score is defined as the probability of receiving treatment rather than the control
for a patient conditional on observed baseline covariates.18 In this study, the propensity score is
the probability of receiving concomitant SSRIs or SNRIs with bisphosphonates versus
bisphosphonate alone users as a function of all the potential confounders listed in Table 4.4.
Medicare beneficiaries who were identified as “White” or “Black”, or “Hispanic” were
categorized as “White”, or “Black”, or “Hispanic” respectively. However, beneficiaries who
were identified as either “North American Native” or “Asian” or “Other” or “Unknown” were reclassified as “Other”. To quantify patients’ comorbidities included in the logistic regression
model, two potential comorbidity indices: Functional or Deyo-adapted Charlson Comorbidity
Index can be used for this pharmacoepidemiologic study. Both of these indeces are described
next, but we calculated the comorbidity scores using the Deyo-adapted Charlson Comorbidity
index. The rationale for the comorbidity index choice is provided in the following description.
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Table 4.3. Baseline patient characteristics of all antidepressant initiators.
Characteristic
Demographic
Age (within 5 year bands): Aging is characterized by changes in pharmacokinetic and pharmacodynamic
processes. These processes when altered increase the risk of adverse drug events, and increased sensitivity
to medications.1
Race (White, Black, Hispanic, or Other)
SES (based on low income subsidy of the beneficiary, as a proxy for socioeconomic status)
Health service-use intensity or Health care utilization factors
Comorbidity score
Number of unique prescribed medications
Medical conditions
Rheumatoid arthritis/ Osteoarthritis
Osteoporosis
Kidney disease
Anxiety or sleep disorder
Epilepsy
Movement disorders (e.g., Parkinson’s disease)
Cognitive dysfunction (e.g., Alzheimer’s disease or other diagnosis of dementia)
Hypertension
Congestive heart failure
Diabetes mellitus
Chronic obstructive pulmonary disease (COPD)
Hyperparathyroidism
Depression
Orthostatic hypotention
Use of other medications that may modify fracture risk
Oral glucocorticoid use/oral corticosteroid use
Proton pump inhibitor use
Aromatase Inhibitors
Thiazolidinediones use
Estrogen use (or hormone replacement therapy)
Warfarin use
Anticonvulsant use
Thyroid medication use
Opioid use
Antihypertensive use (thiazide diuretics, angiotensin II converting enzymes inhibitors, angiotensin II
receptor blockers, beta-adrenergic blockers, or calcium channel blockers)
Loop diuretic use (e.g. furosemide)
Antipsychotics use, Methotrexate, and Lithium
1

Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and
related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571-584.
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4.7.1 Comorbidity score
4.7.1.1 Functional comorbidity index
A functional comorbidity index is an index of comorbid diseases with physical function.
The functional comorbidity index contains 18 diagnoses scored by adding the number of “yes”
answers, with a score of 0, indicating no comorbid illnesses.19 The reason to use this index is
because SSRIs are one of the examples of medications associated with drug-related falls.20
SSRIs-related falls can be injurious and result in fractures. For example, in an observational
study of 368 subjects (SSRI users, n=129; non-SSRIs, n=40; non-antidepressants, n=199)
conducted in a nursing home setting showed high rate of falling in SSRIs users (24%, OR of 1.9
or greater) and high rate of injurious falls (OR, 1.73) that resulted in fractures and/or
hospitalization from a series of adjusted models compared with other two groups of subjects.21
Also, French et al.22 in a national veterans study using outpatient medication data to assess fallrelated hip fracture hospitalization showed that usage of SSRIs was 2-fold higher in hip-fracture
patients compared to the control groups.22 However, risk factors for falls and/or a fracture in
older adults are multifactorial such as comorbid diseases and physical function. The diseases
include but are not limited to diabetes mellitus, dementia, high blood pressure, chronic
obstructive pulmonary disease, and arthritis.23 In fact, the diseases are all included in the
functional comorbidity index.
Overall physical functioning is one of the intrinsic factors associate with falls
recommended to be assessed in an older patient reporting a fall.24 Therefore, the suggested index
might be appropriate in quantifying comorbidities and physical function on fracture outcomes.
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4.7.1.2 Charlson comorbidity index
There are thirteen different methods to assess comorbidity: one disease count and 12
indices. Of these, the Charlson index is the most extensively studied comorbidity index.25 The
Charlson comorbidity index is a summary score based on 19 major medical conditions including
myocardial infarction, pulmonary disease, cancer, diabetes, renal disease, hepatic disease, HIV
infection, etc. A score of 0 represents absence of comorbidity, and a higher score indicates a
greater number of comorbid conditions. The index was originally developed and validated in
1987 to classify prognostic comorbidity for patients enrolled in longitudinal studies; developed
based on the inception cohort study of 604 patients admitted to the medical service at New York
Hospital during 1 month in 1984 and then was tested for its ability to predict risk of death from
comorbid disease in a cohort of 685 patients who were treated for primary breast cancer at Yale
New Haven between 1962 and 1969. Its performance was compared to the method of classifying
comorbid disease developed by Kaplan and Feinstein.26 In later studies, it was validated for a
proposed age-comorbidity index in a different cohort of patients who had essential hypertension
or diabetes and who were undergoing elective general surgery for diagnoses such as peripheral
vascular disease and aortic aneurysm.27
Deyo et al. adapted Charlson comorbidity index, designed for use with clinical records,
for research relying on International Classification of Diseases (ICD-9-CM) diagnosis and
procedure codes to examine the association of the adapted index with health outcomes and
resource utilization. Data of all Medicare claims for beneficiaries who underwent lumbar spine
surgery in 1985 (n = 27,111) was used. This was based on Part A Medicare claims. The study
findings concluded that the Charlson index can be valuable in studies of disease outcome and
resource utilization when used with ICD-9-CM administrative databases.28 In further support,
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other studies have also validated use of Charlson index with administrative databases. D’Hoore
et al. adapted Charlson comorbidity index to ICD-9 codes to perform analysis on 1990-1991
MED-ECHO database (Québec) with 36,012 patient admissions with ischemic heart disease and
associated in-hospital death. The study concluded that the Charlson comorbidity index may be an
efficient approach to risk adjustment from administrative databases.29
Following validation of Charlson comorbidity index with administrative databases, the
index has gained popular use in epidemiologic research. For example, the Deyo-adapted
Charlson Comorbidity index has been used to quantify patients’ comorbidities and scores used in
a propensity score method to estimate the incidence rates and hazard ratios of subtrochanteric
and femoral fractures in elderly patients treated with oral biphosphonates compared with those
treated with either raloxifene or calcitonin.30 Since this dissertation project uses Medicare claims
data (administrative database), which was used to validate Charlson comorbidity index, then the
rationale for using the index is strongly justified and therefore Charlson comorbidity index was
adapted instead of the functional comorbidity index. Another reason is that obesity and/or body
mass index is one of the 18 diagnoses scored in the functional comorbidity index. Medicare
claims data does not provide information for these variables.
4.7.2 Propensity score matching
The primary analysis used a greedy algorithm for 1:1 propensity score matching to
control for confounding. Users of SSRIs were matched to potential users of SSRIs based on the
estimated propensity scores. All potential confounders included in the propensity-score model
are provided in Table 4. To assess achieving balance in baseline covariates between treatment
groups, standardized difference was used.31
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4.8 Statistical analysis
4.8.1 Descriptive analysis
After the propensity score matching, subjects were then analyzed. Descriptive statistics
comparing the baseline characteristics of the cases and the controls was performed. Continuous
variables were expressed as mean ± SD, 95% CI and categorical data was reported as
proportions. The characteristics of patients in each group were compared before and after the
propensity score matching. Baseline characteristics included sociodemographic characteristics
(age, race/ethnicity, and socioeconomic status), distinct prescription drugs (excluding SSRIs) and
co-morbidities (including depression), and prior and current use of exposures of interest (Table
4).
4.8.2 Multivariable analysis
Using bisphosphonate-alone users as our comparison group (controls), Cox proportional
hazard models were constructed to assess the risk of osteoporotic-related fractures among
bisphosphonates, SSRIs, and SNRIs users separately and among concomitant users of
bisphosphonates with SSRIs or SNRIs. Hazard ratios (HRs) and 95% CI were estimated. Since
we matched the groups on propensity scores containing potential confounders, the Cox
regression models contained only a variable for exposure of interest, with bisphosphonate-alone
users as the reference/comparison exposure.
The software SAS 9.3 version (SAS Institute, Cary, NC) was used and the level of
significance of α=0.05 was considered for all statistical tests.
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1,518,401 subjects enrolled
in Medicare Part D claims
data, under stand-alone PDP
plans: 2008-2010

52,258 subjects with
bisphosphonate prescription:
2008-2010

15,281 subjects with
concomitant use of
bisphosphonates and SSRIs:
2008-2010

3,646 subjects with
concomitant use of
bisphosphonates and SNRIs:
2008-2010

Figure 4.2. Flow chart showing selection of subjects from the Medicare part D, under standalone prescription drug plan eligible for analysis (Specific Aim 1): 2008-2010.
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105,894 subjects in the
inpatient file, fee-for-service
claims data: 2008

68,861 subjects in the
inpatient file, fee-for-service
claims data: 2009

75,484 subjects in the
inpatient file, fee-for-service
claims data: 2010

17,805 subjects with BPs
prescription in the Medicare
Part D claims, under standalone PDP: 2008

18,981 subjects with BPs
prescription in the Medicare
Part D claims, under standalone PDP: 2009

15,472 subjects with BPs
prescription in the Medicare
Part D claims, under standalone PDP: 2010

5,894 subjects
(bisphosphonate users)
eligible for analysis: 2008

7,558 subjects
(bisphosphonate users)
eligible for analysis: 2009

9,197 subjects
(bisphosphonate users)
eligible for analysis: 2010

1:1 Greedy matched pairs
(N=1,171): concomitant
users of BPs and SSRIs
matched to bisphosphonate
alone users: 2008

1:1 Greedy matched pairs
(N=1,318): concomitant
users of BPs and SSRIs
matched to bisphosphonate
alone users: 2009

1:1 Greedy matched pairs
(N=1,725): concomitant
users of BPs and SSRIs
matched to bisphosphonate
alone users: 2010

Combined matched pairs for
final analysis: N=4,214

Figure 4.3. Flow chart showing selection of subjects from the Medicare Part A, fee-for-service
and Medicare part D, under stand-alone prescription drug plan (Specific Aim 2): 2008-2010.
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Chapter 5
5.0 Specific Aim 1: Results and Discussion
5.1 Descriptive statistics
5.1.1 Overall summary
Descriptive statistics for the study population across the 3 year period are shown in Table
5.1 and Table 5.2. During the time period examined (2008-2010), there were 17,805 (3.5%)
patients aged 65 years or older who were bisphosphonate users in 2008, 18,981 (3.8%) patients
in 2009, and 15,472 (3.1%) in 2010. Of these bisphosphonate users 28.4% also used SSRIs in
2008, 28.8% in 2009, and 30.7% in 2010 (Table 5.1), whereas 6.7% used SNRIs in 2008, 6.9%
in 2009, and 7.5% in 2010 (Table 5.2).
Table 5.1: Descriptive statistics of Medicare PDP concomitant users of BPs and SSRIs.
Characteristic
2008
2009
510,861
504,574
Composite PDP Enrollees, n
17,805 (3.5)
18,981 (3.8)
Bisphosphonate users, n (%)
5061 (28.4)
5474 (28.8)
Concomitant users, n (%)
Age, n (%)
557 (11.0)
692 (12.6)
65-69
828 (16.4)
852 (15.6)
70-74
959 (18.9)
997 (18.2)
75-79
1109 (21.9)
1214 (22.2)
80-84
1608 (31.8)
1719 (31.4)
85+
Race, n (%)
4366 (86.2)
4730 (86.4)
White
165 (3.3)
181 (3.3)
Black
389 (7.7)
429 (7.8)
Hispanic
141 (2.8)
134 (2.5)
Other
Socioeconomic status, n (%)
2443 (48.3)
2706 (49.4)
Low
2618 (51.7)
2768 (50.6)
High
Abbreviations: PDPs, Medicare stand-alone prescription drug plans
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2010
502,966
15,472 (3.1)
4746 (30.7)
634 (13.4)
713 (15.0)
865 (18.2)
1012 (21.3)
1522 (32.1)
4013 (84.6)
175 (3.7)
409 (8.6)
149 (3.1)
2462 (51.9)
2284 (48.1)

Table 5.2. Concomitant use of bisphophonates and SNRIs.
Characteristic
Composite PDP Enrollees, n
Bisphosphonate users, n (%)
Concomitant users, n (%)
Age, n (%)
65-69
70-74
75-79
80-84
85+
Race, n (%)
White
Black
Hispanic
Other
Socioeconomic status, n (%)
Low
High

2008
510,861
17,805 (3.5)
1191 (6.7)

2009
504,574
18,981 (3.8)
1300 (6.9)

2010
502,966
15,472 (3.1)
1155 (7.5)

189 (15.8)
220 (18.5)
225 (18.9)
265 (22.3)
292 (24.5)

214 (16.5)
238 (18.3)
260 (20.0)
264 (20.3)
324 (24.9)

237 (20.5)
213 (18.4)
210 (18.2)
225 (19.5)
270 (23.4)

1049 (88.1)
33 (2.8)
73 (6.1)
36 (3.0)

1125 (86.5)
34 (2.6)
100 (7.7)
41 (3.2)

1013 (87.7)
34 (2.9)
82 (7.1)
26 (2.3)

577 (48.5)
614 (51.5)

679 (52.2)
621 (47.8)

618 (53.5)
537 (46.5)

It appears that concomitant use of bisphosphonates and SSRIs/SNRIs among Medicare
beneficiaries increased from 2008 through 2010, but utilization was observed to be more
prevalent among SSRI than SNRI users (Figure 5.1). Among those patients who were
bisphosphonate users, the proportions of SSRI use in the year 2010 was 2.3% points higher than
in the year 2008 (30.7% vs. 28.4%) and 1.9% points higher than in the year 2009 (30.7% vs.
28.8%). On the other hand, the proportions of SNRI use in the year 2010 was 0.8% points higher
than in the year 2008 (7.5% vs. 6.7%) and 0.6% points higher than in the year 2009 (7.5% vs.
6.9%). However, linear trends in the standardized rates (Table 5.3 and Table 5.4) were not
statistically significant and thus no evidence for change in concomitant use of bisphosphonates
and SSRIs (slope: +112.5, p-value: 0.2227) or SNRIs (slope: +38.8, p-value: 0.2082) from 2008
to 2010. This may not be surprising since a 3-year period is relatively short.
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Abbreviations: Antidep, antidepressant
Figure 5.1. Overall concomitant use of bisphosphonates and SSRIs or SNRIs.
Table 5.3: Concomitant use of bisphosphonates (BPs) and SSRIs rates.

2008
2009
2010

BPs + SSRIs
users
5061
5474
4746

All BPs users

Rate/10,000

95% CI

17,805
18,981
15,472

2842.5
2883.9
3067.5

2764.2-2920.8
2807.5-2960.3
2980.2-3154.8

Rate=2706.3 + 112.5year; p-value=0.2227

Table 5.4: Concomitant use of bisphosphonates and SNRIs rates.

2008
2009
2010

BPs + SSRIs
users
1191
1300
1155

All BPs users

Rate/10,000

95% CI

17,805
18,981
15,472

668.9
684.9
746.5

630.9-706.9
647.7-722.1
703.1-789.6

Rate=622.5 + 38.8year; p-value=0.2082

Summary of concomitant use by demographic subgroups showed variations in
concomitant use across the 3 years by age, socioeconomic status (SES), race, and geographic
location (by states). Notably, concomitant use showed an increasing trend with increasing age,
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concomitant use increased among those of low SES but showed decreasing trend among those of
higher SES over time, and overall concomitant use was highest among white women compared
to other races. However, these differences were more pronounced for concomitant use of
bisphosphonates and SSRIs than with SNRIs. Small proportions of concomitant use (especially
with SNRIs) as well as usage by race which were highly skewed were not described further in
detail. Therefore, following is a further description of concomitant use of bisphosphonates and
SSRIs by selected demographic characteristics (age, SES, and geographic location).

5.1.2 Concomitant use by age
Overall, we observed a steady and increasing trend of concomitant use across the 5 age
groups and across the 3 years (Figure 5.2). Older adults over 85 years or older were about 2.5
times as likely to have used bisphosphonates and SSRIs as those who were 65-69 years old
(31.8% vs. 11.0% in 2008, 31.4% vs. 12.6% in 2009, and 32.1% vs. 13.4% in 2010). Findings
from the year to year trend within age groups showed that concomitant use increased from 2008
to 2010 for the 65-69 age groups, but we observed unstructured pattern of concomitant use for
other age groups across the 3 years.
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Figure 5.2. Proportions of concomitant use by age.
5.1.3 Concomitant use by socioeconomic status and age
We observed that concomitant use varied by SES and also by age within the two groups
of SES (Figure 5.3). For all ages, concomitant use was slightly higher among women of higher
SES (50.2%) than those of lower SES (49.8%). In terms of trend, we observed increasing pattern
of concomitant use across age groups for those of higher SES, but decreasing pattern for those of
lower SES. The proportions ranged between 56.6% (age group: 65-69) to 46.5% (age group:
85+) among women of lower SES and between 43.4% (age group: 65-69) to 53.5% (age group:
85+) among those women of higher SES. When we observed concomitant use by SES across the
3 year period (Figure 5.4), we found that concomitant use among women of lower SES
increased (from 48.3% in 2008 to 51.9% in 2010), whereas that of higher SES decreased (from
51.7% in 2008 to 48.1% in 2010) over time.
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Figure 5.3. Proportions of concomitant use by socioeconomic status and age.

Figure 5.4. Proportions of concomitant use by SES and year of enrollment.

141

5.1.4 Utilization by state
Overall, we observed that concomitant use of bisphosphonates and SSRIs varied by state
(Figure 5.5). The frequency of use appears to be higher in the South and North East regions of
the U.S. compared to Western regions of the U.S.

Figure 5.5. Overall variation in concomitant use of bisphosphonates and SSRIs: 2008-2010.

Figures 5.6-5.8 shows the proportion of concomitant and bisphosphonate alone users by
state across the 3 year period. The plots are placed side by side for each year. Overall, we
observed that the number of Medicare beneficiaries who were bisphosphonate users or were
concomitant users varied by states and across the years. Quartile ranking in bisphosphonate use
by state for most of the states did not follow a similar pattern as the ranking in concomitant use.
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The concomitant use proportions ranged between 10.0%-36.0% in 2008, 14.9%-36.2% in
2009, and 8.7%-49.9% in 2010. The bottom 3 states with the lowest proportion of concomitant
users in 2008 were Washington, D.C. (10.0%), Puerto Rico (12.5%), and Hawaii (16.4%) and the
top 3 states with the highest proportion of concomitant use were Washington (34.3%), Tennessee
(34.5%), and Delaware (36.0%). In 2009, the bottom 3 states were Hawaii (14.9%), Alaska
(17.4%), and Washington, D.C. (19.0%) and the top 3 states were West Virginia (34.4%),
Missouri (34.9%), and Tennessee (36.2%). In 2010 the bottom 3 states were Puerto Rico (8.7%),
New Mexico (20.6%), and Hawaii (20.6%) and the top 3 states were Tennessee (38.5%), Alaska
(46.7%), and Idaho (49.0%). Overall, we noted that Hawaii had consistently lower concomitant
users in the 3 years, whereas the state of Tennessee had higher and slightly increased over time.
These data suggested that concomitant use is influenced by multiple factors that vary from state
to state.
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(a)

(b)
Figure 5.6. Quartiles of concomitant and bisphosphonate alone use by state in 2008. Figure 5.6a
shows variation in concomitant use, whereas figure 5.6b shows variation of bisphosphonate use.
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(a)

(b)
Figure 5.7. Quartiles of concomitant and bisphosphonate alone use by state in 2009. Figure 5.7a
shows variation in concomitant use, whereas figure 5.7b shows variation of bisphosphonate use.
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(a)

(b)
Figure 5.8. Quartiles of concomitant and bisphosphonate alone use by state in 2010. Figure 5.8a
shows variation in concomitant use, whereas figure 5.8b shows variation of bisphosphonate use.
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5.2 Discussion
This study examined utilization patterns of concomitant use of bisphosphonates and
SSRIs among older postmenopausal women from 2008 to 2010. Our findings confirm that
concomitant use of bisphosphonates and SSRIs is prevalent. Since this study was limited to
Medicare Part D data, indications for these concomitant medications can only be inferred. As
indicated earlier bisphosphonates are the most widely FDA-approved pharmacologic agents for
treatment of postmenopausal osteoporosis.1 On the other hand, SSRIs are the most popular
medications in treating depression.2 Therefore our findings suggest that exposure to concomitant
use is most likely due to the prevalent comorbid osteoporosis and depression among older
postmenopausal women. There is a strong positive relationship between osteoporosis and
depression, and both diseases are more prevalent among women than men.3 Although it is still
unclear the association between these two chronic conditions,3 existing research shows that
depression is associated with increased risk for both low bone mineral density and fractures.4 On
the other hand, fractures which can be clinical consequences of osteoporosis can also cause
psychological symptoms, most notably depression.5
Given the high prevalence of osteoporosis and depression among older women, the use
and pattern of concomitant use of bisphosphonates and SSRIs was not surprising. Our findings
further showed that concomitant use varied with demographic characteristics, notably age, race,
socioeconomic status, and geographic locations in the United States. Medicare beneficiaries
under study were more likely to be concomitant users as they aged, if they were of Caucasian
race or of higher socioeconomic status. It has been shown that relative to women aged 50-54, the
odds of having osteoporosis is 5.9-fold higher in women aged 65-69 and 14.3-fold higher in
women aged 75-79.6 On the other hand, although the prevalence of depression is lower among
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older adults than younger people, aging people experience changes in their health and their
lifestyles (considered risk factors) that make an older adult more vulnerable to becoming
depressed. These risk factors for depression can include changes in physical health or
fumctioning, mental health, or circumstances or social support.7 The increasing trend of
osteoporosis with age and the susceptibility of depression with aging are therefore reflective of
our findings that concomitant use increases with age.
The higher proportions of concomitant use among the white women could be attributed to
the high prevalence of osteoporosis and the propensity to receiving antidepressant treatment
compared to minority groups. Osteoporosis is more frequent in white women than other races. In
the U.S, the rates of osteoporosis and/or osteoporotic fractures are higher among white women
compared to Asian or African American women.8 Similarly, white race has been found to be a
strong predictor of antidepressant use over time. White patients with major depression were
found to be more likely than African Americans to receive antidepressant medications.9 A
previous study had also showed that persons from racial or ethnic minority groups were more
likely than whites to report major depression and less likely to receive treatment.10
The observed concomitant use that varied with socioeconomic status over time was
probably influenced by the economic downturn beginning in 2008 and might have impacted
cost-related non-adherence among those considered to be of higher SES. This is consistent with
a study by Piette et al. that found substantial increase in medication-cost problems was
associated with the economic crisis in 2008 especially among chronically ill older adults. Those
aged 65 or older reported delayed filling a prescription because of financial reasons despite the
availability of Medicare Part D benefits.11 On the other hand, existing research suggests that
socioeconomic status is associated with negative impact on the psychological health of aging
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individuals. Those at the lower levels of socioeconomic status are often most likely to be
afflicted with disorders such as depression.12 The financial crisis probably worsened the situation
and thus increasing the incidence of depression. Therefore, our findings were consistent with the
existing research that patients of low SES were more likely to be prescribed SSRIs for depressive
symptoms beginning 2008 and thus having an overall influence on concomitant usage over time.
Another explanation that could explain the reversed trend over time is that, the financial crisis
beginning in 2008 qualified more beneficiaries to be considered of low SES over time shifting
them from higher SES to lower SES.
With regards to the findings for concomitant use by state, the usage pattern primarily
indicates that the prevalence of use is a nationwide problem. For some states, however, the
prevalence and pattern of use varied across the 3 years. In addition, ranking on quartiles showed
that for most of the states the proportions of concomitant use did not parallel the proportions of
bisphosphonate alone use suggesting that comorbid osteoporosis and depression varies by state.
Because of the haphazard pattern of concomitant and bisphosphonates alone use, it is unclear
what factors might have influenced the pattern that we observed. Using secondary analysis
results, we did not observe a clear pattern with SES status of the patients across the states.
Although it might be obvious that the care that Medicare beneficiaries receive will vary
depending on where they live and their physicians and hospitals, more research is needed to
investigate predictors of use across states.
Overall, the steady rates (2842.5 per 10,000 populations in 2008, 2883.9/10,000 in 2009,
and 3067.5/10,000 in 2010) and non-significant trend of concomitant use did not mirror the
count of those females enrolled with Part D coverage provided under PDPs during the same
period. Using the CMS reported statistics for the actual proportions of female beneficiaries who
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were Part D enrolled for 100% of Medicare beneficiaries during the same period, the female
counts dropped in 2009 and then increased sharply in 2010 compared to 2008. The proportions
enrolled were 59.5% females in 2008, 59.1% in 2009, and 58.8% in 2010 (Table 5.5). 13 Their
corresponding estimated counts were 11,192,051 females with Part D coverage under PDPs in
2008, 11,172,347 females in 2009, and 11,304,283 females in 2010. This lack of parallel trend
suggests that not only did the prevalence rates of concomitant use of bisphosphonates and SSRIs
(a proxy of comorbid osteoporosis and depression prevalence) not change over time, but also
was less impacted by changes in population of older postmenopausal women.
Despite the non-significant trend of concomitant use across the 3 years, our findings
suggest that large numbers of older postmenopausal women prescribed bisphosphonates are also
on SSRIs. These findings were consistent with our preliminary study using MEPS data (see
Chapter 3). Following extrapolation of our estimates to all Medicare beneficiaries with Part D
coverage under PDPs, our findings suggest that there were 391,721 (3.5%) females who were
bisphosphonate users in 2008, 424,549 (3.8%) females in 2009, and 350,432 (3.1%) females in
2010. Of these bisphosphonate users, there were 111,248 (28.4%) females who were also on
SSRIs in 2008, 122,270 (28.8%) females in 2009, and 107,582 (30.7%) in 2010. The positive
side of this is that patients with potential comorbid osteoporosis and depression are receiving
respective therapies for treatment. The National Institute of Mental Health (NIMH) recommends
that treatment of depression (commonly using SSRIs or SNRIs) can help patients manage their
osteoporosis and improve overall health.14 The NMIH also adds that while currently available
common treatments for depression are generally well tolerated and safe, some medications,
including some antidepressants (such as SSRIs or SNRIs), can increase a patient’s risk for
osteoporosis.14
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Table 5.5. CMS Chronic Condition Data Warehouse: Medicare Part D Beneficiary Counts for
2008 through 2010.
Beneficiary
Demographics
Part D Enrolled
Total
Part D Plan Type
PDP
Gender
Female, n (%)
Age
65-74
75-84
85+

2008

2009

2010

27,529,528

28,722,645

29,740,680

18,810,171

18,904,141

19,224,972

16,377,483 (59.5)

16,976,321 (59.1)

17,493,688 (58.8)

10,966,227
7,674,907
3,575,116

11,591,840
7,855,991
3,704,040

12,069,321
7,995,935
3,813,281

Selective serotonin reuptake inhibitors or SNRIs have been documented to be associated
with increasing a patient’s risk for osteoporosis. Two meta-analysis studies have summarized
these findings. Wu et al. results showed that overall, SSRIs use was associated with a
significantly increased risk of fracture (RR=1.72;95% CI, 1.51-1.95).15 Eom et al. in a metaanalysis based on 12-observational studies showed that the overall risk of fracture was higher
among people using SSRIs (adjusted OR=1.69, 95% CI 1.51-1.90).16 This evidence is troubling
especially considering that the patients in reference are those already on bisphosphonates or will
be prescribed bisphosphonates at some point in their lifetime. This situation presents a prime
example of potentially risky bisphosphonate-drug combinations with potential interaction
resulting in increased risk of fracture.
Although there is a paucity of documented reports on these particular interactions,
research has suggested that medications associated with increased risk of fracture might attenuate
the beneficial effects of bisphosphonates when used concomitantly. Concerns about this
phenomenon has focused on medications such as proton pump inhibitors17,18, glucocorticoids19,20,
and levothyroxine21, but the interaction of bisphosphonates and SSRIs or SNRIs has not been
151

investigated yet. The common aspect about proton pump inhibitors, glucocorticoids,
levothyroxine, and SSRIs is that all of these medications are associated with increased risk of
fracture.1 So, SSRIs or SNRIs also have the potential of demonstrating similar attenuating
effects, but this phenomenon in currently unknown. Animal studies have shown that increased
levels of nuclear factor kappa ligand (RANKL) due to high blood levels of serotonin
significantly attenuated (or antagonized) the ability of clodronate and alendronate to induce
osteoclast apoptosis and inhibit bone resorption.22 In normal bone remodeling in healthy
physiologic systems, bone stromal cells, including cells of the osteoblast lineage, provide a
limited amount of RANKL, which leads to osteoclast differentiation, survival, and activation and
subsequent bone resorption. Resorption is balanced by osteoblast-dependent new bone
formation.23 Clearly we can see that there is need for randomized clinical trials or observational
studies to investigate further the interaction between bisphosphonates and SSRIs. The evidence
following this research will be important to the clinicians and the older adult patients with
comorbid osteoporosis and depression to aid in developing optimal care strategies. When
presented with patients with osteoporosis and other comorbidies (such as depression), the
clinician should consider the common disease-disease and drug-disease interactions, and screen
for or treat these as appropriate to the patient’s goals and preferences.24
Similarly, The American Geriatrics Society expert panel has documented an approach by
which clinicians can care optimally for older adults with multimorbidity (multiple chronic
conditions). In this document the society acknowledges that clinicians need a better management
approach to clinical decision- making. One example of such an approach would require an
assessment of patient preferences for all clinical decisions. The first step in the process of
eliciting patient preference is to recognize when the older adult with multimorbidity is facing a
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“preference sensitive” decision. In this step the clinician tries to understand what is most
important to the patient to determine the best option.25 An example would be medications that
may improve one condition but make coexisting condition worse for example inhaled
corticosteroids to treat chronic obstructive pulmonary disease may worsen osteoporosis.26
Clearly, the tradeoff between managing depressive symptoms and worsening osteoporosis varies
from patient to patient. Given supportive evidence from research about whether SSRIs may
worsen osteoporosis when given concomitantly with bisphosphonates, clinicians will have new
information that will aid optimal care for these patients. More emphasis for optimal care will be
among postmenopausal women as they advance in age, those who are of white race, and/or of
low socioeconomic status.

5.2.1 Strengths and limitations of the study
5.2.1.1 Strengths
The strengths of our study are that to the best of our knowledge, this study is the first to
describe concomitant use of bisphosphonates and SSRIs or SNRIs among older postmenopausal
women. Also this study used Medicare Part D data, which is a large national database with
prescription drug data primarily for older adults 65 years or older. Therefore this dataset was
suitable to describe national estimates of medications use for older postmenopausal women 65
years or older and are more generalizable.
5.2.1.2 Limitations
The use of Medicare Part D data, like other administrative databases is faced with
methodological challenges such as verifying data validity. A central limitation with many
implications is that such databases are collected for administrative rather than research purposes.
These limitations are an important source of bias. For example the complexity of preparing
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claims data (prescribing, dispensing, and the third party payer adjudication and entering into the
computer system for billing purposes) can result in misclassification bias. Misclassification of
bisphosphonate or SSRIs or SNRIs could bias estimates of proportions of concomitant use in this
study.
Another bias introduced into the Medicare Part D data that is a limitation to our findings
is the bias of limited generalizability and information bias. This bias is a limitation because of
the assumption that the dataset is accurate and also that the data includes every encounter with
health professionals. Generalizability or external validity is defined as the validity of the
inferences as they pertain to people outside the source population.27 In this study the referred
people outside the source population are those women aged ≥ 65 years old but are not Medicare
part D beneficiaries. By using Medicare Part D data, we have made the assumption that the
database captures every encounter of women aged ≥ 65 years. Although Medicare Part D offers
prescription coverage to all those eligible for Medicare, not all beneficiaries are enrolled in a part
D plan. Of those who were Medicare eligible between 2008 and 2010, 57.5% were enrolled in a
part D plan in 2008, 58.7% in 2009, and 59.4% in 2010. The rest were not covered by part D
and with no credible coverage or with other credible coverage, or were enrolled in retirement
drug subsidy.13 Credible coverage sources are required to have approval from Medicare as being
equivalent or better than part D plans. Examples include the U.S. Department of Veterans
Affairs, the military health plan (TRICARE), the Federal Employees’ Health Benefits (FEHB) or
are active workers under employer sponsored programs.
Furthermore, our findings may not be generalizable to all women ≥ 65 years old
including the more affluent and employed and also those who might be healthier. The healthier
lifestyle could be promoted by insurance under the wellness programs- a feature of the consumer
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driven healthcare which is typical for the employed.28 Finally, exclusion of men in our study can
also be considered a limitation of generazability to the entire older adult population. Although
comorbid osteoporosis and depression is more prevalent among women than men,3 the safety of
concomitant use of bisphosphonates and SSRIs or SNRIs is as important to men as it is to
women.

5.3 Conclusions
In summary, this study determined that concomitant use of bisphosphonates and SSRIs is
prevalent and varies with demographic characteristics and geographic location in the U.S.
Concomitant use seems to increase with aging, among the white race and those who are of low
socioeconomic status. The prevalence and variation of concomitant use is troubling because of
the potential interaction between SSRIs and bisphosphonates with potential antifracture efficacy
of bisphosphonates. With this growing concern, understanding the number of patients exposed to
the concurrent medication use will be used to initiate further studies to assess the potential
consequence of the problem, if any. Given that the population of older adults is high and is
projected to increase in the future, the prevalence of use is expected to grow exponentially and
the associated economic impact of antifracture efficacy of bisphosphonates on the U.S.
healthcare system will be enormous. Potential antifracture efficacy will result in worsened
osteoporosis and greater risk of fractures suggesting more hospitalizations for expensive bone
related procedures, and wasted resources on prescriptions that are suboptimal. This underscores
the need for research to investigate the effect of SSRIs on the beneficial effects of
bisphosphonates which may be useful for physicians to integrate in clinical decision-making for
optimal care of older postmenopausal women with multimorbidity.
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Chapter 6
6.0 Specific Aim 2: Results and Discussion
6.1 Bisphosphonates and fracture reduction
6.1.1 Matching process and patient characteristics
A total of 178,167 postmenopausal female Medicare beneficiaries between 2008 and
2010 were eligible for analysis after application of the inclusion and exclusion criteria. Of these
Medicare beneficiaries, 18,074 were bisphosphonate (BP) users. Figure 6.1a shows the
distributions of propensity scores for the 160,093 BP non-users and the 18,074 BP users before
matching. We can see that the distribution before matching shows a good discrimination between
the two groups of patients. The distributions of propensity scores between the two groups after
1:1 matching are shown in Figure 6.1b. The distributions of the propensity scores for the
matched groups were similar suggesting that treated subjects (BP users) are similar to the control
subjects (BP non-users) with respect to background variables (or covariates) measured on all
subjects, as would be expected in a randomized experiment. Thus, two matched subjects (one in
treated and one in control group), with the same propensity score, are imagined to be ‘randomly’
assigned to each group in the sense of being equally likely to be treated or control.1 Previous
research has demonstrated that matching on propensity score can result in a greater reduction in
treatment selection bias than stratification on propensity score.2
Table 6.1 shows the baseline characteristics of the two groups after matching and the
standardized differences (<0.1) between them. The average age of those who were BP users was
80.6 ± 7.7 (SD) years and that of BP non-users was 80.8 ± 8.4 (SD) years. For both treatment
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groups, there were more white women than other minority races and also within the age groups,
the proportions of older adults 85 years or older was the highest compared to other age groups.
The proportions of both BP users and non-users were higher for women of higher socioeconomic
status and lower for those of lower socioeconomic status.

(6.1a)

(6.1b)
Figure 6.1. Distribution of propensity scores: (6.1a) shows the distribution for 178,167
patients before matching and (6.1b) shows the distribution for 17,953 patients after matching.
The curved lines are normal distribution curves.
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Table 6.1. Baseline patient characteristics of propensity score matched cohort.
Characteristic
Demographic
Age , mean ± SD
65-69
70-74
75-79
80-84
85+
Race, n (%)
White
Black
Hispanic
Other
Socioeconomic status, n (%)
Low income
Higher income
Health care utilization factors, mean
(SD)
Comorbidity score
Number of unique prescribed medications
Medical conditions, n (%)
Osteoporosis
Rheumatoid arthritis/ Osteoarthritis
Depression
Hyperparathyroidism
Kidney disease
Diabetes mellitus
Chronic obstructive pulmonary disease
Congestive heart failure
Hypertension
Anxiety
Parkinson’s disease
Alzheimer’s disease
Epilepsy
Orthostatic hypotension
Medications, n (%)
Oral glucocorticoid use
Proton pump inhibitor use
Aromatase inhibitors
Thiazolidinediones use
Hormone replacement therapy
Antihypertensive use
Anticonvulsant use
Thyroid medication use
Warfarin use
Loop diuretic use
Opioid use
Antipsychotics use
Lithium
Methotrexate

Bisphosphonate
users (N=17,953)

Bisphosphonate nonusers (N=17,953)

Standardized
differences

80.6 (7.7)
1706 (9.5)
2638 (14.7)
3476 (19.4)
4193 (23.4)
5940 (33.1)

80.8 (8.4)
2079 (11.6)
2548 (14.2)
3228 (18.0)
3779 (21.1)
6319 (35.2)

0.021

14928 (83.2)
905 (5.0)
1170 (6.5)
950 (5.3)

15187 (84.6)
809 (4.5)
1114 (6.2)
843 (4.7)

6794 (37.8)
11159 (62.2)

6605 (36.8)
11348 (63.2)

2.2 (2.0)
12.2 (6.7)

2.2 (2.0)
12.3 (7.5)

0.001
0.002

10494 (58.5)
10206 (56.9)
3095 (17.2)
4838 (27.0)
4680 (26.1)
5499 (30.6)
4651 (25.9)
6435 (35.8)
15701 (87.5)
474 (2.6)
260 (1.5)
1994 (11.1)
260 (1.5)
726 (4.0)

10453 (58.2)
10279 (57.3)
3059 (17.0)
4775 (26.6)
4661 (26.0)
5366 (29.9)
4693 (26.1)
6493 (36.2)
15645 (87.1)
467 (2.6)
233 (1.3)
1883 (10.5)
252 (1.4)
737 (4.1)

0.005
0.008
0.005
0.008
0.002
0.016
0.005
0.007
0.009
0.002
0.013
0.02
0.004
0.003

4217 (23.5)
6124 (34.1)
413 (2.3)
674 (3.8)
1284 (7.2)
11306 (63.0)
2795 (15.6)
4862 (27.1)
2531 (14.1)
4781 (26.6)
7382 (41.1)
824 (4.6)
41 (0.2)
467 (2.6)

4257 (23.7)
6161 (34.3)
408 (2.3)
692 (3.9)
1292 (7.2)
11415 (63.6)
2831 (15.8)
4864 (27.1)
2514 (14.0)
4846 (27.0)
7535 (42.0)
814 (4.5)
37 (0.2)
429 (2.4)

0.005
0.004
0.002
0.005
0.002
0.013
0.006
0.0
0.003
0.008
0.017
0.003
0.005
0.014
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6.1.2 Bisphosphonates use and risk of fracture: Minor findings
Table 6.2. Cox proportional hazard model for risk of fractures among BP users and non-users.
Total number of patients
Any fracture
Total events
Hazard Ratio (95% CI)
Hip/Pelvis/Femur fracture
Total events
Hazard Ratio (95% CI)
Vertebral fracture
Total events
Hazard Ratio (95% CI)
Humerus
Total events
Hazard Ratio (95% CI)
Radius/Ulna
Total events
Hazard Ratio (95% CI)
Tibia/Fibula
Total events
Hazard Ratio (95% CI)

Non-Bisphosphonate users
17,953

Bisphosphonate users
17,953

1031
1.00 (Reference)

922
0.89 (0.81, 0.97)

678
1.00 (Reference)

592
0.87 (0.77, 0.97)

164
1.00 (Reference)

153
0.93 (0.75, 1.16)

80
1.00 (Reference)

75
-

39
1.00 (Reference)

41
-

70
1.00 (Reference)

61
-

Table 6.2 presents results from the Cox proportional hazards model. Among the
propensity score matched patients, 922 bisphosphonate users experienced at least one first
fracture of the hip, vertebral, humerus, radius/ulna, or tibia/fibula, whereas 1,031 BP non-users
experienced at least one first fracture during the 3 year period (2008 – 2010). Of these patients,
592 BP users and 678 BP non-users experienced a hip fracture.
With regards to the hazard ratios, we observed that BP use was associated with
statistically significant reduction of any fracture (HR=0.89, 95% CI, 0.81-0.97) and hip fracture
(HR=0.87, 95% CI, 0.77-0.97), and statistically non-significant reduction for vertebral fracture
(HR=0.93, 95% CI, 0.75-1.16). There were no results obtained for the humerus, radius/ulna, or
tibia/fibula fractures because of very small sample size.
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6.2 SSRIs and increased risk of fracture
6.2.1 Matching process and patient characteristics
A total of 206,883 postmenopausal female Medicare beneficiaries between 2008 and
2010 were eligible for analysis after application of the inclusion and exclusion criteria. Of these
Medicare beneficiaries, 46,777 were SSRI users. Figure 6.2a shows the distributions of
propensity scores for the 160,106 SSRI non-users and the 46,777 SSRI users before matching.
We can see that the distribution before matching shows a good discrimination between the two
groups of patients. The mean age was 79.0 ± 8.4 (SD) years for SSRI users and 79.3 ± 8.5 (SD)
years for SSRI non-users. The distributions of propensity scores between the two groups after
1:1 matching are shown in Figure 6.2b. The mean age was 79.1 ± 8.5 (SD) years for SSRI users
and 79.1 ± 8.4 (SD) years for SSRI non-users. Table 6.3 shows the baseline characteristics of the
two groups after matching and the standardized differences between them. All the standardized
differences were < 0.10 suggesting a balance between the two groups on observed covariates.

(6.2a)
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(6.2b)
Figure 6.2. Distribution of propensity scores: (6.2a) shows the distribution for 206,883 patients
before matching and (6.2b) shows the distribution for 39,660 patients after matching.

6.2.2 SSRI use and increased risk of fracture: Minor findings
Our findings showed that SSRI use was associated with statistically significant increased risk for
any fracture (HR=1.17, 95% CI, 1.09-1.26), hip fracture (HR=1.16, 95% CI, 1.06-1.26), and for
Tibia/fibula fracture (HR=1.33, 95% CI, 1.05-1.68). We also observed increased risk for
vertebral fracture (HR=1.10, 95% CI, 0.89-1.36), but statistical significance was not achieved.
(see Table 6.4)
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Table 6.3. Baseline patient characteristics of propensity score matched cohort.
Characteristic
Demographic
Age , mean ± SD
65-69
70-74
75-79
80-84
85+
Race, n (%)
White
Black
Hispanic
Other
Socioeconomic status, n (%)
Low income
Higher income
Health care utilization factors,
mean(SD)
Comorbidity score
Number of unique prescribed medications
Medical conditions, n (%)
Osteoporosis
Rheumatoid arthritis/ Osteoarthritis
Depression
Hyperparathyroidism
Kidney disease
Diabetes mellitus
Chronic obstructive pulmonary disease
Congestive heart failure
Hypertension
Anxiety
Parkinson’s disease
Alzheimer’s disease
Epilepsy
Orthostatic hypotension
Medications, n (%)
Oral glucocorticoid use
Proton pump inhibitor use
Aromatase inhibitors
Thiazolidinediones use
Hormone replacement therapy
Antihypertensive use
Anticonvulsant use
Thyroid medication use
Warfarin use
Loop diuretic use
Opioid use
Antipsychotic use
Lithium
Methotrexate

SSRI users
(N=39,660)

SSRI Non-users
(N=39,660)

Standardized
differences

79.1 (8.5)
6609 (16.7)
6677 (16.8)
7148 (18.0)
7651 (19.3)
11575 (29.2)

79.1 (8.4)
6392 (16.1)
6708 (16.9)
7354 (18.5)
7756 (19.6)
11450 (28.9)

0.002

33859 (85.4)
2838 (7.2)
2286 (5.8)
677 (1.7)

34067 (85.9)
2784 (7.0)
2204 (5.6)
605 (1.5)

19691 (49.6)
19969 (51.4)

19550 (49.3)
20110 (50.7)

2.6 (2.1)
13.4 (6.8)

2.6 (2.1)
13.3 (7.6)

0.001
0.023

6286 (15.9)
21660 (54.6)
23483 (59.2)
10711 (27.0)
12456 (31.4)
16621 (41.9)
12770 (32.2)
17418 (43.9)
35614 (89.8)
2114 (5.3)
780 (2.0)
7829 (19.4)
651 (1.6)
1542 (3.9)

6219 (15.7)
21626 (54.3)
23660 (59.7)
10760 (27.1)
12481 (31.5)
16671 (42.0)
12898 (32.5)
17406 (43.9)
35668 (89.9)
2239 (5.7)
738 (1.9)
7736 (19.5)
642 (1.6)
1539 (3.9)

0.005
0.002
0.009
0.003
0.001
0.003
0.007
0.001
0.005
0.014
0.008
0.006
0.002
0.0

9118 (22.9)
16800 (42.4)
538 (1.4)
1866 (4.7)
2878 (7.2)
25204 (63.6)
8138 (20.5)
11247 (28.4)
5691 (14.4)
13455 (33.9)
18991 (47.9)
4942 (12.4)
155 (0.4)
432 (1.1)

9093 (22.9)
16849 (42.5)
537 (1.4)
1856 (4.7)
2957 (7.5)
25470 (64.2)
8301 (20.9)
11304 (28.5)
5736 (14.5)
13437 (33.9)
19120 (48.2)
4643 (11.7)
177 (0.5)
443 (1.1)

0.001
0.002
0.0
0.001
0.008
0.014
0.01
0.003
0.003
0.001
0.007
0.023
0.009
0.003
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Table 6.4. Cox proportional hazard model for risk of fractures among SSRI users and non-users.
Total number of patients
Any Fracture
Total events
Hazard Ratio (95% CI)
Hip/Pelvis/Femur fracture
Total events
Hazard Ratio (95% CI)
Vertebral fracture
Total events
Hazard Ratio (95% CI)
Humerus
Total events
Hazard Ratio (95% CI)
Radius/Ulna
Total events
Hazard Ratio (95% CI)
Tibia/Fibula
Total events
Hazard Ratio (95% CI)

SSRI non-users
39,660

SSRI users
39,660

1,443
1.00 (Reference)

1,675
1.17 (1.09, 1.26)

994
1.00 (Reference)

1,141
1.16 (1.06, 1.26)

163
1.00 (Reference)

179
1.10 (0.89, 1.36)

116
1.00 (Reference)

143
1.23 (0.97, 1.58)

51
1.00 (Reference)

54
-

119
1.00 (Reference)

158
1.33 (1.05, 1.68)

6.3 Concomitant use of bisphosphonates and SSRIs and increased risk of fracture
6.3.1 Matching process and patient characteristics
A total of 22,702 postmenopausal female Medicare beneficiaries who were BP users
between 2008 and 2010 were identified after application of the inclusion and exclusion criteria.
Alendronate (overall: 61.9%), 70 mg (58.2%) was the most frequently prescribed BP followed
by risedronate (overall: 24.4%), 35 mg (20.6%) and ibandronate 150 mg (13.7%). Of these BP
users, 4,662 were also on SSRIs and 18,040 were BP alone users. Table 6.5 shows baseline
characteristics of all BP users who were eligible for analysis. The average age of those who
were concomitant users of BPs and SSRIs was 80.2 ± 8.0 (SD) years and that of BP alone users
was 80.6 ± 7.7 (SD) years. For both treatment groups, there were more white women than other
minority races and also within the age groups, the proportions of older adults 85 years or older
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was the highest compared to other age groups. Concomitant users were equally distributed
among women of lower and higher socioeconomic status, but BP alone users of higher
socioeconomic status (62.0%) were almost twice that of low socioeconomic status (38.0%).
Figure 6.3a shows the distributions of propensity scores for the 18,040 BP alone users
and the 4,662 concomitant users of BPs and SSRIs before matching. We can see that the
distribution before matching shows a good discrimination between the two groups of patients.
The distributions of propensity scores between the two groups after 1:1 matching are shown in
Figure 6.3b. The distributions of the propensity scores for the matched groups were similar
suggesting that treated subjects (concomitant users) are similar to the control subjects
(concomitant non-users) with respect to background variables measured on all subjects, just like
in a randomized experiment.
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Table 6.5. Baseline patient characteristics of all bisphosphonate users eligible for analysis.
Characteristic

Concomitant users
(n=4,662)

Non concomitant
users (n=18,040)

80.2 (8.0)
552 (11.8)
705 (15.1)
847 (18.2)
1040 (22.3)
1518 (32.6)

80.6 (7.7)
1718 (9.5)
2657 (14.7)
3493 (19.4)
4218 (23.4)
5954 (33.0)

4,041 (86.7)
139 (3.0)
366 (7.9)
116 (2.5)

14,953 (82.9)
906 (5.0)
1179 (6.5)
1002 (5.6)

2350 (50.4)
2312 (49.6)

6860 (38.0)
11,180 (62.0)

2.4 (2.0)
16.0 (7.6)

2.2 (2.0)
12.3 (6.8)

2727 (58.5)
2854 (61.2)
3214 (68.9)
1365 (29.3)
1394 (29.9)
1564 (33.6)
1603 (34.4)
1965 (42.2)
4123 (88.4)
242 (5.2)
134 (2.9)
1096 (23.5)
103 (2.2)
196 (4.2)

10588 (58.7)
10271 (57.0)
3111 (17.3)
4872 (27.0)
4716 (26.1)
5540 (30.7)
4686 (26.0)
6473 (35.9)
15783 (87.5)
475 (2.6)
266 (1.5)
2000 (11.1)
265 (1.5)
729 (4.1)

1296 (27.8)
2236 (48.0)
101 (2.2)
208 (4.5)
362 (7.8)
2869 (61.5)
1051 (22.5)
1405 (30.1)
633 (13.6)
1529 (32.8)
2326 (49.9)
671 (14.4)
27 (0.6)
125 (2.7)

4265 (23.6)
6186 (34.3)
421 (2.3)
678 (3.8)
1291 (7.2)
11,385 (63.1)
2831 (15.7)
4897 (27.2)
2537 (14.1)
4806 (26.6)
7413 (41.1)
827 (4.6)
41 (0.2)
488 (2.7)

Demographic
Age , mean ± SD
65-69
70-74
75-79
80-84
85+
Race, n (%)
White
Black
Hispanic
Other
Socioeconomic status, n (%)
Low income
Higher income
Health care utilization factors, mean (SD)
Comorbidity score
Number of unique prescribed medications
Medical conditions, n (%)
Osteoporosis
Rheumatoid arthritis/ Osteoarthritis
Depression
Hyperparathyroidism
Kidney disease
Diabetes mellitus
Chronic obstructive pulmonary disease
Congestive heart failure
Hypertension
Anxiety
Parkinson’s disease
Alzheimer’s disease
Epilepsy
Orthostatic hypotension
Medications, n (%)
Oral glucocorticoid use
Proton pump inhibitor use
Aromatase inhibitors
Thiazolidinediones use
Hormone replacement therapy
Antihypertensive use
Anticonvulsant use
Thyroid medication use
Warfarin use
Loop diuretic use
Opioid use
Antipsychotics use
Lithium
Methotrexate
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(6.3a)

(6.3b)
Figure 6.3. Distribution of propensity scores: (6.3a) shows the distribution for 22,702 patients
before matching and (6.3b) shows the distribution for 4,214 patients after matching.
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Table 6.6. Baseline patient characteristics of propensity score matched cohort.
Characteristic
Demographic
Age , mean ± SD
65-69
70-74
75-79
80-84
85+
Race, n (%)
White
Black
Hispanic
Other
Socioeconomic status, n (%)
Low income
Higher income
Health care utilization factors,
mean(SD)
Comorbidity score
Number of unique prescribed medications
Medical conditions, n (%)
Osteoporosis
Rheumatoid arthritis/ Osteoarthritis
Depression
Hyperparathyroidism
Kidney disease
Diabetes mellitus
Chronic obstructive pulmonary disease
Congestive heart failure
Hypertension
Anxiety
Parkinson’s disease
Alzheimer’s disease
Epilepsy
Orthostatic hypotension
Medications, n (%)
Oral glucocorticoid use
Proton pump inhibitor use
Aromatase inhibitors
Thiazolidinediones use
Hormone replacement therapy
Antihypertensive use
Anticonvulsant use
Thyroid medication use
Warfarin use
Loop diuretic use
Opioid use
Antipsychotics use
Lithium
Methotrexate

Concomitant users
(N=4,214)

Non concomitant
users (N=4,214)

Standardized
differences

80.2 (8.0)
500 (11.9)
628 (14.9)
765 (18.2)
926 (22.0)
1395 (33.1)

80.4 (7.9)
476 (11.3)
594 (14.1)
774 (18.4)
958 (22.7)
1412 (33.5)

0.025

3653 (86.7)
133 (3.2)
313 (7.5)
115 (2.7)

3620 (85.9)
151 (3.6)
322 (7.6)
121 (2.9)

2043 (48.5)
2171 (51.5)

2083 (49.4)
2131 (50.6)

2.4 (2.0)
15.5 (7.2)

2.4 (2.0)
15.5 (7.9)

0.01
0.005

2476 (58.8)
2574 (61.1)
2767 (65.7)
1224 (29.1)
1245 (29.5)
1405 (33.3)
1397 (33.2)
1725 (40.9)
3725 (88.4)
208 (4.9)
113 (2.7)
920 (21.8)
84 (2.0)
170 (4.0)

2420 (57.4)
2592 (61.5)
2767 (65.7)
1238 (29.4)
1245 (29.5)
1395 (33.1)
1398 (33.2)
1781 (42.3)
3743 (88.8)
213 (5.1)
109 (2.6)
912 (21.6)
88 (2.1)
173 (4.1)

0.027
0.009
0.0
0.007
0.0
0.005
0.001
0.027
0.013
0.005
0.006
0.005
0.007
0.004

1153 (27.4)
1934 (45.9)
96 (2.3)
172 (4.1)
316 (7.5)
2593 (61.5)
927 (22.0)
1254 (29.8)
589 (14.0)
1349 (32.0)
2046 (48.6)
553 (13.1)
21 (0.5)
109 (2.6)

1168 (27.7)
1976 (46.9)
90 (2.1)
182 (4.3)
331 (7.9)
2623 (62.1)
953 (22.6)
1243 (29.5)
589 (14.0)
1392 (33.0)
2101 (49.9)
520 (12.3)
28 (0.7)
114 (2.7)

0.008
0.02
0.01
0.012
0.013
0.015
0.015
0.006
0.0
0.022
0.026
0.023
0.022
0.007
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Table 6.6 shows the baseline characteristics of the two groups after matching and the
standardized differences (difference in means of continuous variables or proportions of binary
variables divided by standard error) between them. The standardized difference effect size can be
treated as equivalent to a Z-score of a standard normal distribution which can suggest nonoverlap in distributions between two study groups (treatment and control groups).3 Standardized
difference of ≥ 0.10 are commonly used to indicate important imbalance between treatment
groups.4 Overall, good balance was achieved on observed variables that entered the propensity
score, with the largest standard difference being equal to 0.027 which is well below the
suggested threshold (< 0.10).

6.3.2 Concomitant use and risk of fractures: Major findings
Among the patients who were eligible for analysis before matching, there were a total of
1,213 patients with the fracture outcome of interest. Specific fractures were hip/pelvis/femur
(762), vertebral (194), humerus (92), radius/ulna or wrist (50), and tibia/fibula fracture (85).
Table 6.7 presents results from the Cox proportional hazards model. Among the propensity score
matched patients, 256 concomitant users and 201 BP alone users experienced at least one first
fracture of the hip, vertebral, humerus, radius/ulna, or tibia/fibula during the 3 year period (2008
– 2010). Of these patients, 161 concomitant users and 140 BP alone users experienced a hip
fracture. Overall, concomitant users of BPs and SSRIs had slightly higher number of fracture
outcomes for individual fracture subtypes of the hip, vertebral, humerus, radius/ulna, and
tibia/fibula.
With regards to the hazard ratios, we observed that concomitant use was associated with
statistically significant increased risk for any fracture (HR=1.29, 95% CI, 1.07-1.57), but not
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with statistically significant increased risk for hip fracture (HR=1.16, 95% CI, 0.92-1.47) and
vertebral fracture (HR=1.55, 95% CI, 0.97-2.48). No results were obtained for the humerus,
radius/ulna, or tibia/fibula fractures because of very small sample size. The estimated results
were graphically presented using a forest plot shown in Figure 6.4. The plot also includes
treatment effects of BPs and risk reduction of any, hip, and vertebral fractures, SSRIs and
increased risk of fracture. These treatment effects serve as references and were obtained from
pooled results of meta-analysis studies5-7 as well as BP use and fracture reduction results and
SSRI use and increased risk of fracture from this study.

Table 6.7. Cox proportional hazard model for risk of fractures among concomitant users of BPs
and SSRIs.
Total number of patients
Any Fracture
Total events
Hazard Ratio (95% CI)
Hip/Pelvis/Femur fracture
Total events
Hazard Ratio (95% CI)
Vertebral fracture
Total events
Hazard Ratio (95% CI)
Humerus
Total events
Hazard Ratio (95% CI)
Radius/Ulna
Total events
Hazard Ratio (95% CI)
Tibia/Fibula
Total events
Hazard Ratio (95% CI)

Non concomitant users
4,214

Concomitant users
4,214

201
1.00 (Reference)

256
1.29 (1.07, 1.57)

140
1.00 (Reference)

161
1.16 (0.92, 1.47)

29
1.00 (Reference)

45
1.55 (0.97, 2.48)

15
1.00 (Reference)

17
-

7
1.00 (Reference)

11
-

10
1.00 (Reference)

22
-
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Abbreviations: RR, Relative risk; HR, Hazard ratio; SSRI&Fract, SSRI use and increased risk of fracture
(reference)5; SSRIAnyFs, SSRI use and increased risk of any fracture (this study); AnyFractc, Any fracture (this
study); SSRI&HIPs, SSRI use and increased risk of hip fracture (this study); HipFractc, concomitant use of BPs and
SSRIs and risk of hip fracture (this study); VrtFractc, concomitant use of BPs and SSRIs and risk of vertebral
fracture (this study); BISPH&AF, BPs use and the reduction of any fracture (this study); Bisp&Hip, BPs use and
the reduction of hip fracture (this study); BISPH&Hip, BPs use and the risk reduction of hip fracture (reference)6;
ALN&vertF, Alendronate and the risk reduction of vertebral fracture (reference); RSN&vertF, Risedronate and the
risk reduction of vertebral fracture (reference); IBN&vertF, Ibandronate and the risk reduction of vertebral fracture
(reference)7. Note: Details and references are provided under the discussion section.

Figure 6.4. Forest plot of treatment effects and risk of fracture

Our findings indicate that concomitant users of BPs and SSRIs have a 1.29 times chance
of experiencing any fracture compared to BP alone users at any given time. These findings
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suggest that SSRIs might be associated with attenuation of antifracture efficacy of
bisphosphonates. Based on the non-significance of our results for hip and vertebral fracture, we
cannot determine the attenuation of the risk reduction associated with concomitant use of BPs
and SSRIs, but we cannot rule out subtle attenuating effects.

6.3.3 Sensitivity analysis
Two sensitivity analyses were performed to assess the robustness of our findings. First,
we conducted a separate analysis among the same patients for the primary analysis, except that
we redefined the exposure of concomitant use. Concomitant use of SSRIs with BPs was defined
as having received at least one prescription for a BP and a SSRI (with no dispensing medication
gap for a SSRI of more than 30 days whereas users of BPs were still defined as those patients
who were exposed for at least 180 days in the 360 day period). The distributions of propensity
scores between the two groups after 1:1 matching are shown in Figure 6.5b. Table 6.8 shows
the fracture outcomes from this analysis. The results were similar to the primary analysis, except
that we observed slightly stronger associations and we also observed statistically significant risk
for vertebral fracture. However, the wide confidence interval suggests that these results might
have not had enough events for statistically reliable estimates.
In the second sensitivity analysis test, we used the matched data from the primary
analysis but instead assessed the effect of short or long term exposure to SSRIs prior to a fracture
event. The durations were exposure to SSRIs up to 90 days versus greater than 90 days. The
fracture outcome results are shown in Table 6.9a and Table 6.9b. The results were similar to the
primary analysis. Both of the durations of concomitant use showed no statistically significant
association between concomitant use and increased risk of any fracture and were still nonsignificant for the hip fracture. However, the results for vertebral fracture were unstable. The
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association was statistically significant when the duration of exposure was less than 90 days (but
with wide confidence interval), but statistically non-significant when the exposure was greater
than 90 days. This instability may be due to small sample size.

(6.5a)

(6.5b)
Figure 6.5. Distribution of propensity scores: (6.5a) shows the distribution for 21,437
patients before matching and (6.5b) shows the distribution for 3,292 patients after
matching.
175

Table 6.8. Cox proportional hazard model for risk of fractures among concomitant users of
bisphosphonates and SSRIs: Sensitivity analysis 1.
Total number of patients
Any fracture
Total events
Hazard Ratio (95% CI)
Hip/Pelvis fracture
Total events
Hazard Ratio (95% CI)
Vertebral fracture
Total events
Hazard Ratio (95% CI)

Non concomitant users
3,292

Concomitant users
3,292

160
1.00 (Reference)

211
1.35 (1.09, 1.68)

116
1.00 (Reference)

139
1.21 (0.94, 1.55)

17
1.00 (Reference)

35
2.13 (1.17, 3.85)

Table 6.9a. Cox proportional hazard model for risk of fractures among concomitant users of
bisphosphonates and SSRIs (concomitant use ≤90 days before fracture): Sensitivity analysis 2.
Any Fracture
Hazard Ratio (95% CI)
Hip/femur/pelvis fracture
Hazard Ratio (95% CI)
Vertebral fracture
Hazard Ratio (95% CI)

Non concomitant users

Concomitant users

1.00 (Reference)

1.38 (1.08, 1.75)

1.00 (Reference)

1.25 (0.93, 1.68)

1.00 (Reference)

1.88 (1.02, 3.44)

Table 6.9b. Cox proportional hazard model for risk of fractures among concomitant users of
bisphosphonates and SSRIs (concomitant use >90 days before fracture): Sensitivity analysis 2.
Any fracture
Hazard Ratio (95% CI)
Hip//pelvis fracture
Hazard Ratio (95% CI)
Vertebral fracture
Hazard Ratio (95% CI)

Non concomitant users

Concomitant users

1.00 (Reference)

1.39 (1.04, 1.86)

1.00 (Reference)

1.27 (0.89, 1.81)

1.00 (Reference)

1.23 (0.59, 2.56)
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6.4 Discussion
This study assessed potential attenuation of the beneficial effects of BPs by SSRIs and
increased risk of fracture. Given the popularity of BPs as the first-line therapy for the treatment
of postmenopausal osteoporosis and reduction of fracture risk,8 the potential antifracture efficacy
of BPs is a major concern. Due to the high prevalence of comorbid osteoporosis and depression
among women,9 concomitant use in these patients is not uncommon. Indeed, our study found that
of the BP users eligible for analysis in the study, the overall proportion of those patients who
were reported with both depression and osteoporosis was 17.5% (i.e., 19.3% in 2008, 15.6% in
2009, and 17.9% in 2010). Furthermore, of the BP users, 20.5% were also on SSRIs.
Overall, our estimates showed an increased risk of fracture for any, hip, and vertebral
fractures which suggested attenuation of BP, but the associations were not statistically significant
for the hip and vertebral fracture. In other words, among all those already prescribed BPs, the
risk of hip and vertebral fractures was not significantly different between those who added on
SSRIs in their medication regimen compared to those who were only users of BPs, but the risk of
any fracture was significantly different between these groups. These findings suggested that
overall there is a potential antifracture efficacy of BPs but the effect was not significantly
different between users and non users of concomitant use for individual fracture subtypes.
Furthermore, sensitivity analysis results were similar: non-significant for hip and vertebral
fracture and were still significant for the any fracture. These results suggested that the period of
SSRIs exposure prior to a fracture event and a wider gap (up to 90 days between dispensing
dates of BPs and SSRIs) did not affect the fracture outcome.
Bisphosphonates have been shown in randomized clinical trials to be beneficial in the
reduction of fracture. A recent meta-analysis study found that oral BPs (i.e., alendronate,
etidronate, risedronate, and clodronate) are effective in reducing the risk of hip fracture by 42%.
177

The pooled estimate of relative risk based on the Bayesian random-effects model was 0.58 (95%
CI, 0.42-0.80).6 Also pooled results as obtained with the network meta-analysis to evaluate the
efficacy of BPs in the prevention of vertebral, hip, and nonvertebral-non hip fractures in
postmenopausal women with osteoporosis found that vertebral fracture reduction with
alendronate was RR=0.53, 95% CI, 0.44-0.65, risedronate: RR=0.59, 95% CI, 0.47-0.75, and
ibandronate: RR=0.51, 95% CI, 0.34-0.74. The risk reduction for nonvertebral-non hip fractures
for alendronate was RR=0.88, 95% CI, 0.77-1.00, risedronate: RR=0.62, 95% CI, 0.43-0.88, and
ibandronate: RR=1.11, 95% CI, 0.80-1.52.7 In this study, we also established antifracture
efficacy of BPs for any and hip fracture.
A possible explanation for the variability observed in antifracture efficacy is that the
antiresorptive relative potencies for osteoclast inhibition leading to increased bone mineral
density and fracture risk reduction is related to their molecular structures.10 Both BPs affinities’
for crystalline hydroxyapatite and inhibitory effects on osteoclasts are important pharmacological
features. The high affinity for bone mineral allows BPs to achieve a high local concentration
throughout the entire skeleton. Suppressed bone resorption after BP initiation suggests BP
efficacy and potency in promoting the apoptosis of osteoclasts actively engaged in degradation
of mineral on the bone surface.11 Antiresorptive therapies that produce larger increases in bone
mineral density tend to have greater antifracture efficacy.12 It is also important to note that
improved BP treatment persistence and compliance are factors that have an overall influence on
fracture risk reduction.13
We hypothesized that the established antifracture efficacy of BPs would be attenuated
through an interaction with SSRIs. We observed this potential phenomenon and increased risk of
any fracture. Although we were not able to determine with statistical certainty that SSRIs may
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attenuate the antifracture efficacy of BPs and increased risk of fracture for hip and vertebral
fracture (may be because of sample size issues), we cannot completely rule out subtle
counteractive effects due to the well-established association of SSRIs and decreased BMD
leading to increased risk of fracture. Using data for this study, we found strong association
between SSRI use and increased risk of any and hip fracture. Both findings were consistent with
reports from two prospective studies on the associations of SSRIs and increased risk of fracture.
Spangler et al. in a prospective cohort study of 93,676 postmenopausal women, found that
compared to women using other types of antidepressants, women using SSRIs had increased
adjusted risk of any fracture (HR=1.30, 95% CI, 1.20-1.41) and hip fracture (HR=1.33, 95% CI,
0.95-1.86), but statistical significance was not achieved at the hip.14 Diem et al. in a recent study
based on a 10-year follow-up medication-use data involving 9,704 women aged 65 years and
older recruited in the prospective Study of Osteoporotic Fractures, showed that of these women,
2,809 experienced an incident nonspine fracture over the follow-up period, including 936 with a
hip fracture. Women taking SSRIs experienced a higher adjusted risk of nonspine fracture
compared with nonusers (HR=1.38, 95% CI, 1.10-1.72) in a multivariable model. The risk of hip
fracture was close to 1.0 (HR=1.01, 95% CI, 0.71-1.44) for SSRI users compared with nonusers
due to potential confounding factors.15 Overall, in a meta-analysis study, a summary of pooled
estimates of risk associated with SSRI use in cohort and case-control studies has demonstrated
that SSRI use is associated with a significantly increased risk of fracture (RR=1.72, 95% CI,
1.51-1.95).5
The link between SSRIs and bone health is based on the adverse effects of serotonin on
the bone remodeling process. Bone cells (i.e., osteocytes, osteoblasts, and osteoclasts) possess a
functional serotonin (5-HT) signal transduction mechanism (5-HT receptors and the serotonin
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transporters [5-HTT]) for both responding to and regulating the uptake of serotonin.16-20 These
reports further suggested that serotonin may be involved in bone metabolism and the potential
consequences on bone health. For example the study by Gustafsson et al. examined the in vitro
effects of 5-HT and 5-HTT inhibitor fluoxetine (Prozac®) and found that serotonin as well as
fluoxetine increased the total number of differentiated human osteoclasts as well as osteoclast
activity. Fluoxetine was also found to increase receptor activator of nuclear factor kappa B
ligand (RANKL) release.20
Possible bone metabolism pathways have also been proposed. In gut-derived 5-HT on
osteoblasts, binding of 5-HT to 5-HT1B, which is linked to the Gαi protein, inhibits adenylyl
cyclase which in turn inhibits second-messenger cAMP production and protein kinase A (PKA)mediated cAMP response element-binding (CREB) phosphoslylation. This process leads to
decreased expression of Cyclin (Cyc D1) genes and decreased osteoblast proliferation. As a
result, bone formation is slowed. On the other hand, in brain-derived 5-HT on osteoblasts,
binding of 5-HT negatively controls osteoblast proliferation via the molecular clock gene (Cyc
D1) cascade and positively regulates bone resorption via activation of a PKA/ATF4-dependent
pathway (ATF-4: a transcription factor protein), leading to increased synthesis of RANKL, an
activator of osteoclast differentiation and function.21,22 In other words, 5-HT activation can also
directly produce RANKL in addition to the RANKL produced during normal bone remodeling
process.
During normal bone remodeling in healthy physiologic systems, bone stromal cells,
including cells of the osteoblast lineage, provide a limited amount of RANKL, which leads to
osteoclast differentiation, survival, and activation and subsequent bone resorption. Bone
resorption is balanced by osteoblast-dependent new bone formation.23 RANKL is a member of
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the tumor necrosis factor (TNF) superfamily, produced and secreted by osteoblasts.24 RANKL
stimulates osteoclasts through its own receptor RANK, which is a membrane-bound protein
present on osteoclast precursors, inducing the formation of osteoclasts and subsequent bone
resorption.25 Increased RANKL expression has been shown to be present in bone marrow cells
from postmenopausal women.26
How does this role of 5-HT-RANKL in bone metabolism relate to its potential
attenuating effects of BPs? The elevation of RANKL because of 5-HT probably reflects a
mechanism counter-regulating excessive bone resorption and increased risk of fracture.
Treatment of homozygous oim/oim mice (the oim/oim mouse is an established model of
moderate to severe osteoporosis) with either a BP (alendronate) or RANKL inhibitor (Rank-Fc)
has been reported to cause decreases in fracture incidence.27 Although research findings have
suggested that treatment with BPs does not change RANKL serum levels,28 Sutherland et al. has
demonstrated that RANKL can attenuate the beneficial effects of bisphosphonates. In an in vitro
study using rabbit osteoclasts treated with the bisphosphonates clodronate or alendronate for up
to 48 hours in the absence or presence of RANKL found that RANKL significantly attenuated
(or antagonized) the ability of both clodronate and alendronate to induce osteoclast apoptosis
and inhibit bone resorption. The authors conclude that RANKL protects osteoclasts from the
apoptosis-inducing and anti-resorptive effects of BPs in vitro.29 This is an example of a
pharmacodynamic drug interaction.
In pharmacodynamic interactions, the two drugs act at the same or interrelated receptor
sites and may behave in an additive, synergistic, or antagonistic fashion.30 Suppression of
osteoclast bone resorption is the pharmacodynamic effect of BPs and so are the elevated levels of
RANKL which in turn leads to osteoclast differentiation, survival, and activation and subsequent
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bone resorption the pharmacodynamic effect of SSRIs. Concomitant BP and SSRI use may
increase the risk of osteoporosis/bone loss and fracture through the antagonizing or attenuating
effects of SSRIs on the beneficial effects of BPs. The pharmacodynamic interaction of these
combinations would result in attenuation of BP effects, hence increasing the risk of fracture for
the patient. However, our study provided evidence which only suggests the possibility of this
phenomenon for any fracture, but was not well powered to determine the treatment effects for
individual skeletal sites. So, further investigations are needed to provide more understanding.
An alternative explanation to our findings is that what we have demonstrated could be
potential good news to patients on SSRIs and also prescribed BPs. It is possible that BPs are
actually protective against SSRI-induced osteoporosis and increased risk of fracture and
treatments effect estimates would have shifted toward less than 1.0. However, due to the
potential for residual confounding bias for fracture not measured in Medicare claims data but are
measured in Medicare Current Beneficiary Survey (MCBS) data (e.g., current tobacco smoking,
alcohol intake, body mass index, or activities of daily living score, cognitive impairment, and
Rosow-Breslau physical impairment scale)31 which we did not control for in this study, both
concomitant users of BPs and SSRIs and those on BPs alone probably had an equal probability
of increased risk of fracture. Hence, the lack of substantial difference in increased risk of hip and
vertebral fractures.
To ascertain this alternative hypothesis, further sensitivity analysis can be performed with
an aim to correct effect estimates for unmeasured confounding using external information such
as MCBS that contains additional survey information for some of the patients that were included
in our study.32 The MCBS is a continuous, multipurpose survey (collected since 1991) of a
representative sample of the Medicare population designed to aid the CMS administration,
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monitoring and evaluation of the Medicare program.33 This sensitivity analysis technique has
been used to investigate the association between selective COX-2 inhibitor use and the incidence
of myocardial infarction.34 With regards to concomitant use of BPs and SSRIs, findings favoring
antifracture efficacy of BPs than antifracture attenuating effects of SSRIs could be welcome
research findings as far as caring for older postmenopausal women that would need long term
use of SSRIs.
6.4.1 Strengths and limitations of the study
6.4.1.1 Strengths
There are two key aspects that contributed to the strengths of findings from this study.
These include the use of Medicare data and the study design strategy. The use of a large,
nationally representative database for older adults 65 years or older is a source of strength
because the findings are more generalizable to the population of older postmenopausal women.
As for the design strategy, we believe that potential confounding of observed variables was well
accounted for through propensity score matching. Confounding bias is of particular concern in
observational epidemiologic studies of drug effects.35 Using propensity score method it is
possible to duplicate one crucial feature of randomized experiment of designing an observational
study without access to the outcome data.36 Propensity score method allows researchers to
reconstruct counterfactuals using observational data, a situation similar to random assignment,
albeit only with respect to observed variables.37 Another strength in our design strategy is that
the study design is better in quantification of exposure with respect to time.38 Sampling is the
equivalent of matching cases and controls on duration of follow-up (or respect to time).
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6.4.2.2 Limitations
On the other hand, our study findings were also faced with some limitations. One key
limitation in this study was the small number of fractures by anatomical site and so the study had
insufficient power to detect treatment effect as statistically significant.39 This can be explained in
part by the existing imbalance in enrollment in Medicare Part A and Part D. Although Medicare
Part D offers prescription coverage to all those eligible for Medicare, not all beneficiaries are
enrolled in a Part D plan. Of those who were Medicare eligible between 2008 and 2010, 57.5%
were enrolled in a Part D plan in 2008, 58.7% in 2009, and 59.4% in 2010. The rest were not
covered by Part D and with no credible coverage or with other credible coverage, or were
enrolled in a retirement drug subsidy.40 This limitation significantly resulted in the exclusion of
many Medicare Part A patients who had no medication history available from the study cohorts.
For example, of the 7,757 patients with hip/pelvis/femur fractures enrolled in Medicare Part A
and were eligible for this study, only 762 (9.8%) patients with hip fracture were enrolled in both
plans (before matching). Also, vertebral fractures are frequently undetected by physicians41 and
so this can lead to the pronounced problem of too small number of events in the 5% random
sample. Both of these issues could be dealt with by obtaining a 10% or greater sample from CMS
rather than a 5% sample.
Second, we lacked precise information about when patients first initiated BPs. The period
after initiating therapy of BPs (≥ 3 months) plays a role in the antifracture efficacy of these
medications and this was the basis for our inclusion and exclusion criteria.42 However, due to the
limitations of the data, patients on BPs for at least 6 months were assumed to be continuous
users. It is likely that BPs would be significantly attenuated among those who are new users than
those who have been on BPs for longer periods of time.
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Third, our study is faced with the increased possibility of bias because of the
retrospective nature of the data collection. Bias may entirely account for any weak associations
that we may have observed. Potential misclassification bias, also called measurement error, is
probably the most common form of bias in epidemiologic research.43 Misclassification can occur
for both drug exposure and the outcome of interest. With respect to drug exposure with
outpatient prescription claims, a greater number of opportunities for misclassification in the
direction of not exposed exist given the multiple channels by which members can receive their
medications outside of the reimbursement arrangements of Medicare program, for example
physician samples. In addition, one of the tips for Medicare Part D patients to avoid the coverage
gap is the recommendation that patients pay cash for selected medications and request that the
pharmacy not bill the Part D plan if cash prices are less than the co-payment. Discount generic
programs (e.g., $4 generic prescription programs) are one of the recommended strategies.44 SSRI
medications in the generic programs include citalopram, fluoxetine, and paroxetine and BPs
include alendronate.45 Another potential misclassification bias of exposure is the assumption we
made in our study that patients in Medicare data with records of dispensed BPs or SSRIs actually
took them even though they may not have. In this case, patients who were non persistent and/or
adherent were misclassified as exposed, thereby biasing our estimates. With respect to outcomes,
misclassification of diagnostic codes can result due to ambiguity in diagnoses for example a selfreported fracture that is not adjudicated with radiographic reports.46
Fourth, coding of claims and filing of complete claims is done by the coding staff. During
this aspect of data generation potential sources of bias introduced are miscoding of primary and
secondary diagnoses and procedures and also failure to file claims properly and hence possible
under-reporting of diagnoses. Finally, the temporal relationship between exposure and disease
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may be difficult to establish given the fact that the study is retrospective.43 This is especially so if
important information may be missing on intermediate clinical outcomes such BMD and
RANKL measurements.
6.5 Conclusions
In summary, we did not observe a significant association of antifracture efficacy of BPs
with SSRIs for hip and vertebral fracture but significance was achieved for any fracture. Because
this is the first study to investigate this phenomenon, further studies are needed to provide more
understanding on the clinical impact of concomitant use of BPs and SSRIs among older
postmenopausal women. Especially further studies that could prospectively assess changes in
biochemical markers of bone turnover (e.g., RANKL) and BMD would provide better
understanding of the potential attenuation of antifracture efficacy of BPs by SSRIs. Currently
there are no clinical guidelines for the treatment of SSRI–related bone loss and such information
would be important to be integrated in its development. It is probable to suggest that future
concomitant use of BPs and SSRIs will continue to rise in this population due to the projected
future increase in population of older adults. Therefore, results from studies such as this could
add to the current body of literature and be useful for physicians treating osteoporosis and/or
osteoporotic fractures by highlighting possible safety concerns that may be important to consider
when optimizing patient care. Also these results might be relevant to policymakers concerned
with meeting the needs of aging Americans, especially the health of older women.
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Chapter 7

Specific Aim 3: To assess the increased risk of osteoporotic-related fractures associated with
the concomitant SNRIs with BPs use and whether the risk of osteoporotic-related fractures is
related to the role of serotonin in bone rather than the disease (depression).
7.0 Results

We did not report findings for this specific aim. This is because we failed to determine
the effects of concomitant use of bisphosphonates and SNRIs and increased risk of fracture.
Although there were enough number of events to investigate the composite effect of SNRIs on
the antifracture effects of bisphosphonates, the events were not sufficient enough to investigate a
dose response effect which was our primary goal (see Table 7.1). SNRIs are less popularly used
for the treatment of depression compared to SSRIs. Indeed, findings from Chapter 5 found that
the prevalence of concomitant bisphosphonates and SSRIs use was higher than SNRIs. This
limitation suggests that for future studies involving SNRIs and increased risk of fracture in older
adults should use a larger sample of the Medicare claims data. If possible we recommend >5% to
100% samples of the Medicare claims data to be able to capture all the associated events with
use of SNRIs.

Table 7.1. Descriptive statistics of matched concomitant users of bisphosphonates and SNRIs,
dosage, and fracture events.
Description
Concomitant users
Hip fracture
Vertebral Fracture
Humerus

≤ 37 mg
590
36
10
5

Dosage
> 37 - ≤ 60 mg
>60 - ≤ 75 mg
511
377
42
34
3
5
2
3
191

>75 mg
205
21
1
4
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